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Eight disorders of the immune system have been described which
are inherited as X-linked recessive conditions. The aim of this study
has been to improve predictive testing in X-linked agammaglobulinaemia
(XLA) and X-linked severe combined immunodeficiency (XSCID) and to
investigate the underlying defect in XSCID.
Precise genetic localisation is essential for accurate predictive
testing and in order to develop strategies to clone the genes. Before
disease localisation can be improved it is necessary to clarify the
order of a number of probes within the region of interest. Fourteen
genetic markers assigned to the X chromosome between the
pericentromeric region and Xq22 were ordered by family studies and
deletion mapping. Pulsed field gel electrophoresis was used to make a
physical map of the markers linked to XLA.
Knowledge of the order of these anonymous DNA probes led to
finding addditional linked probes for both diseases. This makes
predictive testing possible in more families.
There are X-linked and autosomal recessive forms of severe
combined immunodeficiency. This has caused difficulties in counselling
couples who have an affected male child and where there is no previous
family history of the disease. In this study it has been shown that
female carriers of the X-linked disorder have non-random use of the X
chromosome in T lymphocytes. This provides a means of distinguishing
between the autosomal and X-linked forms which enables more accurate
genetic counselling.
XSCID has been mapped to Xqll-ql3 using DNA markers which detect
polymorphic variation (de Saint Basile et al, 1987). No recombinations
have been observed between the disease locus and the anonymous DNA
probe cpX289. In this study the PGK1 locus was also shown to be
closely linked to the disease. Using both of these linked markers
predictive tests can be offered to 65% of families.
The probe pSPT/PGK which detects a polymorphism at the PGK1 locus
can also be used to investigate X chromosome usage. In females who are
heterozygous for the polymorphism detected by this probe, carrier
detection and assignment of phase can be carried out in the same
procedure. This is a unique situation and is particularly useful when
the proband could carry a new mutation or when there are no males
available who can be used to assign linkage phase.
It has been thought that XSCID results from a defect in a T
lymphocyte specific gene because the phenotype is predominantly a lack
of T lymphocytes and because host B lymphocytes produce functional
antibody following transplantation and engraftment of T lymphocytes.
Finding a non-random pattern of X chromosome usage in a mature cell
population implies that the defective gene is expressed in that cell
type and this technique was used to investigate gene expression. Non-
random X chromosome usage was found in T lymphocytes, B lymphocytes,
monocytes and granulocytes. The pattern of expression suggests that
the underlying defect in XSCID is in a general metabolic pathway
rather than a pathway specific to lymphocytes.
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CHAPTER 1. Introduction: X-linked Immunodeficiencies
Eight X-linked disorders of the immune system have been described
(Table 1.1). These disorders affect different aspects of the immune
system. Six affect the lymphoid system, though neither the
immunoglobulin genes nor the T-cell receptor genes are on the X
chromosome. They are X-linked agammaglobulinaemia, X-linked severe
combined immunodeficiency, X-linked hyperimmunoglobulinaemia M,
X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome and
X-linked agammaglobulinaemia with growth hormone deficiency. The
remaining X-linked immunodeficiencies are chronic granulomatous
disease and properdin deficiency. Chronic granulomatous disease is a
defect of phagocytosis due to absence of the (3 chain of cytochrome
b—245 (Teahan et al, 1987). Properdin is a regulator in the
alternative pathway of complement and its deficiency is associated
with meningococcal infections (Sjoholm et al, 1982).




X-linked agammaglobulinaemia with growth hormone deficiency
Wiskott-Aldrich syndrome
X-linked chronic granulomatous disease
Properdin deficiency
Table 1.1 X-linked Immunodeficiencies
1.1 Localisation of the X-linked Immunodeficiencies involving the
Lymphoid System
As six diseases involving the lymphoid system are X-linked it has
been suggested that there are regulatory genes involved in lymphocyte
development on the X chromosome. Cohen and his colleagues isolated a
murine X-linked cDNA clone that is developmentally expressed in
lymphocytes but not expressed in macrophages, liver cells or kidney
cells (Cohen et al, 1985a; Cohen et al, 1985b). This clone, XLR (X-
linked, lymphocyte regulated), detects a family of genes on the mouse
X chromosome.
CBA/N xid mice carry an X-linked mutation which renders them
incapable of producing antibodies to soluble polysaccharide (Scher,
1982). It has been shown that the XLR gene family is closely linked
to the X-linked immunodeficiency locus in the xid CBA/N mouse strain
(Cohen et al, 1985a).
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There is, therefore, an X-linked gene family in the mouse which
is differentially expressed in B and T lymphocytes and is linked to an
immunodeficiency disorder in a mutant mouse strain. This raised the
possibility that the lymphoid X-linked immunodeficiencies in man
could be due to mutations in different genes in a conserved gene
family. However, five of the six X-linked lymphoid disorders have now
been localised and all map to different regions of the X chromosome
(figure 1.1).
X-linked severe combined immunodeficiency (XSCID) has been
localised to Xqll-ql3 (de Saint Basile et al, 1987).
X-linked agammaglobulinaemia (XLA) has been mapped to Xq21.3-22
(Malcolm et al, 1987). X-linked hyperimmunoglobulinaemia M, in which
IgA and IgG are absent as in XLA but IgM levels are normal or
elevated, does not map to the same region of the X chromosome as XLA
(Malcolm et al, 1987) and there has been a report suggesting linkage
to Xq24-q27 (Mensink et al, 1987). X-linked agammaglobulinaemia with
growth hormone deficiency has only been described in one family
(Fleisher et al, 1980). The disorder in this family could either be a
single entity or two X-linked disorders segregating together, although
there have been no reports of isolated growth hormone deficiency being
transmitted as an X-linked recessive condition. There are
recombinations in this family between the disease and a probe, S21,
which maps to Xq21.3-22 (Notarangelo et al, 1988).
Individuals with X-linked lymphoproliferative syndrome are unable
to mount an appropriate response to Epstein-Barr virus infection.
Before EBV infection affected males have normal cellular and humoral
immune responses. After EBV infection 75% develop fatal infectious
mononucleosis. Those that survive have defects in cellular and humoral
immunity and a high incidence of lymphoma. Linkage studies have
demonstrated significant linkage to probes mapped to Xq24-q27 (Skare
et al, 1987).
Wiskott-Aldrich syndrome is characterised by impaired cellular
and humoral immunity, thrombocytopenia and eczema with an increased
incidence of lymphoreticular malignancies. This condition has been
mapped to Xcen-Xpll.3 (Peacocke and Siminovitch, 1987; Kwan et al,
1988).
1.2 Severe Combined Immunodeficiency
Severe combined immunodeficiency (SCID) is a group of disorders
that can be inherited in X-linked or autosomal recessive forms. The
disease is characterised by absence of cellular and humoral immunity.
Affected infants have reduced numbers of T cells, no proliferative
response to mitogens, and hypogammaglobulinaemia although B cell








Figure 1.1 The localisation of X-linked Immunodeficiency Disorders on
the X Chromosome
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Infants present within the first six months of life with failure
to thrive, oral candidiasis refractory to treatment, recurrent
infections and intractable diarrhoea which is often secondary to one
of the enteric viruses. Pulmonary infections with Pneumocystis
carinii, cytomegalovirus, measles virus or parainfluenza virus are
usually fatal. Chronic hepatitis may follow cytomegalovirus infection
and a variant of sclerosing cholangitis with focal disappearance of
bile ducts is also seen.
The incidence of the disease has been estimated to be 1 in 70,000
live births (Fasth, 1982). Without bone marrow transplantation it is
fatal within the first few years of life. There is 90% survival
following a human leucocyte antigen (HLA) matched bone marrow
transplant but only 50% survival after a mismatched transplant
(Fischer et al, 1986). A number of methods of depleting T cells in the
donor marrow have been tried to prevent graft-versus-host disease
(Reinherz et al, 1982; Morgan et al, 1986).
SCID is a heterogeneous group of diseases. Adenosine deaminase
deficiency accounts for half of the autosomal recessive cases.
Deficiency of purine nucleoside phosphorylase, another enzyme in the
purine degradation pathway, also causes SCID. Reticular dysgenesis
can be differentiated from SCID by the absence of granulocytes and
bare lymphocyte syndrome can be differentiated from XSCID by the
absence of expression of MHC class II genes. After excluding these
conditions the remaining group includes both autosomal and X-linked
recessive cases which cannot be distinguished clinically or using
using immunological or biochemical tests. Obligate female carriers of
XSCID do not have any known biochemical or immunological
abnormalities.
The male to female ratio of children with SCID is 4:1 and
therefore 60% of all cases will be X-linked. 75% of sporadic males
will have the X-linked disease and as one third of these will be the
result of a new mutation 50% of the mothers of sporadic males will be
carriers of the X-linked disorder. Where the two enzyme deficiencies
have been excluded the proportion of sporadic males who have the X-
linked form will be 6/7 (86%) and two thirds of their mothers will be
carriers of the disease. Female carriers of XSCID do not have any
known biochemical or immunological abnormalities. Genetic counselling
would be greatly improved if these women could be identified.
The X-linked form of the disease has been mapped to Xqll-ql3 (de
Saint Basile et al, 1987) and in families with XSCID both carrier
detection and prenatal diagnosis can be offered using linked DNA
probes. In those families where the inheritance pattern is not clear
prenatal diagnosis can still be offered, if the abnormality in the
affected child was well defined, by sampling fetal blood in the mid
trimester (Linch et al, 1982).
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A number of observations have led to the theory that the primary
defect in XSCID is in the T cell series. The phenotype in XSCID is
predominantly a lack of mature circulating T cells with normal or high
B cell numbers. In vitro work suggests that the B cells function in
the presence of normal T cells (Seeger et al, 1976; Pahwa et al, 1980)
and that the B cells proliferate in respose to T cell independent
mitogens, such as Staphylococcus aureus Cowan I (Schuurman et al,
1980). However, details of family history are not given in the papers
describing these results and so it is not certain that these findings
apply to XSCID. A further piece of evidence that XSCID is a T cell
defect is that full cooperation has been observed between donor T
cells and host B cells to produce functional antibodies following HLA
identical bone marrow transplantation where only the T cells have
engrafted (Griscelli et al, 1978). The results presented in this
thesis, however, show that the gene defective in XSCID is expressed
in other haematopoietic cells in addition to T cells.
1.3 X-linked Agammaglobulinaemia
XLA was first described by Bruton in 1952 (Bruton, 1952a; Bruton
et al, 1952b). Affected males present in the second half of the first
year of life as maternal antibody levels start to decline. Lederman
and Winkelstein have carried out a survey of 96 affected males. In
this series recurrent sinopulmonary infections were one of the
presenting features in 84 cases, gastrointestinal infections in 34
cases and mono- or oligoarthritis in 19 cases (Lederman and
Winkelstein, 1985). The causative organisms in the arthritis included
bacteria, viruses, and atypical organisms such as Mycoplasma
pneumoniae and Ureaplasma urealyticum. Vaccination with attenuated
live poliovirus has caused paralytic poliomyelitis and no live vaccine
should be given to patients with XLA. Giardia infection is a
recognised cause of chronic diarrhoea and malabsorption in affected
males. The major cause of morbidity in the series of patients
reviewed by Lederman and Winkelstein was chronic lung disease. The two
main causes of death were cardiorespiratory failure, resulting from
chronic pulmonary disease and cor pulmonale, and disseminated viral
infection. The age at death ranged from four years to twenty eight
years. The oldest survivor in the series was twenty six years. It is
difficult to assess the outlook of patients presenting now as in
recent years the diagnosis has been made at an earlier age and
treatment with immunoglobulin replacement started earlier.
The only estimate of the incidence of XLA comes from the
Australian national register (Hosking and Roberton, 1983). This gives
an incidence of 1 in 500,000 but may not reflect the incidence in
other populations.
The disease is characterized by low levels of all serum
5
immunoglobulins and absence of functional antibodies but normal cell-
mediated immunity (WHO Report, 1983). Carrier females have normal
serum levels of immunoglobulins.
Obligate female carriers do not have any detectable abnormalities
and there is no immunological or biochemical carrier test. Neither is
there a reliable immunological method for prenatal diagnosis as
absence of B cells has been observed in normal fetuses at 20 weeks
gestation (Linch and Levinsky, unpublished results). Conversely the
presence of B cells in fetal blood does not entirely exclude the
possibility of an affected male as variation in B cell numbers has
been described (Leickley and Buckley, 1986). Investigation of the B
cell series, therefore, cannot be used for prenatal diagnosis.
The first linkage study of XLA suggested localisation to Xq21.3-
22 with a maximum lod score of 2.17 at 0=0 with S21 and a maximum lod
score of 3.65 at 0=0.04 with 19.2 (Kwan et al, 1986). A linkage study
reported shortly after this localisation suggested that there might be
non-allelic heterogeneity (Mensink et al, 1986). A third study
supported the findings of Kwan with maximum lod scores of 6.6 with
pXG12 and 4.4 with S21, both at 0=0 (Malcolm et al, 1987). The
possibility of non-allelic heterogeneity is very important if these
probes are to be used clinically. A method has been described to allow
for non-allelic heterogeneity in risk calculations using the probes
S21 and pXG12 (Lau et al, 1988).
The disorder in XLA is confined to the B cell series. There are
few or no circulating surface immunoglobulin positive B lymphocytes
but pre-B cells are found in normal numbers in the bone marrow (Pearl
et al, 1978) suggesting that the basic defect affects the maturation
of pre-B cells. However, the failure of differentiation from pre-B
cells to B cells is not absolute as small numbers of surface IgM-
positive B cells are found in the peripheral circulation (Gonley,
1985). There are reports of phenotypic heterogeneity between patients
from different families (Golay, Webster, 1986; Dobozy et al, 1986) and
between patients within families. Thus, in large X-linked pedigrees,
some affected males have cells with surface IgM and IgD and cells
secreting IgM, whilst other affected males in the same family have no
circulating B cells (Leickley and Buckley, 1986). These studies
suggest the primary defect in XLA may affect B cells at more than one
stage of development. X inactivation anlaysis has shown that the
defect is intrinsic to the B cell series rather than lack of an
extrinsic factor (Conley et al, 1986). Cooper has proposed that XLA
could be due to a rate limiting defect in the gene rearrangement
process (Cooper et al, 1986) and this would be consistent with finding
a few cells which express surface immunoglobulin or secrete
immunoglobulin in some affected individuals.
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CHAPTER 2. Introduction: Genetic Map of the X Chromosome
The haploid human genome contains about 3 x 109 DNA basepairs and
is estimated to be 3000 centiMorgans long. The X chromosome is
approximately 200cM long (Drayna and White, 1985; Donis-Keller et al,
1987). When data was collated at the ninth Human Gene Mapping Meeting
there were 32 cloned genes on the X chromosome and 273 anonymous
cloned DNA segments. Restriction fragment length polymorphisms were
detected by 11 genes and 114 of the anonymous DNA fragments, giving a
a total of 125 RFLPs on the X chromosome. As the human X is 200cM long
if the probes were evenly spaced then there would be an RFLP every
1.6cM and it should be possible to map every X-linked trait.
2.1 Linkage Analysis
2.1.1 Background
Mendel's studies of single clearly defined pairs of characters in
the garden pea, presented in 1865, led him to the conclusion that
inherited characterisitics are determined by pairs of hereditary
factors and that the two members of a single pair of genes pass to
different gametes during reproduction. He also observed that each pair
of characterisitics segregated independently from each other pair.
Chromosomes were first described by Flemming in 1877. Reduction
division, meiosis, was described in the 1880s and 1890s. Sutton, a
student at Columbia University recognised the association between
Mendel's inherited factors and the segregation and assortment of
homologous chromosomes at meiosis in 1902. He suggested that factors
segregate independently when carried on different chromosomes but that
factors carried on the same chromosome would be inherited together
i.e. show linkage. As there are more independently inherited
charactersitics than chromosomes de Vries suggested in 1903 that
exchange occurs between paired homologous chromosomes at meiosis.
The first linkage between characteristics was found in the
vetch, Lathyrus odoratus, by Bateson, Saunders and Punnett in 1908. If
the characteristics were A, with loci A and a, and B, with loci B and
b, then an individual who has received AB from one parent and ab from
the other parent would be expected to have gametes carrying AB, ab, Ab
and aB in equal numbers according to the law of independent
segregation. However Bateson and his colleagues found that some
combinations were observed more frequently and others less frequently
than expected. When more progeny are found to inherit AB and ab than
Ab or aB then the markers are said to be linked.
Sturtevant, an undergraduate in T.H.Morgan's laboratory,
suggested in 1913 that genes are arranged linearly on chromosomes and
that the proportion of crossovers between two loci on the same
chromosome is a measure of the distance between them. The term
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recombination fraction was introduced to describe the proportion of
recombinants in the total number of offspring and, therefore, the
genetic distance between the two loci. Sturtevant proposed that the
unit distance over which a cross-over would occur in every gamete be
termed the Morgan (M) and hence the distance over which one would
expect to see a recombinant in one out of a hundred gametes a
centiMorgan (cM).
Recombination fraction and distance in centiMorgans are directly
proportional up to distances of 20cM. If A, B, and C are three loci on
a chromosome, the distance between loci A and C should equal the sum
of the distances AB and BC (when B lies between A and C). This
relationship no longer holds for distances greater than 20cM.
Sturtevant suggested that finding the recombination distance AC less
than AB plus BC could be explained by the occurrence of double
crossovers.
2.1.2 DNA Polymorphisms
Restriction endonucleases cleave DNA at specific nucleotide
sequences. Neutral single base differences are found approximately
every 200bp in genomic DNA. When these abolish or create restriction
endonuclease sites digestion with that enzyme will generate two
distinct lengths of DNA. Such alterations are called restriction
fragment length polymorphisms (RFLPs). The first human RFLP was
detected 3' of the p globin chain by an enzyme from Haemophilus
parainfluenza (Hpal) (Kan and Dozy, 1978). The potential use of these
polymorphisms as markers for mapping was pointed out by Botstein
(Botstein et al, 1980). It has been noted that the X chromosome has
several fold lower density of polymorphism than the autosomes (Hofker
et al, 1986).
A second type of restriction fragment length polymorphism results
from length variation between two restriction sites. This length
variation is usually due to a nucleotide sequence being repeated a
variable number of times in tandem and they are referred to as VNTRs
(variable number of tandem repeats). This type of polymorphism
generates more than two fragment lengths or alleles.
In linkage studies meioses only provide information if it is
possible to differentiate between the two chromosomes at the two loci
being considered. Using the type of RFLP generated by a single base
change at most only 50% of meioses will be informative. From the
Hardy-Weinberg equation it can be calculated that when the restriction
site is present on 50% of the chromosomes in the population then the
number of informative individuals, 2pq, is 50%. When RFLPs result from
tandem repeats more meioses become informative. The polymorphism
information content (PIC) is a numerical index of the usefulness of a
given marker (Botstein et al, 1980).
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2.1.3 Ideal Family Structure for Linkage Studies on the X Chromosome
In X-linked diseases recombinations only occur in female
meioses. Therefore, if a male in generation I has a carrier daughter
in generation II all meioses in that female will be phase known,
providing paternity is certain and the disorder is inherited and does
not represent a new mutation. As carrier status of females is often
not certain on clinical grounds it is more useful to collect samples
from males in generation III. An additional advantage of using only
male offspring in generation III is that non-paternity does not affect
interpretation of results. Hence, the ideal family structure is a
three generation pedigree with a male in generation I who has a
daughter in generation II with male offspring in generation III.
Families with rare X-linked disorders, however, often do not fulfill
these criteria.
2.1.4 Analysis of Pedigree Data for Linkage Studies in Man
Linkage data for two and three generation families is analysed
using the lod score method devised by Newton E. Morton (Morton, 1955).
The lod score is the logarithm to the base 10 of the likelihood ratio,
or odds, for or against linkage. The likelihood ratio is the ratio of
the likelihood of the pedigree data given linkage at a certain
recombination fraction,0, compared to the likelihood of the same
pedigree data given no linkage (recombination fraction,0, of 0.5). Lod
scores are calculated for recombination fractions from 0 to 0.45. The
position at which the highest lod score is found is the maximum
likelihood estimate of the interval separating two loci. Since lod
scores are logarithms, information from separate families can simply
be added. A total lod score of +3.0 is generally taken as proof of
linkage at a given value of theta and a total lod score of -2.0 is
generally taken as exclusion of linkage. When the prior probability of
50:1 that two random markers will not be linked are taken into
consideration a lod score of +3.0 means that the odds in favour of
linkage are 20:1. However if two loci are already known to be on the
same chromosome the a priori odds against linkage are lower and
therefore a lower lod score will give the same odds in favour of
linkage. A lod score of +2.0 is often accepted as indicating linkage
if both loci are already known to lie on the X chromosome. Using these
criteria about one in twenty independent linkages will be spurious
although this is less likely with multilocus analysis.
Lod scores between two loci can be calculated using the computer
programme LIPED (Ott, 1974). Multilocus linkage analysis can be
performed using the LINKAGE pragramme which allows simultaneous use,
or integration, of information from multiple loci in a segment of a




In females carrying X;autosome translocations the normal X
chromosome is inactive in all cells. The female is therefore
effectively hemizygous and if the translocation disrupts a gene on
the X chromosome she will manifest the same signs as a male with a
mutation in that gene. Observations of X;autosome translocations have
been used to localise the genes which are defective in Duchenne
muscular dystrophy (Greenstein et al, 1977), Hunter's syndrome
(Mossman et al, 1983) and X-linked ectodermal dysplasia (Gerald and
Brown, 1974).
2.2.2 Deletion Mapping
Males who have more than one X-linked disorder, or mental
retardation and an X-linked disorder not usually associated with
retardation, may have a deletion on the X chromosome. A male with
Duchenne muscular dystrophy, chronic granulomatous disease, retinitis
pigmentosa and McLeod syndrome and an interstitial deletion of Xp21
localised these conditions to this band (Francke et al, 1985). Another
male with mental retardation, Duchenne muscular dystrophy, adrenal
hypoplasia and glycerol kinase deficiency was found to have a deletion
in Xp21 mapping these two further conditions to the same area (Renier
et al, 1983).
In addition to providing gene mapping information, males with X
chromosome deletions provide a way of cloning DNA sequences from these
regions. When DNA containing normal X chromosomes is digested with an
endonuclease and then reassociated with an excess of sheared DNA from
the individual with the deletion the only fragments that can be cloned
into a vector cut with the same endonuclease map to the deleted
region. This was done with the first deletion above, using phenol
(Kunkel et al, 1985) and high inorganic phosphate (Smith et al, 1987)
to enhance the reassociation.
2.3 Conserved Linkage Groups
Ohno's law states that the X chromosomes of all mammals carry
homologous genes. The chromosome rearrangements that have occurred in
the X chromosome of mouse and man have been studied in detail (Amar et
al, 1988) and, therefore, when there is a mouse model of a human X-
linked disorder localisation of the mouse mutation allows predictions
about the corresponding human disease locus.
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2.4 Somatic Cell Hybrids
Somatic cell hybrids are made by fusing cells from a human
fibroblast or lymphoblastoid line with cells from a rodent line. The
two cell lines are grown in culture together and treated with
polyethylene glycol or Sendai virus to induce fusion. Some of the
heterokaryons produced go on to form hybrid cells with nuclei
containing both human and rodent chromosomes. The hybrid cells
preferentially lose human chromosomes. Each clonal population of cells
is picked, cultured separately and karyotyped. The probe is hybridised
to Southern blots of restriction endonuclease digested hybrid DNA.
Localisations are made by constructing a table showing which
chromosomes were present in hybrids which gave a signal and which
chromosomes in hybrids that did not give a signal hence excluding
localisation of the probe from certain chromosomes leaving a small
group of possible chromosome assignments.
It is possible to select for hybrids containing the X chromosome
by fusing the human cells with a rodent line deficient for
hypoxanthine-guanine ribosyl transferase (HPRT). The hybrid is then
grown in HAT (hypoxanthine, aminopterin, thymidine) medium.
Aminopterin is a folic acid antagonist and will inhibit purine and
pyrimidine metabolism. The pyrimidine pathway can be salvaged in the
presence of thymidine by thymidine kinase and the purine pathway can
be salvaged by the conversion of hypoxanthine to inosine 5'-
monophosphate by HPRT which maps to Xq26. It is also possible to
select against hybrid lines expressing HPRT by adding the purine
analogues, 6-thioguanine or 8-azaguanine, to the culture medium.
Normal cells incorporate these but HPRT- cells do not incorporate them
and therefore survive.
In the case of loci on the X chromosome localisation to the X is
usually obvious from the inheritance within families but somatic cell
hybrids can be very useful in providing regional assignments using
cell hybrids containing X;autosome translocations. The smallest region
of overlap which gives a positive hybridisation signal from a panel of
hybrids containing different translocations allows regional
localisation. Hybrids containing small fragments of human chromosomes
can also be produced by irradiating the human cells before the
formation of the hybrid. Accuracy of results from somatic cell hybrid
work depend on detailed cytogenetic analysis.
2.5 In Situ Hybridisation
In situ hybridisation is a direct method of mapping. Nucleic acid
sequences are hybridised to their complementary DNA in metaphase
chromosome spreads fixed on glass slides. Using in situ hybridisation
a probe can be localised to within a single band of a 300 band
karyotype (approximately 10 Mb). The probe DNA can either be labelled
11
using a radioactive isotope, usually 3H, detected by autoradiography,
or using non-radioactive techniques such as biotinylated probes. The
method was first used to localise repetitive DNA (Gall and Pardue,
1969) but as improvements have occurred single copy sequences have
been localised. Recently sequences of 1 kb have been mapped using
biotinylated probes (Garson et al, 1987).
2.6 Pulsed Field Gel Electrophoresis
The methods of mapping described above have a maximum resolution
of several megabases. Having achieved this level of localisation
pulsed field gel electrophoresis can be used for finer mapping as this
allows separation of DNA fragments from 20 kb up to 9 Mb (Schwartz and
Cantor, 1984; Barlow and Lehrach, 1987). The method uses two
alternating electric fields at an obtuse angle to each other. When
molecules are subjected to an electric field at an angle to their
field of migration they reorientate themselves along the new field
before moving forwards, small molecules reorientate faster than large
molecules and so have a higher mobility. The DNA tracks on the gels
produced by orthogonal field alternation gel electrophoresis (OFAGE),
the first method of pulsed field gel electrophoresis, curve away from
the midline making it difficult to estimate band sizes accurately. One
of the modifications made to give straighter tracks uses a hexagonal
electrode configuration to generate a uniform electric field at all
points on the gel apparatus (Chu et al, 1986). This electrode
configuration is referred to as CHEF, which stands for clamped
homogeneous electric fields. The fragment sizes separated and the
region of maximum resolution can be adjusted by altering the switch
interval, voltage and length of run. The DNA is transferred from the
gel onto nylon filters and hybridised with the probes using standard
techniques. Restriction fragment maps can be generated around each
probe until they overlap giving a map of the region.
When separating DNA fragments in this size range it is important
that the DNA isolated from cells is of very high molecular weight. DNA
made by standard methods is subject to shearing and is not adequate
for pulsed field gel electrophoresis. Methods have been developed of
isolating DNA from cells suspended in agarose blocks to minimise
degradation (Schwartz and Cantor, 1984). Enzymes have to be chosen
which generate DNA fragments in the size range being separated.
Enzymes that cut genomic DNA rarely either have a long recognition
sequence or CpG in their recognition sequence. Sfi has been one of the
most useful endonucleases for pulse field mapping and its recognition
sequence is GGCCNNNNGGCC. Most of the other enzymes used are
methylation sensitive endonucleases with a CpG in the recognition
sequence, for example the NotI recognition sequence is GCGGCCGC and
the BssHII recognition sequence is GCGCGC.
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The dinucleotide, CpG, is found at a fifth of the expected
frequency from the base composition of genomic DNA, which is AT rich.
In addition 60-90% of CpG dinucleotides are methylated. However there
are short sections of DNA where CpG dinucleotides occur at the
predicted frequency and are not methylated. These regions of DNA are
referred to as HTF islands because Hpall, with its recognition
sequence CCGG, digests DNA from these regions to give tiny fragments
(Hpall Tiny Fragments) (Bird et al, 1985). These islands are always
associated with genes although not all genes have HTF islands
(Gardiner-Garden and Frommer, 1987). Many of the endonucleases used to
generate restriction maps with pulse field gel electrophoresis cut
within HTF islands. 89% of NotI sites are in HTF islands and 74% of
BssHII sites are within HTF islands (Lindsay and Bird, 1987). A
cluster of digestion sites using endonucleases which recognise
unmethylated CpGs implies an HTF island and hence the position of a
gene. Therefore pulsed field gel electrophoresis can be used to
generate a map of a region and also pinpoint the site of genes with
HTF islands in that map.
2.7 Mapping Studies of Proximal Xq
Detailed mapping studies provide information of immediate
clinical relevance. The more probes, detecting restriction fragment
length polymorphisms, that are mapped to the area of a disease locus
the greater the probability of a woman being heterozygous for a linked
probe. Hence, predictive tests can be offered to more families. In
addition, probe order is essential information for refining the
localisation of the disease and for building up a physical map of the
region which is a preliminary step in cloning the defective gene.
Following the localisation of X linked agammaglobulinaemia to
Xq21.3-22 and X-linked severe combined immunodeficiency to Xqll-13 a
study was started to determine the order of DNA probes known to be
between the centromere and Xq22. A panel of X-linked probes was tested
in reference families that had been noted to have a recombination on
Xq and in a male with a deletion on Xq to give probe ordering data.
The same probes were then used to refine the mapping information about
XSCID and XLA. In addition physical mapping of the probes in Xq21.3-
22 was started using pulsed field gel electrophoresis.
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CHAPTER 3. Introduction: Use of X Inactivation Studies in the
Investigation of Severe Combined Immunodeficiency
Severe combined immunodeficiency is a group of disorders that can
be inherited in X-linked or autosomal recessive forms. All the
children have absent T cell function but there is considerable
variation in T and B cell numbers and it is not possible to
distinguish between autosomal and X-linked forms on the basis of
immunological tests. Female carriers of XSCID do not have any known
biochemical or immunological abnormalities.
In families where there is a clear X-linked pedigree carrier
detection can be offered using restriction fragment length
polymorphisms detected by probes that are linked to the disease.
However most of the families referred to The Hospitals for Sick
Children have only one affected male child and no previous family
history, or a history of males in previous generations on the maternal
side dying in infancy but not having any further information. It was
therefore important to develop a method of clarifying the inheritance
pattern in these families so that more accurate genetic counselling
could be given to the couple. In addition knowing the inheritance
pattern would affect the management of the extended family: in X-
linked families female relatives should be investigated but in
autosomal recessive cases relatives could be reassured that the risk
of having a child with the same disease is extremely low.
3.1 X Inactivation
The Lyon hypothesis states that permanent inactivation of one of
the two X chromosomes occurs at random in every somatic cell in the
female early in embryogenesis. The pattern of X chromosome
inactivation is transmitted in stable fashion to all progeny cells. In
a mature cell population therefore approximately half of the cells
will have the paternal X active and the remaining cells will have the
maternal X active.
3.1.1 X Chromosome Usage in Females carrying X-linked Disorders
In female carriers of some X-linked disorders there are two
populations of cells, one normal and one abnormal, as expected from
the Lyon hypothesis. Female carriers of chronic granulomatous disease
have normal and abnormal granulocytes when phagocytic function is
tested with nitrotoluene blue. Some cultured fibroblast clones in
female carriers of Hunter's syndrome accumulate polysaccharide, and
presumably have the abnormal X active, and others are normal.
In three X-linked conditions a non random population of active X
chromosomes has been demonstrated in mature cell populations by
investigating women who were also heterozygous for glucose-6-phophate
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dehydrogenase (G6PD) isoenzymes. The first condition in which non-
random X chromosome usage was found was the metabolic disorder Lesch
Nyhan syndrome, which results from hypoxanthine-guanine-phophoribosyl
transferase (HPRT) deficiency.
The other two conditions, Wiskott-Aldrich syndrome and Bruton's
agammaglobulinaemia, are both disorders of the immune system.
Assays of HPRT activity in obligate carriers of Lesch-Nyhan
syndrome showed erythrocyte levels to be in the normal range. Nyhan
investigated two obligate carriers of the disease in one family who
were heterozygous for G6PD types A and B (Nyhan et al, 1970).
Erythrocytes and lymphocytes expressed only type B G6PD, fibroblasts
expressed both type A and type B. These results suggested that the
same X chromosome was active in all erythrocytes and lymphocytes and
that the X chromosome carrying the abnormal HPRT gene was inactive in
these cells.
An obligate female carrier of Wiskott-Aldrich syndrome who was
heterozygous for G6PD types A and B has been investigated (Gealy et
al, 1980). Granulocytes, platelets, monocytes, B lymphocytes and T
lymphocytes had only the A isoenzyme detectable. The ratio of A to B
in her erythrocytes was 3:1 and in cultured skin fibroblasts the
isoenzymes A and B were expressed in equal proportions. Again this
suggested that in some mature cell populations all the cells had the
same X chromosome active.
An obligate carrier of Bruton's agammaglobulinaemia heterozygous
for G6PD isoenzymes A~ and B has been investigated. Neutrophils and
mononuclear cells expressed both isoenzymes but only the B isoenzyme
was detected in B cells (Gonley et al, 1986).
It can be concluded from these four examples that although the
initial X inactivation process is random a non random pattern of X
inactivation can be found in selected mature cell populations of women
carrying some X-linked disorders.
3.1.2 Methods of Investigating X Chromosome Usage
The simplest method of studying X inactivation patterns is to use
glucose-6-phosphate dehydrogenase polymorphisms detected by starch
gel electrophoresis of cell lysates. This method is rapid, simple and
requires relatively few cells. However very few Caucasian women are
heterozygous for the polymorphic variants of this protein and
therefore it would not be useful as a routine test in our population.
Another method for studying X inactivation patterns is to make
somatic cell hybrids and select for hybrids containing the active X
chromosome by culturing in HAT medium. Hybrid clones that retain two
human X chromosomes can be grown in medium containing 6-thioguanine
which is toxic to cells expressing HPRT and, hence, any cells
surviving in this medium will have lost the active X. One can then use
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any polymorphic X-linked trait that the woman is heterozygous for to
test whether X chromosome use is random or not (Puck et al, 1987).
Whilst this method has the advantage that nearly all women will be
heterozygous for one of the protein or DNA polymorphisms on the X
chromosome it obviously takes considerable time and resources for
each woman investigated.
Recently a method has been developed for investigating X
inactivation patterns based on methylation differences between the
active and inactive X chromosome (Vogelstein et al, 1987). Probes from
the 5' end of the HPRT and the phosphoglycerate kinase (PGK) genes
detect both a polymorphism and a difference in methylation between the
active and the inactive X chromosome. One endonuclease detects the
polymorphism and then methylation-sensitive endonucleases (Hpall and
Hhal) are used to demonstrate the methylation pattern.
3.1.3 The PGK Locus
The PGK probe, pSPT/PGK, detects a BstXI polymorphism and a Bgll
polymorphism. These polymorphic sites are in linkage disequilibrium.
A restriction map of the 5' end of the PGK gene is shown in
figure 3.1. The polymorphic sites and Hpall sites are marked on the
figure. The recognition site of Hpall is CCGG but Hpall only digests
DNA when the CpG dinucleotide is unmethylated. The first eight Hpall
sites are methylated on the inactive X chromosome and unmethylated on
the active X chromosome (Keith et al, 1986). The ninth Hpall site is
unmethylated on the active X chromosome but is also unmethylated on
20-40% of inactive X chromosomes.
Two combinations of restriction endonucleases were used to look
at X inactivation patterns with this probe. In the first method Bglll
and EcoRI were used to bracket the Bgll polymorphic site, after
digestion with these three endonucleases the sample was divided and
Hpall added to one aliquot. Polymorphic bands of 1.7 and 1.3 kb, which
are very clear on autoradiographs, are generated using this
combination of endonucleases. In a non random population the band
representing the active X chromosome will become much smaller, the
band representing the inactive X chromosome will remain in the same
position but will be fainter due to digestion at the ninth Hpall site.
In the second combination of enzymes BstXI is used to detect the
polymorphism and PstI added to exclude the ninth Hpall site. The
polymorphic bands generated are 1.05 and 0.9 kb. This method avoids
the difficulties raised by the variable methylation of the ninth Hpall
site but has the disadvantage that the bands on the autoradiograph are
less sharp.
Both combinations of endonucleases were used at different times
during the investigations.
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3.1.4 The HPRT Locus
A BamHI polymorphism of 24/12kb is detected by two contiguous
probes taken from the 5' end of the HPRT gene. Addition of PvuII is
recommended as this reduces the band sizes by 6kb to 18/12kb improving
transfer of the DNA during blotting and allowing the test to be
carried out even if the DNA is slightly degraded (figure 3.2).
Hhal recognizes the sequence CGCG but only digests the DNA when
the CpG dinucleotides are unmethylated. There are 6 Hhal sites within
the DNA fragment that is detected by the probes after BamHI/PvuII
digestion. The first Hhal site is unmethylated on most active X
chromosomes and also on some inactive X chromosomes. Hhal sites 2-6
are methylated in over 95% of active X chromosomes but at least one of
these sites is unmethylated in over 90% of inactive X chromosomes.
Hha I Sites Active X Inactive X
Site 1 most unmethylated seme unmethylated
Site 2-6 methylated >95% 1 unmethylated >90%
Table 3.1 Methylation pattern at the Hhal restriction sites in the
BamHI DNA fragment detected by HPRT-600 and HPRT-800
In more than 95% of active X chromosomes the DNA fragment will
become only 200bp smaller after the addition of Hhal as the DNA will
only be cut at site 1. The DNA fragment will be lOkb or less for
more than 90% of inactive X chromosomes after the addition of Hhal,
depending on which Hhal sites are unmethylated (figure 3.3).
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Hpall recognizes the sequence CCGG but only digests DNA when the
CpG dinucleotide is unmethylated. There are 9 Hpall sites within the
Bam/PvuII fragment detected by the HPRT probes.
All active X chromosomes have the same pattern of methylation at
the Hpall sites but the methylation pattern at these sites on inactive
X chromosomes differs even within the same subject. The first Hpall
site is unmethylated on active X chromosomes and also on some inactive
X chromosomes. Sites 2 and 3 are unmethylated on the active X and
methylated on the inactive X. Sites 4-9 are methylated on the active X
and on type II inactive X chromosomes, but at least one is
unmethylated on type I inactive X chromosomes. Most women have a
mixture of Type I and type II inactive X chromosomes with type I
accounting for 60-100% of inactive X chromosomes.
Hpall Sites Active X Inactive X
Table 3.2 Methylation pattern at the HpaU restriction sites in the
BamHI/PvuII fragment detected by the HPRT-600 and HPRT-800 probes
If a filter of DNAs digested with BamHI/PvuII and Hpall is probed
with the HPRT-800 probe then the active X appears 800bp smaller, type
I inactive X chromosomes are less than 8kb but the type II inactive X
chromosomes remain at the original size. These autoradiographs are
difficult to interpret because over the distances that the gels are
run 17.2 kb and 18 kb cannot be clearly distinguished. If the same
filter is hybridized with the HPRT-600 probe the band representing
the active X is much smaller at 600bp while the bands for the type I
inactive X chromosomes are between 600bp and 8kb and the type II
inactive X chromosomes remain in the original position. In any woman
who has a non random X inactivation pattern it will be seen clearly on
this filter if she has type II inactive X chromosomes but in those
women where nearly all inactive X chromosomes are type I both the
bands will be lost and interpretation will not be possible.
The bands detected by HPRT-600 and HPRT-800 after
BamHI/PvuII/Hpall digestion of active X chromosomes are shown in
figure 3.4 and the bands detected after BamHI/PvuII/Hpall digestion of
type I and type II inactive chromsomes are shown in figure 3.5.
Type I Type II
Site 1
Sites 2 and 3
Sites 4-9
unmethylated unmethylated in seme
unmethylated methylated methylated
methylated at least 1 unmeth methylated
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3.2 Hypothesis
The observations in XLA and Wiskott-Aldrich syndrome led to the
hypothesis that as males with X-linked severe combined
immunodeficiency have abnormal T cell development female carriers of
the disease would have a non-random pattern of X inactivation in their
T cells and this could provide the basis for a carrier test.
Vogelstein's data suggested that approximately fifty percent of
Caucasian women are heterozygous for the polymorphisms detected by
HPRT or PGK. These probes were used to investigate families referred
to The Hospitals for Sick Children and to investigate the expression
of the gene defective in XSCID in other haematopoietic cells.
3.2.1 Investigation of Consultands
Initially a 10 mis sample of blood was taken from each female
referred for investigation. DNA from this sample was tested to see if
she was heterozygous for either the PGK or the HPRT polymorphisms.
Women who were heterozygous for either of the polymorphisms were then
asked to attend the clinic where the study was explained to them. 50
mis of blood was taken from the women who wished to participate for
cell separation and methylation analysis.
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CHAPTER 4. Methods
4.1.1 Phenol/chloroform extraction of DNA
An equal volume of phenol saturated with 50mM Tris-HCl pH8.0 was
added to the solution containing the DNA and, after thorough mixing,
the sample centrifuged. The upper aqueous layer containing the DNA was
gently removed using a wide mouth glass pipette and a second
extraction performed using 1/2 volume phenol saturated with 50mM Tris-
HCl pH8.0 and 1/2 volume chloroform. The upper aqueous layer was again
removed and extracted twice using an equal volume of chloroform to
remove residual traces of phenol.
4.1.2 Ethanol precipitation of DNA
DNA was precipitated by adding 1/10 volume 3M sodium acetate
pH5.2 and 2x/2 volumes ice-cold ethanol or by adding 1/2 7.5M ammonium
acetate followed by 2 volumes ice-cold ethanol.
4.2 DNA Extraction
4.2.1 DNA Extraction from Blood Samples
Blood samples were collected into tubes containing the
anticoagulant ethylenediamine tetraacetate (EDTA) and stored at
-70°C. The following protocols give the volumes of reagents used for
lOmls of blood. Method 1 was used at the beginning of the study but
after publication of the second method it was used in preference
because it reduced the time taken for DNA extraction and also avoided
the use of phenol with its associated hazards.
Method 1
The frozen blood was thawed at room temperature. 40 mis of ice-
coid distilled water was added to lyse the red cells. The sample was
centrifuged for 20 minutes at 800g at 4°C. The supernatant was
decanted and the white cell pellet disrupted by the addition of 25 mis
of ice-cold 0.1% NP40. After mixing the sample was centrifuged for a
further 20 minutes at 800g at 4°C. The supernatant containing the cell
debris was decanted and the nuclear pellet was resuspended in 2.5mls
of 75mM NaCl/24mM EDTA pH8.0. When the pellet was completely dispersed
125pl of 10% sodium dodecyl sulphate (SDS) and lmg of proteinase K
were added and the sample incubated at 37°C overnight or at 56°C for
two hours and then 2.5mls of 75mM NaCl/24mM EDTA pH8.0 added. Phenol
chloroform extractions were then carried out as described in section
4.1.1, spinning the sample at 1800g for 20 minutes for the first two
extractions and then at 1800g for 10 minutes for the chloroform
extractions. After ethanol precipitation the DNA pellet was removed
using a glass pipette with a sealed tip and air dryed for 5 minutes
before dissolving in 0.5mls TE. The sample was then placed on a rotary
mixer in a room at 4°C for 48 hours prior to storing at -20°C.
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Method 2
The nuclear pellet was prepared as in method 1 but then
resuspended in 14mls 6M guanidine hydrochloride and 1ml 7.5M ammonium
acetate. 1ml 20% sodium sarkosyl and 1.5mg proteinase K were added and
the solution incubated at 60°C for 90 minutes. The DNA was then
precipitated by the addition of 35mls of ethanol and the DNA pellet
spooled out using a sealed glass pipette. The sample was dissolved in
0.bails TE ovenight and then reprecipitated using 3M sodium acetate and
ethanol. The DNA pellet was spooled out and redissolved in TE.
4.2.2 DNA extraction from cells
DNA was extracted from cells using the above methods but
ommitting the step for lysis of red cells. The above protocols give
the volumes suitable for approximately 50 X 106 cells and were scaled
down accordingly.
4.2.3 DNA extraction from chorionic villus
The sample was examined under a low-power dissecting microscope
and any contaminating maternal tissue removed. The sample was washed
once in 75mM NaCl/24mM EDTA pH8.0 in an eppendorf tube. 0.5mls of
NaCl/EDTA, 25pl 10% SDS and 0.2mg proteinase K were added and the
sample incubated at 56°C for 1-2 hours. Phenol chloroform
extractions were carried out as in section 4.1 spinning the sample for
4 minutes in a microfuge at each stage. The DNA was then ethanol
precipitated, spooled out and dissolved in 50pl TE.
4.2.4 DNA extraction from placenta for pre-annealing
Placental tissue was cut into small pieces and homogenised in
75mM NaCl/24mM EDTA in a tissue homogeniser and the homogenate seived
through muslin. 1 mg proteinase K was added per gram of placenta and
SDS to a concentration of 0.5%. After overnight incubation at 37°C
phdnol chloroform extractions and ethanol precipitation were carried
out as in sections 4.1 and 4.2. The DNA was sonicated to 500-100bp and
kept at a concentration of 10 mg/ml
4.2.5 Measurement DNA Concentration
A 15pl aliquot was made up to 750pl with distilled water and the
optical density read at 260nm and 280nm. As an optical density(OD) of
1 at 260nm corresponds to 50pg/ml double stranded DNA multiplying the
reading by 2.5 gave the concentration in mg/ml when using this
dilution. The purity of the sample was assessed by the ratio
OD26o/OD28o. A pure sample gives a ratio of 1.8 and a sample
contaminated by phenol or protein gives a lower ratio.
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4.3 Restriction Enzyme Digestion
4.3.1 Standard Restriction Enzyme Digest
5pg of DNA was digested with 10 units of enzyme for 3 hours in a
volume of 40pi using the buffer and temperature conditions recommended
by the manufacturer but with the addition of 3mM spermidine
trihydrochloride. Any sample that failed to digest was precipitated
using ammonium acetate and ethanol prior to redigestion. 4pl of
loading buffer (50% glycerol,ImM EDTA,0.25% bromophenol blue) was
added to each sample.
4.3.2 Restriction Enzyme Digest for Methylation Analysis using HPRT
15pg DNA was digested with 40 units of PvuII and 40 units of
BamHI in lOOmM NaCl, lOmM MgCl2, lOmM Tris-HCl pH8.0, 3mM spermidine
and lOOpg/ml bovine serum albumin (BSA) in a reaction volume of 80pl.
The DNA was then ammonium acetate/ethanol precipitated with 20pg
glycogen present as a carrier. After 1 hour at -20°C the sample was
centrifuged in a microfuge for 30 minutes. The DNA pellet was dried in
vacuo, resuspended in 90pl of TE and divided into three equal
aliquots. One aliquot was digested with 10 units of Hhal in 50mM Tris-
HCl pH8.0, 5mM MgCl2, 6mM mercaptoethanol and lOOpg/ml bovine serum
albumin. Another aliquot was digested with 10 units of Hpall in 6mM
KC1, lOmM Tris-HCl pH7.4, lOmM MgCl2, lOmM mercaptoethanol, lOOpg/ml
BSA and 3mM spermidine. The three samples were loaded in adjacent
wells so that the BamHI/PvuII digest would demonstrate the position of
the polymorphic bands and act as an intensity control as the three
lanes contained an equal amount of DNA.
4.3.3 Restriction Enzyme Digest for Methylation Analysis using PGK
1) 15pg DNA was digested with 30 units of PstI in 50mM Tris-HCl pH8.0,
lOmM MgCl2, 50mM NaCl, lOOpg/ml BSA and 3mM spermidine for 3 hours at
37°C in a reaction volume of 80pl, 30 units of BstXI was added and the
sample incubated for a further 3 hours at 56°C.
The DNA was ammonium acetate/ethanol precipitated with 20pg glycogen
present as a carrier. After 1 hour at -20°C the sample was centrifuged
in a microfuge for 30 minutes. The DNA pellet was dried in vacuo and
then resuspended in 60pl TE. This was divided into two equal portions.
Ore portion was digested with 10 units of Hpall for 3 hours at 37°C in
6mM KC1, lOmM Tris-HCl pH7.4, lOmM MgCl2, lOmM mercaptoethanol,
lOOpg/ml BSA and 3mM spermidine. The two samples were loaded in
adjacent wells so that the Pstl/BstXI digest showed the position of
the polymorphic bands and acted as a dosage control.
2) 15pg DNA was digested with 30 units of Bgll, 30 units of Bglll and
30 units of EcoRI in 50mM Tris-HCl pH8, lOmM MgCl2, 50mM NaCl, lOmM
mercaptoethanol, lOOpg/ml BSA and 3mM spermidine at 37°C. The DNA was
ammonium acetate/ethanol precipitated as in part 1 and divided into
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two equal portions, one to be digested with Hpall and one for the
control track.
4.4 Southern Blotting
4.4.1 Preparation of the Gel, Electrophoresis and Transfer of DNA
An 0.8% agarose gel was prepared by dissolving agarose in
electrophoresis buffer by boiling, cooling the solution to 50°C in a
water bath and then adding ethidium bromide to a final concentration
of 0.5pg/ml immediately prior to pouring the gel. When set the gel was
placed in the electrophoresis tank and electrophoresis buffer (40mM
Tris, 20mM sodium acetate, 2mM EDTA, the pH of the 10 X stock solution
was adjusted to 7.7 using glacial acetic) added to cover the gel to a
depth of about 1mm. Samples were loaded into the wells leaving one
bl^nk track for orientation of autoradiography and with Hindlll
digested lambda or BstEII digested lambda as a size marker in one
track. Electrophoresis was carried out at 1.5V/cm for 16 hours to
detect most polymorphisms. After electrophoresis the gel was placed
next to a ruler on an ultraviolet transilluminator and photographed.
The gel was denatured for 1 hour in 0.5M NaOH,1.5M NaCl and then
neutralised in 0.5M Tris-HCl pH8.0, 1.5M NaCl for 1 hour changing the
neutralising solution once. The Southern blot was then set up for
transfer of DNA onto a nylon filter (Hybond N, Amersham) as shown in
figure 4.1. After overnight transfer the position of the wells and the
number of the filter were marked on the filter with a permanent
marker. The filter was rinsed in 2 X SSC (appendix 2) and baked for 2
hours at 80°C. Filters were stored at room temprature until
hybridised.
4.4.2 Prehybridisation and Hybridisation of Filters
The filters were rinsed in 2 X SSC and placed in polythene bags
with a maximum of three filters per bag. 7 mis of hybridisation
solution (appendix 2) was added to the bag which was then sealed and
incubated at 65°C for three hours. The filters were then transferred
to hybridisation solution containing 106dpm/ml denatured labelled











Figure 4.1 Method of transfer of DNA from agarose gel to nylon filter
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4.4.3 Washing Filters
Filters were removed from the hybridisation bags and washed in 3
X ESC, 0.1% SDS at room temperature three times for twenty minutes and
then monitered with the beta-counter. The temperature was increased to
65°C and the filters washed at increasing stringency changing the
wash solution at thirty minute intervals and monitering with the beta
counter at each change until the counts were acceptable. When the wash
solution was changed the SSC concentration was progressively decreased
to 1 X SSC, 0.5 X SSC, 0.2 X SSC, and if necessary 0.1 X SSC. The
washed filters were wrapped in clingfilm, the position of the wells
and the number of the filter marked with a fluorescent pen (Ultemit,
Dupont), and exposed to Kodak XAR-5 film in cassettes with
intensifying screens at -70°C. The length of exposure required was
dependent on the probe and varied from 3 hours to 10 days.
4.4.4 Washing Filters for Re-use
lOmM Tris-HCl pH8.0 was boiled and poured into a tray containing
the filters. This was left at room temperature for thirty minutes. The
filters were removed, wrapped in clingfilm and autoradiogaphed to
check that they were clean before re-use.
4.4.5 Storage of filters
Filters were stored at room temperature between sheets of tissue
paper.
4.5 DNA Probes
The steps involved in transforming the plasmid DNA into bacteria,
growing the bacteria to prepare batches of plasmid and isolating the
probe insert from the plasmid are described below in addition to the
radioactive labelling of the probe and preannealing.
4.5.1 Transformation of Escherichia coli by Plasmid DNA
Probes were usually received in DNA form. These were introduced
into E.coli cells using the calcium chloride method (Maniatis et al,
1982). The first step in the procedure was the preparation of
competent cells.
a) Preparation of competent cells
25mls of L broth (appendix 2) was inoculated with one colony of
E.coli strain HB101 and incubated at 37°C overnight. 1ml of the
overnight culture was added to lOOmls of L broth and incubated at
37°C, shaking vigorously, for approximately three hours until the
optical density at 550nm was 0.5. The culture was then centrifuged at
1800g for 10 minutes at 4°C and the supernatant discarded. The cell
pellet was resuspended in 12.5 mis of ice-cold 50mM CaCl2, lOmM Tris-
HC1 pH8, placed in an ice bath for 30 minutes and then recentrifuged
at 1800g for 10 minutes at 4°C. The supernatant was discarded and the
cells resuspended in 2 mis of ice-cold 50mMCaCl2, lOmM Tris-HCl pH8.
The cells were dispensed in 0.2ml aliquots into prechilled eppendorfs
and stored at 4°C for 12-24 hours to increase their transformation
efficiency. The competent cells were then ready for use or storage at
-70°C.
b) Transformation
40ng of plasmid DNA in 80pl TE were added to one aliquot of
competent cells, mixed and kept on ice for thirty minutes. The
eppendorf was then transferred to a water bath at 42°C for two
minutes. One ml of L broth was added to the eppendorf and the tube
incubated at 37°C for one hour without shaking. 10, 100 and 500pl
aliquots of the mixture were spread onto LB agar plates containing the
appropriate antibiotic (appendix 2). In addition a control plate was
made using untransformed competent cells on an LB agar plate
containing the same antibiotic. When the liquid had been absorbed the
plates were inverted and incubated at 37°C overnight.
Colonies picked from these plates were grown overnight in LB
medium containing the appropriate antibiotic. 0.85 mis of the
overnight culture was transferred to a sterile vial containing 0.15
mis of sterile glycerol. After thorough mixing the glycerol stock was
stored at -70°C.
4.5.2 Preparation of Plasmid DNA
One colony of transformed cells or a loop from a glycerol stock
was inoculated into 10 mis of LB containing the appropriate antibiotic
and incubated overnight at 37°C. An aliquot of the overnight culture
was added to 250 mis of LB containing the appropriate antibiotic and
grbwn, shaking, at 37°C until the OD600 was betweeen 0.4 and 0.8.
Chloramphenicol was then added to a final concentration of 150pg/ml
and the culture incubated overnight at 37°C with vigorous shaking. The
addition of chloramphenicol stops the bacteria dividing but does not
stop replication of plasmid DNA therefore the ratio of plasmid DNA to
bacterial DNA increases during this time.
The bacterial cells were then harvested by centrifuging the
culture at 7000g for 7 minutes at 4°C and discarding the supernatant.
The cell pellet was resuspended in 10 mis of solution I (25mM Tris-HCl
pH8, lOmM EDTA, 50mM glucose and 5mg/ml fresh lysozyme) and left at
room temperature for 10 minutes. 20 mis of freshly made 0.2M NaOH, 1%
SDS were then added and the mixture placed on ice for 10 minutes. 10
mis of ice-cold 5M potassium acetate pH4.8 was added and the solution
mixed thoroughly and left on ice for thirty minutes. The mixture was
centrifuged at 9000g for 10 minutes and then poured through muslin
into a measuring cylinder. Cell debris and bacterial DNA were retained
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on the muslin. The measured volume was transferred into a clean
container and 0.6 volumes of isopropanol added. After 5 minutes at
room temperature this was centrifuged at 9000g for 10 minutes at room
temperature. The supernatant was discarded and the container left
upside down for five minutes to drain. When the pellet was dry it was
resuspended in 2.5 mis TE and transferred to a clean universal
container. EDTA was added to give a final concentration of 10-20mM and
the solution neutralised using 1M Tris base. The volume was made up to
5 mis with TE containing ethidium bromide to give a final
concentration of lmg/ml and then 5.425g CsCl added. The aggregates of
ethidium bromide and protein were removed by centrifugation at 20,500g
for 10 minutes. The supernatant was put into a Beckman polyallomer
tube which was topped up with liquid paraffin. The tubes were balanced
to 0.05g and sealed. They were centrifuged for 17 hours at 200,000g at
15°C.
The top of the tube was punctured with a 21-gauge needle and the
ethidium stained band of plasmid DNA removed using a needle and
syringe. If two bands were seen only the lower band containing the
closed circular plasmid DNA was taken. The contents of the syringe
were put into a bijou with an equal volume of NaCl saturated
isopropanol. These were mixed and then allowed to separate into
aqueous and non-aqueous phases. The isopropanol (upper) layer,
containing extracted ethidium bromide, was discarded and the process
repeated until the aqueous layer was completely clear. The aqueous
layer was then transferred to a siliconised corex tube. Two volumes of
sterile water and 7.5 times volumes of cold ethanol were added and
the tube left at -20°C overnight. The DNA was then precipitated by
centrifuging at 14,000g for 10 minutes. The DNA pellet was washed with
70% ethanol to remove salt and then dried in a vacuum dessicator. The
DNA was dissolved in 250pl of TE and an aliquot taken for measuring
concentration.
3pg of plasmid DNA was digested with endonucleases to cut out the
insert. This was then electrophoresed on a 0.8% agarose gel alongside
BstEII and Hindlll digested lambda to check the size of vector and
insert.
4.5.3 Cutting out Inserts
Method 1
The plasmid was digested with the appropriate endonuclease and
the insert separated from the vector by electrophoresis through an
agarose gel. DEAE cellulose (Whatman DE81) was cut into small pieces
the width of the tracks run on the agarose gel and soaked for several
hours in 2.5M NaCl. The pieces were then washed several times in
distilled water. Prior to use they were soaked for five minutes in
electrophoresis running buffer containing lpg/ml ethidium bromide. The
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gel was visualised on an ultraviolet transilluminator and slits were
made immediately above and below the insert bands. Pieces of the
prepared cellulose paper were inserted into the slits using millipore
fo-ceps. The gel was then placed back in the electrophoresis tank and
electrophoresis continued for a further thirty minutes. The cellulose
strip positioned above the insert band prevents the vector from
migrating onto the lower strip along with the insert. The gel was
placed back on the transilluminator to check that all of the insert
had run onto the paper strips which were then removed. They were
placed in a petri dish and viewed on the transilluminator to separate
the parts containing DNA from those not containing DNA. The paper was
rinsed in distilled water, squeezed dry and placed in lOOpl NET (1.5M
NaCl, 20mM Tris-HCl pH7.5, ImM EDTA) in an eppendorf. The tube was
incubated for two hours at 37°C. Whilst the sample was incubating a
pin hole made in the top and bottom of a 400pl eppendorf and a glass
wcnl plug made in the bottom of it. This small eppendorf was then
placed inside a 1.5ml eppendorf from which the top had been removed.
The paper and the solution were transferred to the small eppendorf
which was then centrifuged for thirty seconds. 2.5 volumes of absolute
ethanol was added to the eluate to precipitate the DNA. The sample was
placed at 4°C for thirty minutes then centrifuged for thirty minutes.
The supernatant was discarded and the pellet rinsed once with 70%
ethanol before resuspending it in 25pl TE.
A series of aliquots of known concentration ranging from 10
pg/ml to 100 pg/ml were made using commercial lambda. A piece of
parafilm was placed on the ultraviolet transilluminator and lpl of
each of these controls added to 9pl of 2pg/ml ethidium bromide
solution, lpl of the insert was also added to 9pl of the ethidium
bromide solution. A photograph was taken and the concentration of the
insert compared with the control range. The insert was then diluted to
lOpg/ml for use in oligolabelling.
Method 2
The plasmid was digested with endonuclease and the insert
separated from vector by electrophoresis through an agarose gel. The
insert was then purified from the agarose using a commercial kit
"Geneclean" (BIO lOlinc.). The band containing the insert was
visualised on an ultraviolet transilluminator and excised. The
agarose was placed in an eppendorf and broken into pieces using the
tip of a pipette. Two to three volumes of saturated sodium iodide
solution was added and the eppendorf was incubated at 50°C for 5
minutes or until the agarose was completely dissolved. The "glassmilk"
silica matrix was vortexed well before adding 5pl to the eppendorf.
The eppendorf was placed on ice for five minutes and then centrifuged
for 5 seconds and the supernatant discarded. The pellet was washed
three times with "NEW" solution; the pellet was resuspended in 500pl
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of ice-cold "NEW" solution, spun for 5 seconds and the supernatant
discarded each time. After ensuring that all of the supernatant had
been removed the pellet was resuspended in an equal volume of TE and
incubated at 50°C for three minutes to elute the DNA from the silica
matrix. The tube was centrifuged for thirty seconds and then the
supernatant removed and diluted further in TE. After estimating the
concentration as described in method 1 it was adjusted to lOng/pl.
4.5.4 Oligolabelling probes
Labelling solution was prepared by mixing 25pl DTM (25mM dATP,
25mM dGTP, 25mM dTTP, 250mM Tris pH8, 25mM MgCl2), 7pl OL (ImM EDTA,
ImM Tris pH7.5 containing 90 optical density units/ ml of
oligodeoxyribonucleotides) and 25pl 1M Hepes buffer pH6.6.
60ng of probe DNA was sealed in a capillary and denatured by
placing in boiling water for two minutes and then cooling to 0°C in an
ice bath. The denatured probe was added to an eppendorf tube
containing 11.4pl labelling solution, lpl bovine serum albumin
(lOmg/ml), 5pl 32PdCTP (50-100pCi) and 2.5 units DNA polymerase I in a
total reaction volume of 25 pi. The reaction was left at room
temperature for at least two hours.
The oligolabelled probe was separated from unincorporated DNA on
a small Sephadex G-50 column made in a glass pipette. The
disintegrations per minute were counted in a Bioscan QC.2000 counter.
4.5.5 Preannealing
Two of the probes, HPRT and p212 (DXS178), were preannealed with
sonicated human DNA because they cross hybridised with human
repetitive DNA sequences. The labelled probe was placed in an
eppendorf in a final concentration of 2.5mg/ml sonicated human DNA and
5 X SSC. The mixture was boiled for 10 minutes to denature the DNA and
then incubated at 65°C for thirty minutes to allow the repetitive
sequences to anneal. The preannealed probe mixture was then added to
hybridisation solution and used to hybridise filters as described
above.
The protocol given by Vogelstein with his probe PGK included a
preannealing step using sonicated salmon sperm DNA to reduce the
background on the autoradiographs. The labelled probe was placed in an
eppendorf in a final concentration of lmg/ml sonicated salmon sperm
and 5 X SSC. The mixture was boiled for 10 minutes to denature the DNA
and the incubated at 65°C for thirty minutes prior to use.
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4.6 Pulsed Field Gel Electrophoresis
Pulsed field gel electrophoresis requires high molecular weight
DNA. DNA prepared by normal methods undergoes shearing during the
pipetting procedures and therefore is not satisfactory for this
technique. DNA for pulsed field gel electrophoresis is prepared in
agarose blocks as described below. In addition when handling the
agarose blocks or any of the solutions contamination by nucleases or
pysical damage will result in smaller DNA. All solutions used were
sterile. Blocks were manipulated using glass pipettes which were
sterilised by holding in a flame which also allowed the end to be
sealed and a hook to be formed. When blocks had to be moved they were
usually cooled to 4°C first as this made them more rigid and less
likely to be broken.
4.6.1 Preparation of DNA from Lymphocytes
High molecular weight DNA was prepared in agarose blocks from
fresh lymphocytes and EBV transformed cells. Lymphocytes were prepared
from blood samples taken into preservative free heparin by separation
on a Ficoll-Hypaque gradient as described in section 4.7.1. EBV
transformed cells were taken during active cell division i.e. 24-48
hours after splitting as overconfluent cells contain more
mitochondrial DNA. They were also separated on a Ficoll-Hypaque
gradient to remove any dead cells and debris and so reduce the amount
of degraded DNA in the final sample.
Cells were suspended in sterile PBS at 14.3 X 106 per ml so that
when the blocks were formed there were 0.5 X 106 diploid cells per
block. As each haploid cell contains 6 pg DNA this is equivalent to
3pg per block. The same amount of DNA was used per block throughout
all the experiments as it has been reported that migration is faster
with a lower concentration of DNA and that excessively overloaded
lanes hardly focus at all.
The blocks were made in a perspex block formers (LKB). The base
of these were sealed with tape and they were precooled on ice. The
cell suspensions were mixed with an equal volume of 1% ultra-pure low
melting point agarose in PBS which had been melted and then kept at
42°C. 70pl aliquots of the mixture were immediately dispensed into the
wells of the block former. Precooling the block former helped the
agarose to set quickly before the cells settled so that the DNA was
evenly distributed throughout the block. The block formers were then
left at 4°C for 45 minutes. At the end of this time the tape was
removed from the bottom of the block former and the blocks gently
tapped out onto clean clingfilm and transferred to falcon tubes for
protein digestion.
Ten agarose blocks were added to 2.5 mis of 0.5M EDTA pH8, 1%
SDS and 2mg/ml proteinase K in each Falcon tube. This was incubated
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fc- 48 hours at 50°C, inverting the tube occasionally. The blocks
were then washed to remove the protein digestion buffer by adding TE
buffer to the top of the Falcon tube allowing the blocks to sink to
the bottom and decanting the TE. This was repeated three times and the
tube then filled with TE plus 0.04 mg/ml PMSF
(phenylmethylsulphonylfluoride, freshly prepared in anhydrous
isopropanol) and incubated for 30 minutes at 55°C. The fluid was
decanted and this last step repeated. The blocks were then ready for
use or storage in 0.5M EDTA pH8 at 4°C. Blocks stored in this way were
washed twice for thirty minutes in TE to remove the EDTA prior to
digestion.
4.6 2 Restriction Enzyme Digestion
Restriction enzyme digests were carried out in 1.5 ml eppendorf
tubes. All the solutions including the enzyme were placed in the tube
and mixed by vortexing before the addition of the block. 20 units of
enzyme were used for digestion of each block following the buffer and
temperature conditions recommended by manufacturer but adding lOOpg of
bovine serum albumin. The final volume including the 75pl agarose
block containing the DNA was 200pl. Sfi partial digests were generated
by stopping digestion after fifteen, thirty or fortyfive minutes by
addition of lOpl of 0.5M EDTA and placing the eppendorf on ice. NotI
digests were done overnight. To generate double digests digestion was
carried out with one enzyme first, the agarose block was then tipped
into a plastic weighboat and washed with sterile water and then added
to an eppendorf containing the second buffer and enzyme. With the
exception of deliberate partial digests and NotI digests the blocks
were digested for 4 hours in each enzyme.
4.6.3 Preparation of the Gel and Electrophoresis
LKB pulsed field gel electrophoresis apparatus was used with the
clamped homogeneous electric field electrode array. Two litres of \ x
electrophoresis buffer was put into the electrophoresis tank and
precooled for 2 hours before starting electrophoresis, with the
cooling system set to 8°C. The concentration of the electrophoresis
buffer was reduced because using standard electrophoresis buffer the
cu'/rent rose during the run and invariably became a limiting factor
resulting in a drop in voltage. Using 20mM Tris, lOmM sodium acetate,
ImM EDTA the current rose only a small amount during the run, never
becoming the limiting factor and so conditions could be reliably
reproduced.
'
"A 1% agarose gel in k x electrophoresis buffer was poured in the
LKB mould and precooled to 4°C. The eppendorfs containing the digested
DNA blocks were placed on ice for thirty minutes. The blocks were then
tipped out into clean weigh boats. The blocks were manipulated into
36
the wells of the gel using glass pipettes as described above.
Saccharomyces cerevisiae markers, made by M O'Reilly, were put into
the wells at each end of the DNA tracks and, depending on the number
of lanes run, a marker track was also run in the middle of the gel.
The loaded gel was then submerged in the electrophoresis buffer in the
tank. The switch times and length of run were adjusted to give maximal
separation in different size ranges.
4.6.4 Staining the Gel
The gel was stained with 20pg/ml ethidium bromide in running
buffer for twenty minutes and then destained in running buffer for at
least one hour with one change of buffer. The gel was placed next to
the ruler on the ultraviolet transilluminator and photographed.
4.6.5 Transfer of the DNA
Large DNA fragments will not transfer and therefore the very
large fragments of DNA in the pulsed field gel had to be nicked before
transfer. This was done by placing the gel in 240mM HC1 for twenty
minutes (acid depurination). The gel was then rinsed in denaturing
solution and then denatured and neutralised using the standard method
(section 4.4.1). The blot was set up as shown in figure 4.1 but
transfer continued for 36 hours changing the towels several times
during the process. The filter was then marked and baked for two hours
at 80°C.
4.6 6 Prehybridisation and Hybridisation of Filters
Initially the hybridisation solution and conditions described in
section 4.4.2 were used. However, it was found that the addition of
dextran sulphate at a final concentration of 10% in the hybridisation
solution improved the band intensity of the autoradiographs.
4.6.7 Washing Filters
The filters were washed using the protocol described in section
4.4.3. After use filters were stripped as described in section 4.4.4
and stored at room temperature between sheets of tissue paper until
re-probing.
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4.7 Preparation of Cells
4.7.1 Purification of Mononuclear Cells
Heparinised venous blood was diluted with an equal volume of RPMI
1640 supplemented with 25mM Hepes. This was layered onto Ficoll-
Hypaque (specific gravity 1.077) in a 2:1 ratio. The sample was
centrifuged at 1250g for 20 minutes at room temperature with the
centrifuge break off. Mononuclear cells were collected from the
interface and made up to an equal volume with RPMI 1640 then
centrifuged at 200g for 15 minutes at room temperature. The pellet was
gently resuspended and washed twice in RPMI 1640, 25 mM Hepes and 5%
fetal calf serum. Cell viability was assessed by trypan blue
exclusion.
4.7.2 Purification of T Lymphocytes
Peripheral blood mononuclear cells were resuspended at 5 x 106/ml
and 0.5mls of 10% S-2-aminoethylisothiouronium bromide hydrobromide
treated sheep red cells (Kaplan and Clark, 1974) were added to each 2
mis of mononuclear cells and the fetal calf serum concentration
increased from 5% to 15% to prevent the rosettes clumping. The tube
was centrifuged at 200g for 15 minutes with the brake off and then
placed on ice for one hour. The rosettes were then resuspended by
gentle rotation of the tube and the cell suspension layered onto
Percoll ( specific gravity 1.080) in a 2:1 ratio. The sample was
centrifuged at 1250g for twenty minutes at room temperature with the
brake off and then the interface containing the non-rosette forming
cells, the E~ fraction, was removed. The remaining Percoll layer was
aspirated, taking care not to disrupt the red cell pellet, and
discarded. The pellet was resuspended in 5mls of Gey's solution for
one minute (appendix 2) and immediately after red cell lysis diluted
with wash medium. The E~ cells were resuspended in wash medium and
both the E+ and E- cells were washed twice. Cell purity was assessed
by monoclonal antibody staining and viability by trypan blue exclu¬
sion.
4.7.3 Purification of Granulocytes
Granulocytes were purified from the red cell pellet remaining
after Ficoll Hypaque separation for the purification of mononuclear
cells. An equal volume of RPMI 1640 was added to the pellet followed
by an equal volume of Dextran sulphate. These were mixed by inversion
and left at room temperature for 40 minutes to allow red cell
sedimentation. The upper phase containing the granulocytes was then
aspirated, and washed three times.
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4.7.4 Counting Cells
An aliquot from the cell suspension was mixed with an equal
volume of trypan blue. The number of viable cells was counted by
trypan blue exclusion on a haemocytometer.
4.7.5 Monoclonal Antibody Staining
The purity of the E positive cells, E negative cells and
granulocytes was assessed using the monoclonal antibodies B1(CD20),
UCHM1(CD14), T3(CD3), HNK1 and TG1(CD15). This was carried out by
staff in the clinical immunology laboratory.
4.7.6.Establishing Epstein-Barr Virus Transformed B Cell Lines
5-20 X 106 mononuclear cells or E_ cells were incubated with 1ml
of supernatant from the EBV secreting B958 marmoset line for 1 hour at
37°C for 1 hour. The cells were then washed twice resuspended at 106
cells/ml in culture medium (appendix 2) and lug/ml cyclosporin A and
dispensed into the wells of a 24-well Costar plate. The outer wells of
the plate were filled with sterile water to prevent evaporation of the
culture medium. The plates were incubated at 37°C in 5%C02 in air. The
cell lines were expanded into culture flasks when established.
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4.8 Data Analysis
Data was prepared for analysis using LINKSYS (Attwood and Bryant,
1988). Two point linkage was carried out using LIPED (Ott, 1974).
Multipoint linkage analysis was carried out using the LINKMAP section
of LINKAGE version 4.7 (Lathrop et al, 1984).
The output files from LINKMAP analysis give information about
points on the map in the form of -2 In likelihoods. To generate
location scores from these the -2 In likelihood at 0.5 recombination
from the markers at the left and right of the fixed map is subtracted
from the -2 In likelihood at the point of interest. The figure is
divided by 2 to give the In likelihood. In order to convert the
resulting number to a log10 location score it is divided by 2.303.
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CHAPTER 5. Mapping Results
5.1 Ordering Probes on the Long Arm of the X Chromosome
5.1.1 Families
Recombinations were noted on proximal Xq in four families. These
four families were used as a reference panel for ordering probes
between Xpll and Xq22. Family MAN had been collected for linkage
studies to localise Bruton's agammaglobulinaemia and was included in
this study after a recombination was observed between pDP34 and the
disease locus in one of three affected sons. Family BER had been
collected for linkage studies to localise severe combined
immunodefieciency and was included in this study after observing a
crossover between the disease locus and 19.2. Family LIT was referred
for the prenatal diagnosis of X-linked ectodermal dysplasia and
included in this study after a recombination was observed between the
disease locus and the most closely linked probe at the time of
referral, pDP34 (MacDermot et al, 1986). Family HIS was also referred
for genetic counselling. The affected males had choroideremia, mental
retardation and additional neurological findings. They were included
in this study after a recombination was observed between the disease
locus and pDP34 which is closely linked to choroideremia.
5.1.2 Probes
These families were investigated using a panel of 14 DNA markers
detecting restriction fragment length polymorphisms between Xpll and
Xq22 (Table 5.1).
Locus Probe Name Regional Assignment
DXS146 pTAKS pll-ql2
DXS1 P8 qll-ql3
DXS159 cpX289 pll. l-q21. 3
PGK1 pSPT/PCX ql3
DXS106 cpX203 pll-q21. 3
DXS72 pX65H7 ql3-q22
DXYS1 pDP34 ql3-q21. 1
DXS3 pl9. 2 q21. 3-q22
DXS94 pXG12 qll-ql3
DXS178 p212 qll-qter
DXS17 S21/S9 q21. 3-q22
DXS87 pA13. R1 q21-q24
DXS88 G3-1 qll-q22
DXS255 M37J3 pll.3-centromere
Table 5.1 Regional assignments of the probes based on information
available at the start of the study (Eighth Human Gene Mapping
Meeting). M270 (DXS255) was described after this Meeting (Fraser et
al, 1987). Details of the polymorphisms are given in Appendix 1.
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5.1.3 Analysis of Recombinant Chromosomes
Cosegregation of alleles was used to place probes above or below
the site of the crossover. There were at least 11 crossovers
observed on 10 recombinant chromosomes. No linkage analysis was
carried out because the sample was selected for recombinations and
therefore biased.
The probes p8, pTAK8, pXG12 and the PGK1 locus were mapped
proximal to the XY homologous region, pDP34 within it and 19.2, S21,
pA13.Rl distal to it at the Eighth Human Gene Mapping Meeting (Human
Gene Mapping 8, 1985). The localisation of pXG12 was revised to
Xq21.3-q22, distal to the region of homology, prior to this study
(Malcolm et al, 1987). cpX289, cpX203, pX65H7, pG3-l and p212 were not
localised proximal or distal to the region of XY homology at the
Eighth Human Gene Mapping Meeting. Table 5,2 is a summary of the results
from the 10 chromosomes where recombinations were observed within
haplotypes. It shows the number of recombinations and the number of
informative meioses for cpX289, cpX203, pX65H7, pG3-l, p212 and pXG12
against probes on proximal Xp, and probes on the long arm proximal to,
within and distal to the XY homologous region. M27{3 was used as the
short arm probe. Five of the 10 recombinant chromosomes gave
information for p8 and six for PGK. As there were no recombinations
between PGK and p8 they are considered as a haplotype for the region
proximal to the homologous region. pDP34 was chosen as the probe
within the region of homology. 19.2 was chosen as the probe distal to
the region of XY homology.
NE7j3 PGK and p8 pDP34 19. 2
cpX289 0/7 0/6 3/9 5/7
pX65H7 0/5 0/6 2/7 4/5
cpX203 0/4 1/4 3/5 5/6
p212 2/2 2/2 1/2 1/2
G3-1 1/2 - 0/2 1/2
pXG12 1/1 1/2 1/2 0/1
Table 5.2 Recombinations observed between unassigned probes and a
probe on the short arm of the X chromosome, and probes on the long
arm localised proximal, within or distal to the XY homologous region.
The number of informative meioses is given as the denominator.
The probes are plotted as haplotypes (figure 5.1) in the order
giving the least number of recombinations per chromosome. The probes
are placed proximal or distal to the region of XY homology based on
the HGM8 assignments for pTAK8, p8, PGK1, 19.2, S21, and pA13.Rl and

























Figure 5.1 Diagramatic representation of the recombinant chromosomes.
The probes are shown on the left hand side. Informative loci are
represented by circles. Open circles correspond to loci derived from
one maternal X chromosome and closed circles correspond to the other
maternal X chromosome. Chromosome MB shows the deletion of pDP34 and
19.2 in patient MB who has choroideremia. A indicates absence of probe
hybridisation to DNA from patient MB.
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In these four families no recombinations were observed between
M27J3, pTAK8, p8, cpX289, pSPT/PGK or pX65H7. There is one
recombination between cpX203 and pSPT/PGK and p8 consistent with
cpX203 being proximal to p8 (recombinant chromosome 6). The meiosis
leading to this recombinant chromosome was not informative for cpX289,
pX65H7, pTAK8 or M27p.
The recombination on recombinant chromosome 1 (figure 5.1) places
p212 distal to 19.2. There is no information however about the order
of p212 relative to pXG12 or S21. Neither is there any information
about the order of pXG12 relative to 19.2 or S21.
The two recombinations between 19.2 and S21 do not resolve the
order of the two probes. One of the recombinant chromosomes
(recombinant chromosome 8 in figure 5.1) is also informative for pDP34
which segregates with 19.2 but not S21 suggesting that S21 is distal
to 19.2. The second chromosome with a recombination between 19.2 and
S21 is not informative for pDP34 (recombinant chromosome 9 in figure
5.1). With either order there would be two crossovers on one of the
recombinant chromosomes.
Two meioses gave information about the position of G3-1,
recombinant chromosomes 3 and 4 in figure 5.1. Neither of these
meioses were informative for pXG12, S21 or p212. On recombinant
chromosome 3 the crossover occurs between pX65H7 and the XY homologous
region. G3-1 segregates with the XY homologous region and 19.2 on this
chromosome and recombines with pX65H7 and more proximal probes. On
recombinant chromosome 4 there is a crossover between 19.2 and G3-1
with G3-1 segregating with all the informative probes in and proximal
to the XY homologous region. This data places G3-1 between pX65H7 and
19.2.
5.1.4 Deletion Mapping
Family MB was referred for prenatal diagnosis. The affected male
had choroideremia and mental retardation. His mother and sister had
been seen by an ophthalmologist and found to have the clinical
features of carriers of choroideremia. On investigation the X
chromosome allele of pDP34 was deleted in the affected male. Both a Y
specific and an X chromosome specific pDP34 allele was present in the
fetus. When examined at eighteen months of age the child was
developing normally and had no abnormalities on ophthalmoscopy.
The affected male was investigated using the panel of X linked
probes. He was deleted for pDP34 and 19.2 but not for any of the









Figure 5.2 Pedigree MB showing the pDP34 and 19.2 alleles. I2 and U2
are hemizygous for both probes.
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5.1.5 pG3-l and pA13.Rl
These probes were isolated from a wes 19/20 flow sorted library.
pG3-l is a l.Okb EcoRI/BamHI fragment cloned into pBR328 and pA13.Rl is a
1.6kb EcoRI fragment cloned into pBR328. In the original description they were
given different physical localisations and different allele frequencies
(Upadhyaya et al, 1986). It was noted when rehybridising a nylon filter that
the upper allele detected by the probes was in the same position at 4.7kb. The
lower allele was 3.5kb for pG3-l and l.lkb for pA13.Rl. The sum of the two
lower alleles is 4.6kb, approximately the size of the upper allele for both
probes. pA13.Rl detects a constant band at 5.4kb in addition to the
polymorphic bands. When these probes were hybridised to a filter with BamHI
digested DNA both hybridised to the same band. In addition complete
disequilibrium was noted between the alleles. These two probes therefore











Figure 5.3 The Position of Probes A13.R1 and G3-1 Relative to the Same Bglll
Polymorphic Site.
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5.1.6 Pulsed Field Gel Electrophoresis Results
The pXG12, p212 and S21 bands generated by hybridising filters
with DNA digested with Sfi, NotI, BssHII and Sfi/NotI, Sfi/BssHII
double digests are listed in table 5.4. A photograph of one of the
gels used in obtaining this information and the corresponding
autoradiographs are shown in figure 5.4.
Sfi Sfi/NotI NotI Sfi/BssHII BssHII




p212 180 180 LM 180 505
400 LM LM






Table 5.4 Band sizes in kilobases detected by the probes pXG12, p212
and S21. LM indicates hybridisation to the region of limiting
mobility.
The band sizes recorded for the Sfi partial digests were
generated by rehybridisation of filters with the three probes.
Differences between the results are, therefore, not due to different
degrees of Sfi digestion or differences in calibration of filters. The
bands detected by the probes do not coincide at the top of the
ladders. These probes have not been physically linked using Sfi
partial digests.
All three probes hybridised to the limiting mobility region in
the NotI tracks. The probes also hybridised to the limiting mobility
in the BssHII tracks but, in addition, a 425kb band was detected by
pXG12 and a 505kb band by p212. The bands seen in the Sfi/NotI double
digest tracks were Sfi bands, no new bands were generated by these
digests. The bands detected by p212 and S21 in the Sfi/BssHII double
digests were Sfi bands. A new band of 210kb was detected by pXG12 in
the Sfi/BssHII double digest.
Hybridisation of the filter from the gel shown in figure 5.3 with
these three probes did not give a clear band in the Sfi/Hpall track.
In all three cases a smear was seen of less than 120kb.
The total length of the Sfi bands detected by the probes was
1.575 megabases. Adding the BssHII bands onto the restriction map
gives a total length of 1.895 megabases detected without linking any
of the three probes.
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Figure 5.4a Photograph of Ethidium Stained Gel following 39 hour
electrophoresis at 170 volts using the CHEF electrode configuration,
buffer temperature 12.5°C, switch time 70 seconds. From left to right
the tracks are marker, Sfi partial, Sfi/NotI, NotI, Sfi/BssHII,
BssHII, Sfi/Hpall, Sfi partial and marker. The S.cerevaciae yeast












Figure 5.4b Autoradiograph of the filter from the gel in figure 5.4a
hybridised with pXG12. The position and size of the yeast bands are
marked on the figure. The smallest band using this strain is a
fragment of S.cerevaciae chromosome 7. The chromosome sizes were
calculated by D.Williamson, National Institute for Medical Research,
Mill Hill (personal communication)
The 620 kb Sfi band, 425kb BssHII band and the 295kb and 210kb Sfi/BssHII














Figure 5.4c Autoradiograph of the filter from the gel shown in figure
5.4a hybridised with p212. The position and size of the yeast bands
are marked on the figure. The smallest band using this strain is a
fragment of S.cerevaciae chromosome 7. The chromosome sizes were
calculated by D.Williamson, National Institute for Medical Research,
Mill Hill (personal communication)





Figure 5.4d Autoradiograph of the filter from the gel shown in figure 5.4a
hybridised with S21. The bands on this autoradiograph were not clear enough
to give accurate size estimations. The S21 band sizes in Table 5.4 were based
on hybridisation of filters from different gels.
5.2 Localisation of X-linked Diseases
The clinical features and investigation of two of the families
that had recombinations on the long arm of the X chromosome and were
used in the probe ordering study are described in detail below. In
these two families, which were clinical referrals, the results of DNA
investigation did not fit with the available information about the
disease localisation.
5.2.1 Choroideremia
Family HIS was referred for genetic counselling. The three males
in generation II had the ophthalmological findings of choroideremia.
The notes from the referring hospital state that all three had mental
retardation, in addition II2 had signs of mild spastic cerebral palsy
and II3 had cerebellar ataxia, dysarthria and nystagmus. The
diagnosis of choroideremia had been confirmed by ophthalmologists at
The Hospitals for Sick Children, Great Ormond Street. Unfortunately
the family did not wish the affected males to be re-examined at the
time of referral for genetic counselling. The fundi of both of the
females in the pedigree had the classical appearance found in carriers
of choroideremia. Neither of the women had mental retardation or
abnormal neurological findings.
They were investigated using the panel of DNA probes in table
5.1. The mother, I2, was informative for only five of the fourteen
probes - M27J1, cpX289, pDP34, 19.2 and S21. As both mother and
daughter were heterozygous for cpX289, pPD34, 19.2 and S21 the
haplotype in II4 was deduced from the paternal haplotype. Paternity
was checked using pXg3 (Jeffreys et al, 1988).
The disease did not segregate with any of these five informative
probes in the three affected males. The results were analysed using
the LINKMAP section of LINKAGE 4.7. The probability of the disease
locus being between the probes cpX289, pDP34 and 19.2 was considered
using a distance of 8 cM between cpX289 and pDP34 and 4.4 cM between
pDP34 and 19.2 (Arveiler et al, 1987). The results are shown in figure
5.6. The maximum lod score between cpX289 and pDP34 was -1.85 and the
maximum lod score between pDP34 and 19.2 was -2.39.
Cytogenetic analysis in the three males failed to reveal a
microsocopic deletion on the X chromosome. All fourteen probes tested
gave a hybridisation signal with DNA from the affected males.
Following a report that plbD5 (DXS165) failed to hybridise to DNA from
two out of eight males with choroideremia (Cremers et al, 1987) a
filter of DNA samples from the three males was sent to H-H Ropers who
kindly hybridised it with this probe. This sequence and the probes
pJL8 and pJL68, which were generated by reassociation techniques from
a patient with a deletion of the X chromosome and choroideremia










Figure 5.5 Pedigree HIS showing haplotypes for the probes M27J3,
cpX289, pDP34, 19.2 and S21. + indicates presence of a polymorphic
site and - indicates absence of the polymorphic site. Recombinations









Figure 5.6 Multipoint linkage analysis using LINKMAP to calculate the
probability of the disease locus in pedigree HIS lying between cpX289
and 19.2 using a framework of cpX289, pDP34 and 19.2. A recombination
distance of 8 cM was used between cpX289 and pDP34, and a
recombination distance of 4.4 cM between pDP34 and 19.2.
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5.2.2 Hypohydrotic Ectodermal Dysplasia
Family LIT (figure 5.7) was referred for predictive testing for
ectodermal dysplasia. The affected male 11^ had few conical shaped
teeth and fine sparse hair. He had periorbital pigmentation but his
nasal bridge appeared normal. His nipples were absent. The
distribution of subcutaneous fat was normal. His parents gave a
history of poor sweating and heat intolerance. A whole back starch and
iodine sweat test was performed and sweat pores were present over most
of his back but absent from the nape of his neck. Fingertip
impressions were made in dental impression material. The sweat pore
count was normal and the dermatoglyphic pattern was well preserved.
In addition to the findings which led to the diagnosis of hypohydrotic
ectodermal dysplasia he had reflux nephropathy secondary to ureteric
valves and had a unilateral nephrectomy because of this.
His mother lacked both mandibular first premolars and the left
lateral incisor in the maxilla. Her right lateral incisor in the
maxilla was abnormally pointed and both mandibular incisors were
small. She had pale, fine hair and was noted to have an accessory
nipple. Both individuals in generation I were reported to be normal
but not examined.
Subject II2 lacked both upper lateral incisors. She had pale,
fine hair and eczema. The third sister, II3, lacked a right upper
lateral incisor and her left upper lateral incisor had been extracted
because it was small and pointed. Her appearance differed from her two
sisters as she had thicker, dark hair. Her sons, dizygotic twins, have
no features of the condition.
A whole back sweat test was carried out on all three sisters and
was normal. Dental X rays were examined from all four women. There was
definite hypodontia in subject II x and a suggestion of hypodontia in
subjects I2, II2 and II3.
The referral diagnosis of HED was confirmed in the affected boy.
Taking two missing or abnormally shaped teeth as being diagnostic of
carrier status when there is a family history, all three sisters were
diagnosed as carriers. The accessory nipple in subject II3 was further
evidence that she is a gene carrier. Blood samples were taken for DNA
extraction and analysis.
The results are shown on the pedigree in figure 5.6. The order of
the probes on which the haplotypes are based is (M27£ - pTAK8) -
cpX203 - p8 - cpX289 - pSPT/PGK - pX65H7 - pDP34 - 7b - 19.2 - pXG12 -
S21 - G3-1. This order is based on studies of somatic cell hybrids,
deletions (Arveiler et al, 1987; Mahtani, Willard, 1988) and results
in this thesis. Recombinations have occurred within this haplotype in
four out of six meioses in females. In the meiosis leading to IIX a
recombination has occurred between pX65H7 and pDP34. In the meiosis
leading to II3 a recombination has occurred between pDP34 and 19.2 and
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a second recombination between 19.2 and G3-1. In the meiosis leading
to Illi a recombination has occurred between pDP34 and pXG12. Finally
in the meiosis leading to III2 a recombination has occurred between
cpX203 and p8.
The segments of the X chromosome that the three sisters have in
common from the maternal haplotype are between pX65H7 and 19.2 and
distal to 19.2. The affected boy has inherited the region between
pX65H7 and 19.2 from his grandfather. The two normal boys in
generation III also inherited this region of the X chromosome from
their grandfather. The disease does segregate with the region distal
to 19.2.
The HED locus is thought to lie between cpX289 and PGK1 (Zonana
et al, 1988a; Zonana et al, 1988b). The meiosis leading to the
affected male was informative for both of these probes and the














































































Figure 5.7 Pedigree LIT with haplotypes. + indicates presence of a
polymorphic site and - indicates its absence. As M27J3 is a length
polymorphism the alleles are referred to as a and b. Recombinations
are marked by arrows.
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5.2.3 Severe Combined Immunodeficiency
Five families with XSCID were investigated using the probes
cpX203, p8, cpX289, pSPT/PGK, pX65H7 and pDP34.The families and the
haplotype results are shown in figure 5.8. The order of the probes in
the haplotypes has been established by studies of somatic cell hybrids
derived from females with X;autosome translocations (Arveiler et al,
1987), males with X chromosome deletions (Schwartz et al, 1988) and
the analysis of recombinant chromosomes presented in this thesis. The
haplotype for subject I2 of pedigree HAL is ambiguous but there are no
crossovers between the five informative probes in any of the possible
haplotypes.
There were no recombinations between XSCID and p8, cpX289,
pSPT/PGK or pX65H7. Calculating two point lod scores using obligate
carrier females and their male offspring only, the maximum two point
lod scores between XSCID and p8, cpX289, pSPT/PGK, and pX65H7 were
1.7, 2.61, 1.63 and 2.31 respectively, all at 0 = 0. Including females
whose carrier status had been established by X inactivation patterns
the maximum two point lod scores between XSCID and p8, cpX289,
pSPT/PGK, and pX65H7 were 1.7, 3.21, 3.01, and 2.91 respectively, all
at 0 = 0.
A recombination was observed between the disease and cpX203 in
subject II2 of pedigree TEB and between the disease and pDP34 in
subject IVx of pedigree KHA. In the first the recombination occurred
between cpX203 and cpX289, the meiosis was not informative for p8. In
the second the recombination occurred between pDP34 and cpX289, the
meiosis was not informative for pSPT/PGK and unfortunately no result
was obtained for pX65H7 for this individual.
LINKMAP analysis was carried out using the probes cpX203, cpX289,
pSPT/PGK and pDP34. Females whose carrier status had been established
by X inactivation patterns were included in the analysis. There is no
figure for the cpX289-cpX203 distance. The p8-cpX289 distance is 1 cM
(Arveiler et al, 1987) and p8 is between cpX203 and cpX289. The
cpX289-cpX203 distance used in the analysis was 2 cM. The distance
estimated between cpX289 and pDP34 is 8 cM (Arveiler et al, 1987).
There is no published estimate of the distance between cpX289 and
pSPT/PGK or pSPT/PGK and pDP34. Three analyses were carried out using
recombination fractions 0.02 0.01 0.07, then 0.02 0.04 0.04 and
finally 0.02 0.07 0.01 so calculating the lod score for varying
positions of pSPT/PGK between cpX289 and pDP34. The maximum lod
scores using LINKMAP were 5.11 at cpX289 and 5.03 at pSPT/PGK in the
first analysis (figure 5.9). The lod score at pSPT/PGK falls to 4.7 in
the second analysis and 4 in the third analysis with pSPT/PGK placed 7
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Figure 5.9 Lod scores calculated by LINKMAP analysis for the XSCID
locus with cpX203, cpX289, pSPT/PGK and pDP34 as fixed points. A
recombination rate of 0.02 was used between cpX203 and cpX289, 0.01
between cpX289 and pSPT/PGK and 0.07 between pSPT/PGK and pDP34.
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5.2.4 X-linked Agammaglobulinaemia
Two families, pedigrees CAS and MON, referred for counselling
after the initial localisation of XLA to Xq21.3-q22 (Malcolm et al,
1987) were investigated using the probes pXG12, S21, and p212. British
families used in the initial study were reinvestigated with the probe
p212. The pedigrees and results of families CAS, MON and the families
informative for p212 are shown in Appendix 3. Families CAS and MON
were informative for S21, with a lod score of 2.4 at 0 = 0, but were
uninformative for pXG12. Combining the data from these families with
other published data the maximum lod score is 12.9 at 9 = 0 for S21
and 6.6 at 0 = 0 for pXG12. No recombinations were observed between
the disease locus and p212 and the maximum lod score was 3.74.
One of the first XLA families to be documented was also
investigated (Jamieson and Kerr, 1962). The pedigree is shown in
figure 5.1Q Subjects IV4, IV5 and IV7 have died since the family was
first reported and subjects IV6, IV8 and IV9 have been born since
1962.
Two males, subjects IV4 and IV5, had been investigated in detail
when the family was first presented. Both had profound
hypogammaglobulinaemia and failed to produce any functional
antibodies. Subject IV4 developed a lower motor neuron paralysis
affecting the muscles of the right leg and although there was evidence
of infection with poliovirus type 2 and type 3 in the family he
produced no antibodies to their serotypes. He had a positive Mantoux
test indicating that his cell mediated immunity was normal. Both males
died in infancy of bacterial infections.
Subject IV9 has complete absence of circulating B cells in
peripheral blood and lacks all immunoglobulin isotypes. His bone
marrow has not been investigated for presence or absence of pre B
cells. He remains well on intravenous immunoglobulin replacement
therapy.
An additional seven males in the pedigree died at less than three
years of age. No females died in infancy. The cause of death in II2
was gastroenteritis, II5 bronchopneumonia, II6 miliary tuberculosis
and diarrhoea, and in III5, III6 and III9 bronchopneumonia. IV3
presented at six months of age with diarrhoea and failure to thrive
and after he died at eighteen months post mortem examination showed
miliary tuberculosis.
The surviving family members who could provide linkage
information were traced and samples taken for DNA extraction. DNA was
extracted from II3, II4, III4, III8 and IVx in Manchester. Filters of
TaqI digested and PstI digested DNA from these individuals were kindly
given by Dr A Read. An EBV transformed cell line from IV9 was
generously given by Dr C Roifman (Toronto).
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The results obtained for 19.2, pXG12 and S21 are shown on the
simplified pedigree in figure 5.11. The family was uninformative for
the probe p212. The obligate carrier sisters, III4 and III8 inherited
different alleles from their mother for the most closely linked
probes, pXG12 and S21. Their mother is homozygous for 19.2. III4 is
heterozygous for all three probes and her normal son has inherited the
grandmaternal haplotype. III8 is homozygous for pXG12 and S21. She is
heterozygous for 19.2 and her affected son has inherited the
grandmaternal allele. Thus the two obligate carrier sisters did not
inherit the same maternal X for the region Xq21.3-22 and both the
normal and affected males inherited that region of the X chromosome
from their grandmother.
Non-paternity or confusion over sample labelling was excluded
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Figure 5.11 Simplified pedigree showing 19.2, pXG12 and S21 results
on for individuals in the JAM pedigree from whom DNA was obtained.
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The data for 19.2, pXG12 and S21 were analysed using the LINKMAP
section of LINKAGE version 4.7 using a distance of 4 cM between 19.2
and pXG12 and 2 cM between pXG12 and S21 (Arveiler et al, 1987).
Fifteen points were calculated in each interval and therefore the
first figure calculated distal to S21 was for the position 3.3cM from
S21. The lod score at this position was -1.8. The maximum lod score
between 19.2 and pXG12 was -3.8 and between pXG12 and S21 was -6.5
(figure 5.12). As a lod of -2 is usually accepted as excluding linkage
this excludes linkage of the disease to Xq21.3-22 between 19.2 and S21




Figure 5.12 LINKMAP analysis of the 19.2, pXG12 and S21 results from
pedigree JAM to calculate the probability of the disease locus in this
family mapping to this region of the X chromosome.
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CHAPTER 6: Results of X Inactivation Studies
6.1 Use of X Inactivation Analysis for Carrier Detection
6.1.1 Information Content of Probes
Thirteen normal females were tested for polymorphisms for
pSPT/PGK and three heterozygotes were found. Two out of eighteen
normal females were heterozygous for the polymorphism detected by
HPRT. Seven obligate carriers of X-linked severe combined
immunodeficiency were tested. Two of these were heterozygous for the
pSPT/PGK polymorphism and none for the HPRT polymorphism. Twenty five
women at risk of being carriers of the disease were tested, nine were
heterozygous for pSPT/PGK and two for HPRT.
Combining these figures 8% of women were heterozygous for the
HPRT polymorphism and 31% of women were heterozygous for the pSPT/PGK
polymorphism. One woman of Asian origin was homozygous for the rare
allele of the HPRT polymorphism. The frequencies of the alleles
observed for the HPRT polymorphism were 0.94 and 0.06 in the 100 X
chromosomes tested and hence the probability of a woman being
heterozygous for this polymorphism is 11.3%. Approximately 40% of
women will therefore be heterozygous for one or both polymorphisms and
can be offered investigation.
6.1.2 Normal Controls
DNA extracted from the E positive cell fraction of two normal
females was shown to have a random X inactivation pattern using
pSPT/PGK and DNA from E positive cells of one control female was shown
to have a random pattern using HPRT (figure 6.1). In addition Fearon
has shown a random X inactivation pattern in E positive cells in one
female control with pSPT/PGK in one female control with HPRT (Fearon
et al, 1987).
6.1.3. Confirmation of Method in X-linked Pedigrees
There were three pedigrees which were clearly X-linked at the
start of the study. Two obligate carriers from these families were
heterozygous for the pSPT/PGK polymorphism, subject I2 in pedigree TEB
and subject II2 in pedigree KHA. DNA extracted from the E positive (T
lymphocyte enriched) fraction from both of these women showed a non
random pattern (figure 6.2). In both of these cases tracking a
haplotype of p8 - cpX289 - pSPT/PGK - pX65H7 in the family
demonstrated that the mutant gene was on the inactive X chromosome.
The obligate carrier in pedigree TEB was heterozygous for the
linked probe cpX289. Her daughter, subject II4 was at low risk of
being a carrier as she had received the same allele as her normal
brother and the opposite allele from her carrier sister (fig 5.8). She
was heterozygous for the polymorphism detected by pSPT/PGK and
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methylation analysis of DNA from E positive cells showed a random X
inactivation pattern consistent with these results (fig. 6.2)
The obligate carrier from pedigree KHA was homozygous for cpX289
itself but heterozygous for two probes flanking it. For both of these
flanking markers, cpX203 and pX65H7, her daughter, subject III7,
inherited the same allele as her normal brother and the opposite
allele from her affected brother and obligate carrier sister (fig
5.8). These results indicated that she was at low risk of being a
carrier. Subject III7 was heterozygous for the polymorphisms detected
by pSPT/PGK and methylation analysis demonstrated a random X
inactivation pattern in the E positive cell fraction (fig 6.2).
Pedigree BER (fig 5.8) is the third family with a clearly X-
linked pedigree. The haplotypes for the obligate carrier have been
inferred. The two obligate carrier sisters inherited the opposite
alleles from their at risk sister, subject II3, for the flanking
probes cpX203 and pDP34. Subject II3 was therefore at low risk of
being a carrier of the disorder. She was was heterozygous for the
pSPT/PGK polymorphism and had a random pattern of X inactivation in
the T cell enriched DNA.
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Figure 6.1a Analysis of X Inactivation in E positive Cells from Two
Control Subjects using the Polymorphism Detected by pSPT/PGK.
In the first and third tracks the DNA has been digested with PstI and
BstXI. In the second and fourth tracks the DNA has been digested with
Pstl/BstXI and Hpall. The 1.05 and 0.9kb polymorphic bands are
indicated by arrows. Both polymorphic bands are seen in all tracks.
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Figure 6.1b Analysis of X Inactivation in E Positive Cells from One
Control Subject using the Polymorphism Detected by HPRT.
The DNA has been digested with BamHI/PvuII in the first track,
BamHI/PvuII and Hhal in the second track and BamHI/PvuII and Hpall in
the third track. The filter has been hybridised with HPRT-600. The 18
and 12kb polymorphic bands are indicated by arrows. Both polymorphic
bands are of equal intensity in all tracks.
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Figure 6.2 Analysis of X Inactivation Patterns
Paired tracks have been run from each DNA sample. In the first track
from each sample the DNA has been digested with PstI and BstXI. In the
second track from each sample the DNA has been digested with
Pstl/BstXI and Hpall. The filters have been hybridised with pSPT/PGK.
The polymorphic bands are indicated by the arrows. Sample 1 is E
positive cell DNA from subject III2in pedigree KHA. Sample 2 is E
positive cell DNA, sample 3 is E negative cell DNA and sample 4 is DNA
from an EBV transformed cell line from the obligate carrier, subject
II2, in pedigree KHA. Sample 5 is E positive cell DNA from the
obligate carrier, subject I2, in pedigree TEB. Sample 6 is E positive
DNA from subject II4 in pedigree TEB. In both obligate carriers the
lower allele is absent after the addition of Hpall. In the E negative
cell DNA from the obligate carrier in pedigree KHA the lower allele is
absent after the addition of Hpall. Both polymorphic bands were
present after the addition of Hpall in the samples from their
daughters who were predicted to be at low risk of being carriers using
linked DNA probes.
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6.1.4. Testing for X-linkage
The proband in pedigree HAL is clearly a carrier of severe
combined immunodeficiency as she has had two affected sons, however
the disease could be autosomal recessive or X-linked recessive (figure
6.3a). Her mother had two brothers who died in infancy which is
suggestive of X-linked inheritance but no details were available. The
proband, her mother and both sisters were informative for the pSPT/PGK
polymorphism. The proband was found to have a non random pattern of X
inactivation in DNA extracted from the E positive cell fraction,
losing the 1.05kb band after the addition of Hpall (figure 6.3b). Her
mother and both sisters also had a non random pattern of X
inactivation in T cells, all losing the 1.05kb band after the addition
of Hpall.
Pedigree MOR (figure 6.4a) has a similar structure to pedigree
HAL. The proband had an affected male child who died in spite of bone
marrow transplantation. A fetal blood sample was taken for prenatal
diagnosis in her second pregnancy. There were no T lymphocytes and the
PHA response was absent. The affected male fetus was aborted. Prenatal
diagnosis was also carried out in the third pregnancy which resulted
in a normal male child. Having had two affected males diagnosed this
woman was either a carrier of autosomal recessive or X-linked
recessive SCID. She was heterozygous for the pSPT/PGK polymorphism.
Methylation analysis of DNA from the E positive cells showed a random
pattern of X inactivation (figure 6.4b) suggesting that in this family
the disease is autosomal recessive.
The proband in pedigree LAW has had only one child, a male with
SCID. Adenosine deaminase deficiency was excluded as the cause of the
disease. The affected child received a mismatched bone marrow
transplant but died. The proband has one normal brother and there is
no family history of males dying in infancy.
The proband was heterozygous for pSPT/PGK. Methylation analysis
showed a non random pattern of X inactivation and she is therefore a
carrier of the X-linked form of the disease.
The allele that is lost after the addition of Hpall represents
the active X chromosome and the allele that remains represents the
inactive X chromosome. In this case the band remaining, which
represents the X chromosome carrying the disease mutation, is the
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Figure 6.3b Analysis of X Inactivation Patterns in Pedigree HAL
Paired tracks have been run from each DNA sample. In the first track
the DNA has been digested with Pstl/BstXI and in the second track of
each sample the DNA has been digested with Pstl/BstXI and Hpall. The
filter has been hybridised with pSPT/PGK. Sample 1 is E positive cell
DNA from subject II2, sample 2 is E negative cell DNA from subject II4
and sample 3 is granulocyte DNA from subject II4. In all three samples
the 1.05kb band is absent after the addition of Hpall.




Figure 6.3c pSPT/PGK bands in a Bgll digest of DNA from subject II4 in
the first track and from the chorion sample in the second track.
Arrows indicate the 5 and 12 kb bands of the polymorphism. The fetus
has inherited the upper allele, which represents the X chromosome
carrying the normal gene.
Figure 6.3d pDP34 hybridised to TaqI digested DNA from a female
control, the chorion sample and a male control. The arrow indicates
the Y specific band. The 11 and 12 kb bands show the X chromsome






Figure 6.4a Pedigree MOR
Figure 6.4b X Inactivation Analysis of E Positive DNA from the Proband
in Pedigree MOR.
The DNA in the first track has been digested with Pstl/BstXI and the
DNA in the second track has been digested with Pstl/BstXI and Hpall.
The filter was hybridised with pSPT/PGK. Both bands remain after the
addition of Hpall.
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Figure 6.5a Pedigree LAW
Figure 6.5b X Inactivation Analysis. The three DNA samples are from E
positive cells, E negative cells and granulocytes from the proband in
Pedigree LAW. The DNA in the first track from each sample has been
digested with Pstl/BstXI and the DNA in the second track has been
digested with Pstl/BstXI and Hpall. The filter was hybridised with
pSPT/PGK. The 1.05 and 0.9kb polymorphic bands are indicated by
arrows. The 0.9kb allele is absent in the E positive, E negative and
granulocyte track after the addition of Hpall.
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The proband in pedigree EIS has one normal daughter and one son
who had severe combined immunodeficiency. He died three weeks after
his first admission to hospital at the age of seventeen months. The
proband has two normal brothers and there was no previous family
history of males dying in infancy.
The proband was heterozygous for the HPRT polymorphism. After the
addition of Hhal the 18kb band is fainter than the 12kb band and
after the addition of Hpall the 12kb band is lost when using HPRT-600
as the probe (figure 6.6). Using this probe in a sample with non
random X inactivation the band representing the inactive X chromosome
becomes fainter after the addition of Hhal and the band representing
the active X chromosome is lost after the addition of Hpall. This is
consistent with the proband being a carrier of X-linked disease and
with the 18kb allele representing the inactive X chromosome which
carries the disease mutation.
The proband's mother was heterozygous for the HPRT polymorphism
and her father had the 18kb band. Therefore the band representing the
inactive X chromosome in the proband has been inherited from her
father. Paternity was checked using two locus specific probes, M270
and pXg3, because if this had been a case of non-paternity the
subject could have inherited this allele from her heterozygous mother.
Clarifying this has important implications for the counselling of the
extended family.
The proband in this family is a carrier of the disease as the
result of a new mutation inherited from her father.
The couple in pedigree SPE have had one daughter and an affected
son who died in spite of bone marrow transplantation. The proband was
heterozygous for the HPRT polymorphism. Methylation analysis of DNA
extracted from the E positive cell fraction showed the normal random
pattern (figure 6.7). She is therefore not a carrier of the X-linked
form of the disease. Her son could either have carried a new mutation
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Figure 6.6b X Inactivation Analysis using HPRT
Tracks 1, 2, and 3 contain E positive cell DNA and tracks 4, 5 and 6
contain granulocyte DNA from the proband in Pedigree EIS. The DNA in
tracks 1 and 4 has been digested with BamHI and PvuII. The DNA in
tracks 2 and 5 has been digested with BamHI/PvuII and Hhal. The DNA in
tracks 3 and 6 has been digested with BamHI/PvuII and Hpall. The
filter was hybridised with HPRT-600. Arrows indicate the 18 and 12kb
polymorphic bands. In the BamHI/PvuII/Hhal tracks the 18kb band is
fainter than the 12kb band in E positive DNA (track 2) but not in
granulocyte DNA (track 5). In the BamHI/PvuII/Hpall tracks the 12kb
band is absent in the E positive DNA (track 3) but is present, and of
equal intensity with the 18kb band, in the granulocyte DNA (track 6).
The decreased intensity in the 18kb band in the Hhal track and the
absence of the 12kb band in the Hpall track of the E positive cell DNA
shows non-random use of the X chromosome in these cells. As the band
representing the active X chromosome is digested into smaller
fragments after the addition of Hpall but the band representing the
inactive X chromosome is digested into smaller fragments after the
addition of Hhal in approximately 90% of cases the 12kb represents the
active X chromosome. The presence of bands of equal intensity after
the addition of methylation sensitive endonucleases in the granulocyte
DNA tracks indicates random use of the X chromosome in these cells.
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Figure 6.6c X Inactivation Analysis of EBV Transformed Cell Lines.
The DNA in the first track has been digested with BamHI and PvuII to
show the position of the polymorphic bands. The DNA in the remaining
five tracks is from five EBV lines from the proband in Pedigree EIS
and has been digested with BamHI/PvuII/Hpall and hybridised with HPRT-
600. The two bands are of equal intensity in DNA from the first EBV
line. In the remaining four EBV lines the 12kb band is absent.
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Figure 6.7a Pedigree SPE
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Figure 6.7b X Inactivation Analysis of E Positive Cells from the
Proband in Pedigree SPE using HPRT.
The DNA in the first track has been digested with BamHI and PvuII. The
DNA in the second track has been digested with BamHI/PvuII and Hhal
and the DNA in the third track has been digested with BamHI/PvuII and
Hpall. The filter has been hybridised with HPRT-600. The presence of
bands of equal intensity after the addition of both methylation
sensitive endonucleases shows random X-chromosome usage in these
cells.
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6.1.5 Use of PGK for Carrier Detection and as a Linked Probe
It has been shown in section 5.2.3 that the probe pSPT/PGK, which
detects non-random X chromosome usage in heterozygous female carriers
of XSCID, is also linked to the XSCID disease locus. When methylation
analysis reveals a non-random pattern of X chromosome usage the allele
that remains after the addition of Hpall represents the inactive X and
hence the X chromosome carrying the defective gene.
In family HAL there are no males, normal or affected, who could
be used to assign phase. The three sisters are homozygous for the
linked probe cpX289. All four women are heterozygous for pSPT/PGK and
in all four the pSPT/PGK allele which remained after the addition of
Hpall was the 0.9kb band. The X chromosome carrying the defective gene
in these females is therefore the chromosome which has the BstXI
polymorphic site present.
During the time that the family was being studied the second
sister, II4, became pregnant for the third time. The couple were told
that she was a carrier of the disease and they requested prenatal
diagnosis. As she was homozygous for the polymorphism detected by
cpX289 this could not be used for prenatal diagnosis. They were
offered the following options: ultrasound sexing at eighteen weeks
gestation followed by fetal blood sampling in a male fetus, fetal
sexing on chorion villus sampling with termination of all males, or
DNA studies on chorion villus sampling to determine sex and also high
or low risk depending on the pSPT/PGK allele inherited. The couple
chose to have chorion sampling for determination of sex and DNA
analysis with pSPT/PGK, deciding to terminate a male fetus who had
inherited the allele carrying the high risk and to continue the
pregnancy if a male fetus had inherited the low risk allele but to
confirm this result on fetal blood sampling.
The results of the DNA analysis are shown in figure 6.3. The
BstXI and Bgll polymorphisms are in linkage disequilibrium. DNA
digested with Bgll was probed with pSPT/PGK and DNA digested with TaqI
was probed with pDP34 which detects a Y specific band. The fetus was
shown to be female using pDP34 and had inherited the low risk allele.
The proband in family LAW has been shown to be a carrier by
methylation analysis using pSPT/PGK (figure 6.5). The allele remaining
after the addition of Hpall was the 1.05kb band and the 0.9kb band is
no longer seen on the autoradiograph. The chromosome with the
polymorphic site therefore represents the normal X and the chromosome
that does not have the polymorphic site carries the defective gene. A
male fetus inheriting the pSPT/PGK lower allele when the DNA is
digested with BstXI or Bgll has a low probability of being affected
and a male fetus inheriting the upper allele has a high risk of being
affected.
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6.2 Use of X Inactivation to Investigate the Expression of the Gene
Defective in XSCID
Gene expression was studied in the E positive and E negative cell
fractions, granulocytes and EBV transformed cell lines. Seven of the
eight women above who were found to have non-random X chromosome usage
in their E positive cells were included in the study though results
were not obtained for all cell types on each woman. The results are
shown in Table 6.1.
Subject Pedigree Epos Eneg Adherent Granulocytes
1 KHA N N _ R
2 LAW N N N N
3 EIS N - - R
4 HAL N N - N
5 HAL N - - R
6 HAL N - - R
Table 6.1 Results of methylation analysis in E positive, E negative,
adherent cells and granulocytes in six subjects. N indicates non-
random use of the X chromosome. R indicates random use of the X
chromosome. When no result was obtained the symbol - is used.
6.2.1 Gene Expression in T Lymphocytes
The T lymphocyte enriched (E positive) fraction contained on
average 84% (range 74-93%) CD3 positive cells. In addition there were
7-23% HNK1 positive cells present. There was less than 1% B lymphocyte
(CD20) and monocyte (CD14) contamination in this fraction. As shown
above a non-random pattern was found in this cell fraction in all of
the carriers.
6.2.2. Gene Expression in E Negative Cells
The E negative fraction was shown to contain predominantly
monocytes, B lymphocytes and NK cells by specific monoclonal antibody
staining, but T lymphocyte contamination occurred in some
preparations. A result for this cell fraction was obtained in subjects
1, 2 and 4. A non-random pattern of X inactivation was found in all
three women. In addition a monocyte enriched fraction was kindly
separated by Dr R.Callard for subject 2 by plastic adherence. In this
population 46% of the cells were CD14 positive, 17% CD3 positive and
11% CD20 positive. This monocyte enriched fraction also showed a non-
random pattern of X inactivation.
6.2.3 Gene Expression in Granulocytes
The granulocyte fraction was 99% pure both by morphological
criteria and by immunofluorescence with the CD15 antibody. Variation
was found in the X inactivation patterns of the six subjects for whom
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results were obtained. Subjects 2 and 4 had a non-random pattern but
in subjects 1, 3, 5 and 6 two bands remained after Hpall digestion.
Not only was there variation between unrelated carriers but also
within a family. Subject 4 had a non-random pattern of X inactivation
in her granulocytes but her mother and sister, subjects 5 and 6, were
found to have a random pattern of X chromosome usage in their
granulocytes.
6.2.4 Gene Expression in B Lymphoctyes
As it was impossible to isolate sufficient B lymphocytes for DNA
extraction from the blood sample taken, multiple EBV transformed lines
were established from each subject. The lines were grown only until
sufficient cells (5 x 106) were available for DNA extraction to
minimise the possibility of the lines becoming oligoclonal. The X
inactivation pattern was investigated in individual lines. The number
of lines examined and the proportion showing non-random X chromosome
usage is shown in Table 6.2. In subject 2, ten individual lines were
tested and a non-random pattern found in each. The same X chromosome
was active in each of the ten EBV lines and this corresponded to the
active X in the woman's T lymphocytes. These results provide good
evidence that the defect causing XSCID is expressed in this woman's B
lymphocytes. In contrast, in subjects 3, 5 and 6 whilst some EBV
transformed B lymphocyte lines had become non-random others still
retained random use of the X-chromosome. No individual was found who
showed random X chromosome usage in all EBV transformed cell lines and
in each EBV line which became non-random the active X correspnded to









Table 6.2 Results of methylation analysis from individual EBV
transformed cell lines from six subjects. The number of lines with
non-random X chromosome usage is shown in the numerator and the number
of cell lines tested from each individual in the denominator. No
results were obtained from subject 4.
80
6.2.5 Gene Expression in Total Circulating Haematopoietic and Lymphoid
Cells
Analysis of DNA made from whole blood from subject 2 showed a
non-random pattern of X inactivation, as had her E positive, E
negative, monocyte and granulocyte preparation. Analysis of DNA
prepared from whole blood from the obligate carrier, II4, in pedigree
TEB also showed a non-random pattern of X inactivation. In this
subject the only other cell fraction investigated was the E positive
fraction which also showed loss of the lower band after the addition
of Hpall. In the remaining subjects the band representing the X
carrying the normal gene was fainter than the band representing the X
carrying the defective gene after the addition of Hpall but both bands
were still present (figure 6.8). X inactivation analysis of whole
blood would not be reliable for carrier testing.
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Figure 6.8 X Inactivation Analysis of DNA Extracted from Venous Blood
of Carriers of XSCID
The four DNA samples have been extracted from whole blood. The DNA in
the first track from each sample has been digested with Pstl/BstXI and
the DNA in the second track with Pstl/BstXI and Hpall. The filter was
hybridised with pSPT/PGK. The 1.05 and 0.9kb polymorphic bands are
indicated by arrows. The first sample is from subject II4 in pedigree
TEB. The second sample corresponds to subject 2, the third to subject
4 and the fourth to subject 5 in Tables 6.1 and 6.2.
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CHAPTER 7. Discussion: Mapping
7.1 Genetic Map of Proximal Xq
7.1.1 Order of Probes used in this Study
The investigation of both recombinant chromosomes and the X
chromosome deletion in patient MB have provided information about the
order of probes on proximal Xq.
From the recombinant chromosome data cpX289, cpX203 and pX65H7
are proximal to the XY homologous region along with M27J3, pTAK8, p8,
pSPT/PGK. Within this group order information was only obtained from
one recombinant chromosome. This placed cpX203 proximal to p8 and
pSPT/PGK but was uninformative for M27|3, pTAK8, cpX289 and pX65H7. No
information was obtained about the relative order of M27{3, pTAK8, p8,
cpX289, pSPT/PGK and pX65H7 or about the order of M27J3, pTAK8 and
cpX203 as there were no recombinations between them.
The recombinant chromosome data shows that the probes pXG12 and
p212 are distal to the XY homologous region along with 19.2 and S21.
One recombinant chromosome gave information about the position of p212
within the group suggesting a localisation distal to 19.2 which was
confirmed by the observation that p212 hybridised to DNA from MB. Two
recombinant chromosomes were informative for S21 but gave conflicting
information about its position relative to 19.2. This was resolved by
the MB deletion. S21 hybridised to DNA from MB and is, therefore,
distal to 19.2. pXG12 also hybridised to DNA from patient MB and is
therefore distal to 19.2.
Results presented here show that G3-1 and pA13.Rl detect the same
polymorphism in contrast to their different regional assignments at
HGM8 when pA13.Rl was assigned to Xq21-q24 and G3-1 to Xqll-22.
Recombinant chromosome 3 in figure 4 gives evidence for their
localisation distal to pX65H7. Recombinant chromosome 4 has only one
recombination if they are proximal to 19.2 but a double recombination
if they are distal to it. Explaining the data with the minimum number
of recombinations would, therefore, place G3-1 and pA13.Rl between
pX65H7 and 19.2. As they hybridised to DNA from patient MB the region
between pDP34 and 19.2 is excluded suggesting a localisation between
pX65H7 and pDP34.
The order based on the results in this thesis is (pTAK8 - M270 -
p8 - pSPT/PGK - cpX289 - pX65H7) - (pA13.Rl - G3-1) - pDP34 - 19.2 -
(pXG12 - S21 - p212) with cpX203 lying proximal to p8 and pSPT/PGK.
Studies using somatic cell hybrids from females with X;autosome
translocations and EBV transformed cell lines from males with X
chromosome deletions are in agreement with these findings for all but
the localisation of G3-1 and pA13.Rl. The results of this study and
other published work are discussed below. Combining all the
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information the order of the probes is (pTAK8 - M27j3) - cpX203 - p8 -
cpX289 - PGK - pX65H7 - pDP34 - 19.2 - (pXG12 - p212) - S21. The
position of G3-1 and pA13.Rl in this framework is not clear.
The results in the thesis place cpX203 proximal to p8 and
pSPT/PGK but give no information about its position relative to the
other probes in this group. Recent studies have shown pTAK8 and M27{1
present in a somatic cell hybrid (MOCH) cultured in 6-thioguanine
medium and derived from a female with incontinentia pigmenti and an
X;9 translocation with the X chromosome breakpoint pll.21 (Sefiani et
al, 1988). cpX203 is present in the hybrids grown by HAT selection. As
the translocation product with the long arm of the X chromosome active
is present in hybrids grown in HAT medium but not in hybrids grown in
medium containing 6-thioguanine pTAK8 and M27J3 are distal to Xpll and
cpX203 is proximal to Xpll. It is not clear from this data whether
cpX203 is on the short arm of the X chromosome or the long arm.
Five cell lines (AnLy, GM73, W4-1A, CerS and CerH,) have given
information about the order of p8, pSPT/PGK and cpX289. The
information from these cell lines is summarised in figure 7.1.
The AnLy cell line was derived from a female with X linked
hypohydrotic ectodermal dysplasia who had an X;9 translocation (Cohen
et al, 1972) with the X chromosome breakpoint at Xql3.1 (Zonana et al,
1988b). Hybrids made by HAT selection, and hence retaining the
translocation product with the long arm of the X chromosome, have
been shown to express the enzyme PGK by starch gel electrophoresis.
Cell lines grown in 8-azaguanine lose the chromosome expressing HPRT
and also lose PGK expression (Shows and Brown, 1974). The probes p8
and cpX289 do not hybridise to DNA made from the AnLy cell line which
contains Xql3.1-qter (Arveiler et al, 1987). These probes therefore
lie centromeric to the breakpoint and PGK distal to the breakpoint
Xql3.1. The cell line W4-1A containing Xql3-Xqter is also positive
for PGK but negative for cpX289 (Mahtani and Willard, 1988) and the
cell line GM73 which contains Xql3-Xqter is positive for PGK but
negative for p8 and cpX289 (Arveiler et al, 1987) adding further to
the evidence that p8 and cpX289 are proximal to PGK.
The order of p8 and cpX289 depends on information from two
somatic cell hybrids CerS and CerH which contain complementary
chromosomes of a reciprocal translocation X;22 (qll.2,ql3) (Hors-Cayla
et al, 1981). CerH contains Xqll.2-qter and expresses PGK while CerS
which contains Xpter-Xqll.2 does not express PGK. cpX289 hybridises to
CerH but not CerS placing it distal to Xqll.2. However p8 hybridises
to both of the cell lines (Arveiler et al, 1987). In addition two
probes from the short arm of the X chromosome hybridise to DNA from
the CerH hybrid implying that CerH has additional X chromosome DNA to
Xqll.2-qter. The results from CerS imply that p8 is proximal to the
breakpoint and cpX289 is distal to the breakpoint.
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Figure 7.1 Physical mapping of X-linked probes by hybridisation to
human-rodent cell hybrids and DNA from males with X chromosome
deletions.
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Information about the position of pX65H7 has been derived from
the cell line (TEL26). This cell line was made from a male with cleft
lip and palate, agenesis of the corpus callosum and severe mental
retardation who had an X chromosome deletion with breakpoints at Xql3
and Xq21.3 (Tabor et al, 1983). pX65H7 does not hybridise to DNA made
from this line (Schwartz et al, 1988). As p8, cpX289 and PGK all
hybridise to TEL 26 (Ivens et al, 1988) pX65H7 is distal to PGK.
Distal to the XY homologous region is the group of probes which
includes 19.2, pXG12, S21, and p212. Several studies confirm the
finding that 19.2 is proximal to S21, pXG12 and p212. Analysis of
TEL26 has shown that 19.2 is proximal to S21 (Schwartz et al, 1988)
and recombinations in family studies have shown that 19.2 is proximal
to pXG12 and p212 (Arveiler et al, 1987). Recombinations in Arveiler's
study also showed that both pXG12 and p212 are proximal to S21. There
is no evidence for the order of pXG12 and p212.
The original localisations given for G3-1 and pA13.Rl were Xqll-
q21 and Xq21-24 respectively (Upadhyaya et al, 1986). Combining the
data from recombinant chromosomes and the MB deletion suggests a
localisation between pX65H7 and pDP34. However, Schwartz presented
deletion mapping results at the Ninth Human Gene Mapping Meeting
placing pA13.Rl distal to 19.2 (Schwartz et al, 1987). No
information has been published about the position of G3-1 but as shown
in this study these probes detect the same polymorphic site.
Unfortunately Arveiler did not use either of these probes in his study
which was confined to probes detecting PstI or TaqI polymorphisms.
There is more evidence for a location distal to 19.2 from deletion
mapping than the localisation proximal to pDP34.
The localisation of G3-1 in this study hinges on one recombinant
chromosome. Accepting a localisation distal to 19.2 means that a
double recombination has occurred on this chromosome and shows that
the use of haplotypes on individual recombinant chromosomes can lead
to errors. In this study double recombinations occurred on two out of
ten recombinant chromosomes. One of the double recombinations occurred
between pDP34 and G3-1 and the genetic distance between these markers
is not known. The second occurred between pX65H7 and S21 which, based
on the results of Arveiler, are more than 10 cM apart (Arveiler et al,
1987). Whilst analysis of recombinant chromosomes can lead to errors
it is the only method of probe ordering that does not require
cytogenetic expertise and in this panel of probes provides the only
evidence for the order of pXG12 - S21 and p212 - S21.
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Somatic cell hybrids are an important tool in the localisation of
probes. Nearly all of the information about the order of M270, pTAK8,
cpX203, p8, cpX289 and the locus PGK1 is based on the study of somatic
cell hybrids. However the facilities for tissue culture are expensive
and considerable expertise is required for the constant checking of
the hybrids by karyotyping. There is the potential problem of further
rearrangements occurring in culture as demonstrated by the CerS and
CerH lines discussed above. The use of somatic cell hybrids,
therefore, is expensive, requires more skill and errors can still
occur.
Deletion mapping in males with X chromosome deletions is
relatively straightforward after the first detailed karyotype has been
done. The only potential drawback is the possibility of a more complex
rearrangement that cannot be seen using cytogenetic techniques.
All three approaches have given information about the order of
some of the probes in this panel that was not given by the other two
methods and, therefore, all three have a role. Ideally the order
should be based on more than one piece of evidence for each probe and
any localisation based on a single piece of evidence should be
regarded as tentative until further supporting evidence is found.
cpX289 was found to be proximal to PGK1 in four somatic cell hybrids
providing strong evidence for the order of these two probes. Similarly
the localisation of pXG12 and S21 distal to 19.2 is based on more than
one X chromosome deletion. In conclusion it is useful to use evidence
frdm one method to confirm order evidence obtained using one of the
other methods. Family studies and deletion mapping can be carried out
in laboratories without tissue culture facilities and cytogenetic
expertise. The potential problems of each method should be considered
when interpreting data.
7.1.2 Linkage Analysis of Xq
A genetic linkage map of the X chromosome was published in 1985
(Drayna and White, 1985). The linkage relationships were determined by
studying 38 normal families where DNA was available from all four
grandparents and which which had large sibships, averaging nine
children in each. This study included four DNA markers between the
centromere and Xq22. A further study (Arveiler et al, 1987) provided a
more detailed genetic map of the region Xqll-Xq22. This analysis,
using nine DNA markers, was performed on 44 normal families, incuding
17 families from CEPH ( Centre d'Etude du Polymorphisme Humaine,
Paris), and 27 families with various diseases.
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7.1.3 Physical Mapping
Pulsed field gel electrophoresis was used to map the probes
pXG12, p212 and S21 which are linked to XLA. The first aim of the
experiments using pulsed field gel electrophoresis was to create a map
linking the probes and determine the distances between them. The
second aim was to identify potential HTF islands. Information about
the distance between the probes and the distance between the probe
sequences and HTF islands would affect the strategies used to clone
the XLA gene.
Sfi partial digests were used to attempt to link the probes
together. A ladder of bands is detected by probes hybridised to
partial digests. Two probes are linked when they detect identical
bands above a certain band in the ladder. Similarities in smaller band
sizes without larger bands in the ladder coinciding, as in the case of
the 295kb band detected by pXG12 and S21, simply reflect the fact that
many DNA fragments of this approximate size are generated by Sfi
digestion and do not demonstrate linkage of the probes. The total
length of the genome detected without linking the three probes was
approximately 2 megabases.
Calculations assuming an average length of lkb per HTF island
predict that 89% of NotI sites will occur within HTF islands and that
74% of BssHII sites will occur within HTF islands (Lindsay and Bird,
1987). It was also calculated by Lindsay and Bird that there would be
0.12 NotI sites per island and 1.2 BssHII sites per island. Bird has
since analysed 19 genes with HTF islands and found 30 NotI sites and
37 BssHII sites indicating that NotI sites occur more often than
predicted in HTF islands (personal communication). NotI, BssHII
digests and Sfi/NotI, Sfi/BssHII double digests were done to identify
potential HTF islands and position them on the physical map.
All three probes hybridised to the limiting mobility in the NotI
tracks. Sfi sites must be closer than NotI sites both proximal and
distal to the probe sequence as the bands seen after Sfi/NotI
digestion were all seen in the Sfi tracks. In order to estimate the
distance between a NotI site and the probe partial Sfi digestion could
be carried out after NotI digestion. The smallest band to disappear
from the Sfi ladder after NotI digestion provides an upper estimate
for the distance between the probe and the closer NotI site. However,
great care must be taken using this approach to achieve reproducible
Sfi partial digests and ensure that absence of a band is not the
result of more complete Sfi digestion.
The three probes hybridised to the limiting mobility in the
BssHII tracks but, in addition, pXG12 hybridised to a 425kb band and
p212 to a 505kb band. A new band of 210kb was detected by pXG12 in
the Sfi/BssHII track indicating a maximum distance of 210kb between
the probe sequence and a BssHII site. No new bands were detected by
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p212 or S21 in the Sfi/BssHII track.
Hpall sites occur approximately every 100 bases in HTF islands
but as Hpall has a four base pair recognition sequence only a fifth of
Hpall recognition sequences occur in islands. However, Hpall will not
digest at many of the sites outside islands because the cytosine in
the recognition sequence will be methylated. An Sfi/Hpall double
digest was included in the gel shown in figure 5.4. Hybridisation of
all three probes to the filter from this gel failed to give a distinct
band. All three gave a smear below 120kb. This could either have
resulted from degradation of the DNA in this track or reflect that
Hpall digestion is not confined to HTF islands.
Long range physical maps have been generated using pulsed field
gel electrophoresis around the Duchenne locus on Xp21 (10 megabases)
and the cystic fibrosis locus on 7q31 (12 megabases) (Fulton et al,
1989; Burmeister et al, 1988). Four NotI bands were detected using
eight probes from Xp21 and five NotI bands were detected using eight
probes from 7q31. The smallest NotI band detected was 0.9 megabases
and the largest was estimated to be 4.3 megabases. All of these bands
are larger than the DNA fragments resolved in the pulsed field gels
run in this project. In Burmeister's study the Sfi/NotI double digests
gave the same bands as Sfi digests for seven out of the eight probes.
However, use of Sfi/NotI digests generated bands of around 300
kilobases for one probe from Xp21 and two of the probes from 7q31.
Many endonucleases and double digest combinations were used in the
generation of both of these maps and electrophoresis conditions which
separated much larger fragments of DNA used.
No recombinations have been observed between two of the probes
used in this study but pulsed field gels resolving DNA fragments up to
one megabase have failed to link them. It is interesting to note in
Fulton's study that the physical distance between D7S97 and D7S73 was
12 megabases, which is equivalent to 12cM, although linkage analysis
had given a distance of 3.5cM between these two probes. Conversely
recombination events have been noted between the probes D7S97 and
D7S101, which were within 350kb of each other on the physical map.
Recombinations have been observed between DXS52 and DXS15 but physical
mapping of Xq27.3 has placed them within 60kb of each other (Patterson
et al, 1987). Thus the correlation between recombination rate and the
physical distance between probes is not always good.
The results from pulsed field gel electrophoresis presented here
provide the start of a physical map of Xq21.3. Despite the low
frequency of recombination in this area the probes have not been
physically linked. The most likely distance between pXG12 and S21 from
genetic linkage data is 2cM (Arveiler et al, 1987). No recombinations
have been observed between pXG12 and p212. In this study pXG12, p212
and S21 detected two megabases of DNA fragments without linking the
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probes. This minimum distance map is still consistent with the genetic
linkage data. To extend the map, further experiments are needed using
conditions which separate larger DNA fragments. It may not be possible
to make a physical map of this region using pulsed field gel
electrophoresis until more DNA sequences have been isolated which map
to Xq21.3.
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7.2 Localisation of X-linked Disorders
7.2.1 Choroideraemia
Choroideraemia is an X-linked recessive tapetochoroidal dystrophy-
causing night blindness by early adulthood, progressive loss of vision
and eventually blindness in affected males. Female carriers have
normal vision but show progressive degenerative changes in the fundus
(Kama, 1986).
Evidence for localisation of the gene which is defective in
choroideremia has come from linkage studies and from X chromosome
deletions in affected males.
The first linkage study reported linkage to pDP34 with a lod
score of 5.78 at 9 = 0 (Nussbaum et al, 1985). The next linkage study
was carried out in three large families in Northern Finland. This
study confirmed the earlier findings with a lod score of 11.44 at 9 =
0 for pDP34 and 3.31 for st25 also at 9 = 0, but recombinations were
observed between 19.2 and the disease locus (Sankila et al, 1987).
Recombinations have since been reported between the disease locus and
pDP34, st25, and pX65H7 (Lesko et al, 1987). Multipoint linkage
analysis suggested that the choroideremia locus is proximal to 19.2
but the data was insufficient to give a localisation proximal or
distal to pDP34 (Lesko et al, 1987).
The first male with an X chromosome deletion and choroideremia to
be reported also had severe mental retardation, macrocephaly, and a
left sided cleft lip and palate. The initial studies showed that this
boy had an interstitial deletion of Xql3-q21.3 and that pDP34 did not
hybridise to his DNA but S21 did (Schwartz et al, 1986). High
resolution banding later showed that the deletion was Xq21.1-21.33
(Schwartz et al, 1988). pX65H7, st25-l, 19.2, pDP34 and p31 (DXYS5)
failed to hybridise to his DNA (Schwartz et al, 1988) but S21 and
PGK did hybridise to his DNA (Ivens et al, 1988). Patient MB,
described in this thesis, was the next reported case. The probes pDP34
and 19.2 failed to hybridise to his DNA (Hodgson et al, 1987), later
results have shown that pX65H7 proximally and pXG12 distally did
hybridise to his DNA. Two brothers with choroideremia, mental
retardation and sensorineural deafness associated with an interstitial
deletion of Xq21.2-q21.3 have also been investigated (Schwartz et al,
1988). pDP34 did not hybridise to their DNA but 19.2 did hybridise to
their DNA. The XY homologous region probe p31 (DXYS5) gave an altered
band size when the DNA was digested by several different enzymes
demonstrating that this probe detects the deletion breakpoint in
these brothers. A further family was reported in which affected males
had choroideremia, mental retardation, obesity, deafness and an
interstitial deletion in Xq21 (Ayazi, 1981). pX65H7 and pDP34 were
deleted in the males in this family but st25, 19.2 and PGK were all
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present (Nussbaum et al, 1987). An additional family with the same
combination of choroideremia, deafness and mental retardation has been
described in which none of the above loci were deleted and where no
deletion was seen on cytogenetic analysis. Phenol enhanced
reassociation was carried out using DNA from a 48,XXXX lymphoblastoid
line and DNA from one of the males from this family. Sequences
characterized from this library, pJL8 and pJL68, were found to be
deleted in the males described by Ayazi with the microscopic deletion
The common probe to all of the microscopic deletions has been
pDP34. In addition the gene locus must be proximal to or within the XY
homologous region as pX65H7 and pDP34 were deleted in the family
described by Ayazi but not st25 and 19.2.
In family HIS the characterisitic ophthalmological features of
choroideremia were associated with mental retardation and neurological
abnormalities but not deafness. Cytogenetic analysis failed to reveal
a microscopic deletion. pDP34 hybridised to DNA from the males in this
family as did the probe plbD5, which has been deleted in some affected
males with submicroscopic deletions, and the probes pJL8 and pJL68,
generated from the male with a submicroscopic deletion and
choroideremia. In this family the disease did not segregate with the
closest polymorphic probe, pDP34, or two more loosely linked probes,
cpX289 or 19.2. Recombinations occurred between choroideremia and the
linked marker, pDP34, in two out of four offspring. Analysis with
LINKMAP of the likelihood of the disease in this family being
localised between cpX289 and pDP34 gave a lod of -1.85 using a
distance of 8 cM between the two probes. This raises the possibility
that this is a previously unreported X-linked condition with a
different X chromosome localisation causing neurological and eye
problems.
It would be helpful to repeat the ophthalmological examination in
this family to confirm the diagnosis and exclude retinitis pigmentosa.
In addition audiometry and a detailed neurological assessment should
be performed. Unfortunately as the family do not wish to undergo
further assessment the situation is unlikely to be clarified until the
gene defective in choroideremia has been cloned.
7.2.2 Hypohydrotic Ectodermal Dyspasia
Hypohidrotic ectodermal dysplasia (HED) is an X linked disorder
with deficiency of eccrine sweat glands, anodontia or oligodontia with
conical teeth, sparse scalp hair and absent body hair in affected
males. A distinctive face has been described with a depressed nasal
bridge and periorbital pigmentation and wrinkling. Subcutaneous fat is
often diminished and over a third of boys have breast abnormalities,
including absent or accessory nipples. Affected males may have
recurrent chest infections, failure to thrive and life threatening
91
pyrexias. In one study 50% of affected individuals had a severe
illness in early childhood and the mortality was 30% (Clarke, 1987a).
Dental abnormalities were found in 78% of women examined in one
series of 46 obligate carriers (Clarke et al, 1987c). Female carriers
may also have areas of absent sweat glands, patchy scalp or body hair
and breast abnormalities. The starch and iodine whole back sweat test
of Happle and Frosch will identify some of the female carriers (Happle
and Frosch, 1985).
The first linkage study was carried out by MacDermott, who found
linkage between HED and pDP34 with a lod score of 2.7 at 0 = 0.06
(MacDermot et al, 1986). Shortly after this Kolvraa investigated
families with the probe, pTAK8, which is now known to be on the short
arm of the X chromosome, and found a lod of 2.41 at 0 = 0 (Kolvraa et
al, 1986). Further linkage studies have confirmed a recombination
distance of approximately 5 cM between the disease locus and pDP34
(Clarke et al, 1987b; Zonana et al, 1988a; Hanauer et al, 1988).
cpX289 has been used in two linkage studies (Zonana et al, 1988a;
Hanauer et al, 1988). In the study by Zonana and his colleagues,
probes detecting the PGK1 locus were also used and the maximum lod
scores were 14.84 for cpX289 at 8 = 0.01 and 13.44 for PGK1 at 0 =
0.02. One recombination was observed between the disease locus and
cpX289 in each of these studies and in the study by Zonana the meiosis
also showed a recombination between the disease locus and PGK1. Both
of these recombinants are based on the classification of females as
carriers. One of these women was classified as a carrier because she
gave a history of two missing permanent teeth, her dental records were
not available for review and she was edentulous at the time of the
study. The other woman had a dry skin and a slight decrease in sweat
glands at the age of fifty six. One recombination has been observed
between pX65H7 and the disease in the son of an obligate carrier.
A manifesting female with an X;9 translocation was described at
the First Human Gene Mapping Meeting in 1972. The AnLy cell line has
recently been recognised to be from this female (Zonana et al, 1988b).
The breakpoint is at Xql3.1 and DNA analysis has shown the breakpoint
to be between cpX289 and PGK1 (Arveiler et al, 1987).
The crucial factors in the interpretation of the haplotype
information in family LIT are the diagnosis of HED in the affected
male, the assignment of carrier status in his mother and her two
sisters, and paternity.
The affected male in this family has many of the classical
features of HED but is not completely typical because his whole back
sweat test and the finger tip impressions show that he does have sweat
pores. Other atypical features are the normal nasal bridge and the
normal distribution of subcutaneous fat. His hair, teeth, periorbital
pigmentation and absence of nipples, however, all support the
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diagnosis. Renal anomalies have not been described before in the
condition and were considered as a coincidental finding.
The mother of the affected child had three missing teeth , a
pointed right upper lateral incisor and small mandibular incisors. She
was noted to have an accessory nipple. Her whole back sweat test was
normal.
One sister lacked both upper lateral incisors and the second
sister had an absent right upper lateral incisor and an abnormally
shaped left upper lateral incisor. Their whole back sweat tests were
normal. There was a suggestion of hypodontia on the dental X-rays from
these two women and their mother.
In this family there is one boy with major abnormalities and
three females with minor abnormalities of teeth and hair. Either the
condition in the family is X-linked HED or an autosomal dominant
condition with partial penetrance mimicing HED. If the condition is X-
lirked HED it could be a new mutation in the affected male, a new
mutation in his mother, or as thought on clinical grounds all three
sisters could be gene carriers.
There is strong support for carrier status in the mother of the
affected boy as she has three teeth missing, three abnormal teeth and
an accessory nipple. She is heterozygous for the flanking markers,
cpX289 and pSPT/PGK. Her paternity was checked using pXg3. In
addition the paternal allele for pSPT/PGK is certain as her mother is
homozygous for this probe. The affected male has received her paternal
allele for both of these probes. One explanation for this is that she
carries a new mutation on the paternal X chromosome. If this is
correct then either the two sisters are carriers as a result of
gonadal mosaicism, or they are not carriers despite the dental
abnormalities. Paternal gonadal mosaicism, however, cannot account for
all the data as the two normal males in generation III have inherited
the grandpaternal haplotype for this region. This means that if II x
carries a new mutation on the paternal X chromosome, which is
compatible with the mapping information on HED, then her sisters are
not carriers.
Alternative explanations for III! receiving the grandpaternal
allele for cpX289 and pSPT/PGK are a double recombination between
these probes or that the disease in this family is at a separate
locus. Data from other family members is not consistent with a disease
localisation between cpX289 and pSPT/PGK as IIx has not inherited the
sa'ae haplotype as her sisters for five informative probes between
Xpll-Xql3.
The prior probabilities of the women being carriers of HED are
greater than the probability of their dental abnormalities being
incidental findings as only 0.6% of the population have three absent
permanent teeth and only 2% have two absent permanent teeth, excluding
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third molars (Rose, 1966). If all three sisters are carriers of the
disorder then a second locus for HED remains the most likely-
explanation. However, families from Britain, Switzerland, Finland,
Denmark, France and the United States have been studied without any
suggestion of non-allelic heterogeneity. In addition, the study by
Zonana and his colleagues analysed results for the probes cpX289 and
pSPT/PGK from thirty six families without finding any evidence for
non-allelic heterogeneity.
There are, therefore, two possible explanations of the haplotype
results. The first possibility is that the sisters, II2 and II3, are
not gene carriers and the second possibility is that there is non¬
allelic heterogeneity. Either of these explanations raises concern
about counselling of females in families with HED.
As this family raises the possibility of a second locus for HED
the use of cpX289 and pSPT/PGK for clinical testing should be treated
with caution in small families where it is not possible to demonstrate
that the disease is segregating with the region Xqll-qll.3.
7.2.3 Severe Combined Immunodeficiency
XSCID was mapped to Xqll-13 in a collaborative study between
groups in London, Paris and Strasbourg (de Saint Basile et al, 1987).
There were no recombinations between cpX289 and the disease in that
study. pDP34 and p8 were found to be flanking markers. Two additional
probes between these flanking markers have been used in this study to
improve the localisation. Three of the families investigated were used
in the collaborative study (families KHA, BER, and TEB). Families GWA
and HAL have been identified since the preliminary mapping study.
Two recombinations were observed between the disease locus and
probes in this study. They occurred between cpX203 and the disease and
pDP34 and the disease and so have not provided closer flanking
markers. However there is evidence that the disease locus is proximal
to pX65H7 from two families with deletions on the X chromosome
extending from the XY homologous region to include pX65H7 (Schwartz et
al, 1988; Nussbaum et al, 1987). The males carrying the deletions in
these families had choroideremia but did not have XSCID (Schwartz et
al, 1988; Ayazi, 1981). The order is therefore cpX203 - p8 - (cpX289 -
pSPT/PGK - XSCID) - pX65H7 - pDP34.
Lod scores were calculated between XSCID and p8, cpX289, pSPT/PGK
and pX65H7 first confining the analysis to obligate carrier females
and their male offspring and then repeating the analysis including
females whose carrier status was determined by methylation studies.
This increased the XSCID - pSPT/PGK lod score from 1.63 to 3.01. As
families with XSCID are rare a carrier test for females is useful not
only for counselling but also in order to generate more data in
linkage studies.
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Adding the information from the two new families to the results
from the published study increases the two point lod score for XSCID -
cpX289 to 7.08. Analysing the results from the five families in this
study using LINKMAP increases the lod score at pSPT/PGK to at least 4
The linkage data for pSPT/PGK and XSCID taken with the mapping
information which places pSPT/PGK between cpX289 and pX65H7 provide
evidence that it is linked to the disease locus. Its use as an
additional polymorphic marker for predictive testing with cpX289 means
that 65% of females should now be heterozygous for a linked marker.
7.2.4 X-linked Agammaglobulinaemia
XLA has been mapped to Xq21.3-22 (Kwan et al, 1986; Malcolm et
al, 1987). The probes pXG12 and S21 have been used for predictive
testing in XLA. In this study linkage has also been demonstrated
between p212 and the disease locus with a lod score of 3.74 at 0 = 0.
The order of the probes in this region is 19.2 - (pXG12 - p212) - S21.
This probe can, therefore, be added to those used in predictive
testing increasing the number of females who will be informative for
a polymorphism detected by a linked marker.
Recombinations have been observed between the disease locus and
19.2 (Kwan et al, 1986; Malcolm et al, 1987; Mensink et al, 1986).
This study has not provided a closer proximal flanking marker or a
distal flanking marker.
Soon after the initial localisation was reported non-allelic
heterogeneity was suggested. This was based on a significant negative
lod score in one family for the disease locus at 6cM from 19.2 family
(Mensink et al, 1986). This family has since been shown to be a case
of gonadal mosaicism with paternal transmission. Excluding this family
no recombinations have been reported with either pXG12 or S21.
Family JAM is phenotypically identical to classical XLA and yet
recombinations have occurred between the disease and the haplotype of
19.2 - pXG12 - S21 in two out of four meioses in this family. The
paternity of III4 and III8 were shown to be correct using
minisatellite probes and therefore there is no doubt about the
haplotype that they inherited from their mother. II3 and II4 had
three sons who died at less than three years of age. The diagnosis was
bronchopneumonia in all three. As male to male transmission never
occurs in X-linked disorders, and these three males were almost
certainly affected, gonadal mosaicism in II3 cannot be the explanation
for the results. Even if these three males were not affected gonadal
mosaicism alone would not explain the results as the affected male has
not inherited the complete grandpaternal haplotype.
In this family recombinations have been observed between the
disease locus and pXG12 and S21 in one meiosis and 19.2 in a second
meiosis out of four meioses. A lod score of -2 is accepted as
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excluding linkage. Analysing the probability that the disease locus is
becween 19.2 and pXG12 or between pXG12 and S21 using LINKMAP the
maximum lod scores were -3.8 and -6.5 respectively. The disease locus
in this family is, therefore, not between 19.2 and S21. Using the
convention of (maximum lod score - 1) to give an upper confidence
limit for the estimate of distance between two markers (Conneally et
al, 1985) the XLA locus could be lOcM distal to S21 (Malcolm et al,
1987). The results in this family are consistent with non-allelic
heterogeneity or a disease localisation distal to S21. If the disease
locus in this family is the same as in the other families studied then
the XLA locus is distal to S21.
Recombinations with S21 have been reported in the family that has
growth hormone deficiency and XLA (Notarangelo et al, 1988). In
addition it has been shown that the mechanism of
hypogammaglobulinaemia in this family is different from the mechanism
in classical XLA. In classical XLA a non-random pattern of X
inactivation is found in B lymphocytes but not in T lymphocytes or
granulocytes (Conley et al, 1986). In the family with growth hormone
deficiency and XLA a non-random pattern of X inactivation was found in
T as well as B lymphocytes (personal communication). It would be
interesting to do X inactivation studies in purified cell populations
in the three obligate carriers in family JAM.
Linkage analysis of this family and the family with XLA and
growth hormone deficiency, and the X inactivation studies in classical
XLA and the family with XLA and growth hormone deficiency, suggest
that there is more than one gene on the X chromosome which, when
defective, leads to absence of all immunoglobulin isotypes.
This possibility raises questions about the reliability of using
the linked probes for predictive testing. No recombinants had been
found prior to this family, with a lod score of 12.9 which is
equivalent to 43 informative meioses for S21. A method has been
developed which makes allowance for non-allelic heterogeneity in
calculations of risk (Lau et al, 1988). The larger the family and the
more members tested the smaller the uncertainty attached to predictive
testing. Using this method for taking non-allelic heterogeneity into
consideration it is reasonable to continue using pXG12 and S21 for
predictive testing in XLA.
7.2.5 Pitfalls in the Use of Linked Markers in Genetic Counselling
There are a number of potential pitfalls that can occur in the
use of linked markers for genetic counselling. Some of these problems
are demonstrated by families HIS, LIT and JAM discussed above.
The information resulting from marker studies will not be correct
if there has been an error in diagnosis. It is essential that when
families with rare genetic disorders are referred that the diagnosis
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is ..confirmed and that all conditions that can present with similar
findings are considered. For example when a family with XLA is
referred it is important make certain that the family does not have
Hyper IgM as the localisation of the two conditions is different.
It is also important to confirm the carrier status of females in
X-linked pedigrees if their DNA results are going to be used in
assigning phase. Family LIT demonstrates the difficulties that can
arise in trying to decide if females are carriers of X-linked
conditions on the basis of clinical findings.
In many clinical situations the information given to families is
dependent on correct paternity and this should be made clear to
families at the time of counselling.
The possibility of new mutation and germ line mosaicism should
also be considered whenever the DNA findings do not fit the expected
pattern.
Before considering the final possibity, non-allelic
heterogeneity, as the explanation for unexpected results incorrect
diagnosis, confusion over sample labelling, non-paternity, new
mutation and germ line mosaicism should all be considered.
In view of all of the potential problems that can lead to errors
in counselling it would seem wise to restrict the clinical use of
linked genetic markers to a limited number of specialised centres.
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CHAPTER 8. Discussion: X-inactivation Studies
8.1 Validity of X-inactivation Studies for Determining Carrier Status
Two obligate carriers in this study were shown to have non-random
use of the X chromosome in E positive cells.
During the course of this study non-random use of the X
chromosome in T lymphocytes of female carriers of X-linked SCID has
been demonstrated by another group using somatic cell hybrids (Puck et
al, 1987). Purified T cells were fused to HPRT deficient male Chinese
hamster lung fibroblasts using polyethylene glycol. The hybrids were
grown in HAT medium to select for those retaining the active X
chromosome. Hybrid clones that retained two human X chromosomes were
grbwn in medium containing 6-thioguanine, which is toxic to cells
expressing HPRT and so selects for clones that have lost the active X
chromosome. In this way clones were generated that contained only one
human X chromosome which was known to have been active or inactive in
the human parent cell. Genomic DNA from the women was tested to find
X-linked polymorphisms for which they were heterozygous. Southern
blots made using the hybrid DNA were then tested with these probes to
see which allele the hybrids retained. Three obligate carriers were
investigated and the following results obtained: 22 out of 24 clones
with the same X active, 20 out of 21 with the same X active and 17 out
of 17 with the same X active. These results were significantly
different from the normal random X inactivation pattern. In addition
in' one of these three carriers they were able to show that the
haplotype of the inactive X was tracking with the mutation in the
family. This method provided strong evidence for a non-random X
inactivation pattern in mature T cells of carriers of the X-linked
disease. However the procedure takes months for each subject
investigated, is expensive and labour intensive and therefore it is
not practical as a routine test.
As the non random pattern of X inactivation in T cells of female
carriers has now been demonstrated by two independent methods it seems
reasonable to give genetic counselling on the basis of X inactivation
patterns. DNA methylation analysis is the more practical of the two
methods for carrier testing for XSCID. The basis of the method is that
when an X-linked gene is required for cell survival, the normal gene
will always be found on the active X chromosome and the defective gene
on the inactive X chromosome in the mature cell population, even
though initial X inactivation is random.
8.2 Potential Errors Associated with the Use of X Inactivation
An incorrect diagnosis would be reached if a carrier female had a
random pattern or a normal female had a non random pattern as assessed
by methylation analysis. If female carriers of the X-linked disorder
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always have a non random distribution of active X chromosomes in the
mature T cell population then the only cause of a carrier female
having an apparently random distribution would be if digestion with
the methylation sensitive enzyme was incomplete. In order to avoid
this happening an excess of the methylation sensitive enzyme was added
and in addition the experiment was performed twice for each woman
before any result was given to the family.
As X chromosome inactivation is a random event mature cell
populations from a number of females would have a mean of 50% of cells
having paternal X inactive and 50% having the maternal X inactive.
However the results from a group of women are scattered around the
mean in a normal distribution. The possibility of erroneously saying
that someone has a non random pattern and is therefore a carrier
depends on the distribution around the mean and the sensitivity of the
test.
To assess the distribution around the mean neutral polymorphisms
have been studied to see how many heterozygous females express only
one allele in mature cell populations. Fialkow studied 41 subjects who
were heterozygous for the G-6-PD isoenzymes A and B (Fialkow, 1973).
Purified lymphocytes were investigated in 20 of these women. The mean
percentage of enzyme A in lymphocytes was 48, SD±11.39, range 25%-75%
The range for two standard deviations is 25-71% and for three standard
deviations is 19 - 77%. The sensitivity of the isoenzyme analysis is
not clear but both alleles were identified in the lymphocyte fraction
of all the women studied.
Fearon and Vogelstein have published methylation analysis results
for E positive cells from 2 women using pSPT/PGK and from one woman
using HPRT (Fearon et al, 1987). Lymphocytes from the E positive cell
fraction have been investigated with pSPT/PGK from two women and with
HPRT from one woman in this study. In these six women random use of
the X chromosome was observed in the T lymphocytes. Vogelstein has
studied DNA from normal tissues, including lymphocytes, from 40 women
using the pSPT/PGK and 42 women using the HPRT probes (Vogelstein et
al, 1987). In two of the women heterozygous for the polymorphism
detected by pSPT/PGK the density of one of the bands decreased by 80%
and the other by only 20% as assessed by dosimetry. In one of the 42
women heterozygous for the polymorphism detected by HPRT the intensity
of one band decreased by 85% and the intensity of the other band
decreased by 15% in several tissues examined. However in all 82 women
two bands were present after the addition of the methylation sensitive
endonuclease.
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8.3 PGK Linkage in Combination with X Inactivation
It has been shown in this thesis that pSPT/PGK is linked to the
XSCID disease locus in families which have a clearly X-linked
pedigree. It has also been shown that analysis of X inactivation
patterns with pSPT/PGK can be used for carrier testing in heterozygous
females.
All of the CpGs in the Pstl/BstXI fragment of DNA detected by
pSPT/PGK are unmethylated on the active X chromosome but methylated on
the inactive X chromosome. Thus when Hpall is added the DNA from the
inactive X chromosomes is not digested but the DNA from the active X
chromosomes is digested into much smaller fragments. The allele which
is lost after the addition of Hpall in a heterozygous female with a
non-random pattern of X inactivation, therefore, represents the active
X. The allele that remains after the addition of Hpall represents the
inactive X i.e. the X chromosome carrying the mutation. As pSPT/PGK is
linked to the disease it is possible to assign phase in a female shown
to be a carrier by methylation analysis using pSPT/PGK without
analysing DNA from any other member of the family. pSPT/PGK can then
be used as a linked probe for prenatal diagnosis of the condition. A
male fetus inheriting the band that remained after the addition of
Hpall during methylation analysis is at high risk of being affected
and a male inheriting the allele which was lost after the addition of
Hpall is at low risk of being affected.
This unique situation of using the same probe in a carrier
detection test and as a linked probe for predictive testing is
especially useful when the consultand may carry a new mutation. In
this situation one cannot assign phase using DNA from the consultand's
father. In addition in these families with sporadic cases the affected
males often die shortly after presentation. In the three families with
sporadic cases presented here the affected males all died before
tissue was stored for extraction of DNA and there were no normal male
offspring who could be used for phase assignment. In pedigree HAL both
affected males had died without tissue being stored for DNA extraction
and none of the three carrier sisters have any normal male offspring
who could be used to assign phase and their father is deceased.
Prenatal tests could not be offered in pedigree LAW or pedigree
HAL without the use of pSPT/PGK for both carrier detection and for
assignment of phase.
8.4 Affect on Counselling
Developing a carrier test for XSCID has helped in the genetic
counselling of women at risk in X-linked families where the key
females were not heterozygous for linked probes. However it has been
most useful when the pattern of inheritance was not clear from the
pedigree. This is demonstrated by pedigrees HAL and MOR which have a
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similar structure with a proband having two affected male children in
each family.
In pedigree HAL the proband was shown to be a carrier of the X-
linked form of the disease. This not only allowed better counselling
of the couple but has also led to more accurate counselling of the
extended family. The two sisters had previously been told that they
might be at risk of having affected children but counselling was
difficult because the disease could have been autosomal or X-linked
and, if X-linked, the proband could represent a new mutation.
Following methylation analysis both sisters have been given precise
information and offered prenatal testing.
In pedigree MOR the proband had a random X inactivation pattern
in her T cells suggesting that the disease was autosomal recessive in
this family. Again this allowed more accurate genetic counselling to
the extended family. In this situation the proband's sister was
reassured that her own risk, and her daughter's risk, of having
affected children is extremely small as although they may be carriers
of the autosomal recessive form the chance of an unrelated individual
being a carrier is less than one percent.
The proband in pedigree EIS who has had a single affected male
had a non-random pattern of X inactivation and is therefore a carrier
of the X-linked form of the disease. However, the chromosome carrying
the mutation is the X that she has inherited from her father. She
therefore carries a new mutation and her own mother is not a carrier
of the disease. The proband's sister can only be carrier of the
disease if there is significant germ line mosaicism in their father.
Whilst germ line mosaicism has been demonstrated in a Duchenne family
(Darras and Francke, 1987) and also in the XLA family discussed
earlier it is still a rare event. The risk of the proband's sister
being a carrier of the disease is therefore low and she has been
reassured.
When the mother of a sporadic case does not have a non-random
pattern of X inactivation the counselling becomes more difficult
because there are two possible explanations for the finding. The
affected child could have had autosomal recessive SCID or could have
had X-linked SCID as a result of a new mutation. Considering the 4:1
ratio of males to females affected the ratio of X-linked to autosomal
recessive must be 3:1 and hence the probability of a single male
having the X-linked type is 75%. As with all X-linked lethal
conditions the proportion of sporadic males carrying new mutations is
theoretically one third. Therefore in a family with one affected male
and no normal sons the ratio of autosomal: X-linked inherited: X-
linked new mutation is 1:2:1. When the possibility of the child having
inherited the X-linked form has been excluded, as in pedigree SPE, the
possibilities of autosomal recessive and X-linked new mutation are
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equally likely. One can therefore give a recurrence risk of 1 in 8 of
a child being affected. If, as in this family, the child did not have
adenosine deaminase deficiency the balance is more in favour of a new
mutation than autosomal recessive inheritance. However the couples are
still at significant risk of having another affected child but early
prenatal diagnosis cannot be offered. Even in this situation the
information is useful when counselling female relatives of the
proband. The probability of a female relative having an affected child
is low, whether the affected boy carries a new mutation or has the
autosomal form, and reassurance can be given.
8.5 Usefulness of Test
Methylation analysis using pSPT/PGK and HPRT allows carrier
detection in women heterozygous for the polymorphisms detected by
these probes. Vogelstein estimated that over 50% of American females
would be heterozygous for one or other probe (Vogelstein et al, 1987).
The information content for pSPT/PGK in this study was the same as
that observed by Vogelstein. However using the HPRT allele frequencies
observed in this study only 11% of females would be heterozygous
compared with a figure of 29% given by Vogelstein. Using the figures
obtained in this study 40% of women would be heterozygous for one of
the probes and therefore 60% of women referred because they have had
an affected male cannot be offered the test.
Recently it has been suggested that the probe M27J3 (DXS255) may
also detect methylation differences between the active and inactive X
chromosome (Y Boyd, personal communication). The advantage of this
probe over the probes developed by Vogelstein is that it detects a
length polymorphism resulting from tandem repeats which vary
considerably in number between individuals. It has been estimated that
over 95% of women are heterozygous for the length polymorphism
detected by this probe. If these methylation differences are confirmed
then carrier detection could be offered to most women using
methylation analysis with this probe.
8.6 Expression of the Gene Defective in XSCID
The E positive fraction of cells in all obligate carriers and
women known to be at high risk because of their family history and
linked probe analysis had a non-random pattern of X chromosome usage
on methylation analysis. This cell fraction contained on average 84%
(range 74 - 93%) T lymphocytes as determined by indirect
immunofluorescence following staining with CD3 monoclonal antibody .
HNK1 positive natural killer cells accounted for the remaining cells
with B lymphocytes and monocytes accounting for less than 1% of the
cells.
When the purity of a cell population is 75% then two bands could
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be observed after the addition of the methylation sensitive
endonuclease when the predominating cell type is using only one X
chromosome if the contaminating cells use the X chromosome randomly.
However, a non-random pattern would never be seen as an artefact of
cell mixing. Therefore, although the T lymphocyte enriched population
contained some contamination the conclusion that there is non-random
use of the X chromosome in T lyumphocytes is valid. The fact that all
of the E positive fractions gave only one clear hybridising band after
the addition of Hpall suggests that there is also selection for HNK1
positive natural killer cells with the normal gene on the active X
chromosome.
The only cell population in which a random pattern of X
chromosome usage was found was the granulocyte fraction. As the
granulocyte fractions were 99% pure these results could not have been
an artefact of cell mixing. A random pattern was observed in the
granulocyte DNA from four women but a non-random pattern was observed
in the DNA from two of the women.
The findings in E negative cells and in the monocyte enriched
population are strongly suggestive that the gene is expressed in
monocytes.
it was not possible to isolate sufficient B lymphocytes for DNA
extraction from the venous blood sample taken and so multiple EBV
transformed lines were established from the subjects. The results,
therefore, apply to B lymphocytes carrying the EBV receptor. EBV
transformed lines from normal individuals can become monoclonal after
continuous culturing. In a recent study Migeon et al (Migeon et al,
1988) showed that 50% of EBV lines from women heterozygous for
electrophoretic variants of G6PD expressed only one of the G6PD
alleles by the tenth subculture, within eleven weeks of establishing
the culture. In Migeon's study no lines assayed prior to subculture
expressed only one G6PD allele. In this study DNA was isolated when
there were 5 x 10 5 cells in each line to minimise the possibility of
lines becoming oligoclonal or monoclonal. An alternative method of
ensuring that the lines were not clonal when the X-inactivation
studies were carried out would have been the use of immunoglobulin
gene probes to investigate immunoglobulin gene rearrangements (Arnold
et al, 1983). The presence of clear bands in addition to the germline
band would indicate clonal expansion of EBV transformed cells. The
conclusion, however, is based not on finding use of only one X
chromosome in individual EBV lines but on the finding that for each
subject the same X chromosome was active in each culture with a non-
random pattern, and that this was the same X as in the corresponding T
lymphocytes. In subject 2, ten lines were tested and all ten retained
only one active X chromosome, the same X as in the corresponding T
lymphocytes. The loss of the mutant X in all ten lines is
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statistically significant and cannot be explained by the lines
developing oligoclonality. The gene is therefore expressed in B
lymphocytes with the EBV receptor in this subject. Results were also
obtained for nineteen EBV transformed cell lines from subjects 3, 5
and 6. Non-random X chromosome usage was observed in eight of these
cell lines and again the active X chromosome was the same in all these
lines as in the corresponding E positive cells indicating that the
gene is expressed in the B lymphocytes of these subjects. However, two
bands were seen after the addition of the methylation sensitive enzyme
in eleven of the nineteen EBV transformed lines showing that some
circulating B lymphocytes do have the defective gene on the active X
chromosome.
There was variation between the subjects for the X-inactivation
patterns observed in granulocytes, EBV lines and DNA extracted from
venous blood. Comparing the two obligate carriers a non-random X
inactivation pattern was found in DNA extracted from venous blood in
subject 7, but a random pattern was observed in DNA from venous blood
and granulocytes from subject 1. Both of these women came from large
families in which the disease segregated with polymorphic markers
assigned to Xqll-13. As the genetic evidence argues against there
being more than one locus for XSCID it seems that the gene defective
in this disorder is expressed in B lymphocytes and granulocytes, but
that this has a variable affect on cell survival. This is supported by
the differences in the granulocyte X inactivation patterns observed in
subjects 4, 5 and 6 who were members of the same family.
Conley has investigated expression of the gene in different cell
types using the somatic cell hybrid method (Conley et al, 1988). She
found a non-random pattern of X chromosome usage in T lymphocytes and
B lymphocytes but a random pattern in monocytes. She did not
investigate granulocytes. The findings presented here showing that
some B lymphocytes do have the defective gene on the active X
chromosome differ from those of Conley. This difference may be
explained by the fact that Conley cultured EBV transformed lines until
there were 50 x 106 cells before using them to make somatic cell
hybrids. It is therefore possible that at the time that the hybrids
were made selection had occurred and that cultured cells no longer
reflected the phenotype of the circulating B lymphocytes in the
subjects. Conley's finding of random X chromosome usage in monocytes
also differs from the results presented here. Neither result is based
on analysis of pure monocyte populations. As discussed above a random
pattern of X inactivation can be an artefact of contamination but a
non-random pattern cannot be caused by cell mixing.
The methylation method of determining X inactivation which we
have used is not able to distinguish between complete absence of cells
expressing the mutant gene and a few surviving cells. The somatic cell
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hybrid method used by Conley and her colleagues is also inefficient at
detecting a low proportion of cells carrying the mutant gene on the
active X chromosome. Similarly, neither method distinguishes between
completely random X chromosome usage and a system in which survival is
biased towards cells with one of the X chromosomes active. In the case
of the methylation method this is because dosimetry of bands is
unreliable and in the somatic cell hybrid method because of the
statistical nature of the sampling.
A mutant gene leading to an immunodeficiency is unlikely to
affect the initial pattern of X inactivation. A non-random X
inactivation pattern in a mature cell population could be a result
either of a failure of cells without the gene to become fully
differentiated due to the lack of a regulatory function or
differential survival of the cells. The gene defective in XLA is
likely to be in the first category as pre-B cells are found in
affected males but no circulating B cells and as the only
haematopoietic cells to show non-random use of the X chromosome in
carrier females are the B lymphocytes. Differential survival of cells
with the normal gene on the active X is a more likely explanation for
the findings in XSCID as non-random use of the X chromosome has been
observed in cell types which are present in the affected males.
Differential survival has been found in Lesch-Nyhan disease which
is caused by deficiency of hypoxanthine phosphoribosyl transferase, an
enzyme in the purine salvage pathway. Female carriers of Lesch Nyhan
disease have a non-random pattern of X inactivation in erythrocytes
and lymphocytes, demonstrating that differential survival can result
from a defective gene in a metabolic pathway, but they have the normal
random pattern in fibroblasts (Nyhan et al, 1970). It would be
interesting to find out if female carriers of XSCID had random use of
the X chromosome in non-haematopoietic cells but even if random use
was found in fibroblasts this would not exclude the possibility that
the-disease resulted from a defect in a gene in a metabolic pathway.
When an X-linked immunodeficiency results from a mutation in a
gene involved in a process specific to the immunological function of
the mature cell and not necessary for its differentiation or survival
one would expect to find random use of the X chromosome in the mature
cells of a female carrier. This is the case in female carriers of
chronic granulomatous disease. The mutation in this disease is in the
cytochrome b_245 gene. Cytochrome b_245 is not required for cell
growth or survival but is essential for bacterial killing activity.
When cytochrome b_245 is absent the oxidase activity that normally
accompanies phagocytosis is absent and hence granulocytes from
patients fail to reduce nitroblue tetrazolium. In female carriers two
populations of cells are seen, some granulocytes are normal but others
fail to reduce nitroblue tetrazolium and this is used as a carrier
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test. As non-random use of the X chromosome has been found in females
carrying XSCID the abnormality is unlikely to be in a pathway required
specifically for the immune function of the cells.
The pattern of expression found in XSCID is consistent with the
gene causing XSCID being a metabolic enzyme in a pathway to which T
lymphocytes are particularly sensitive, in a similar way to adenosine
deaminase in the autosomal form.
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Summary
XLA and XSCID are disorders of the immune system which are
inherited as X-linked recessive conditions. Females carrying these two
conditions have no known immunological or biochemical abnormalities.
XLA has been localised to Xq21.3-q22 (Malcolm et al, 1987) and XSCID
has been localised to Xqll-ql3 (de Saint Basile et al, 1987). The DNA
probes linked to the disorders have been used for carrier detection
and prenatal diagnosis.
A genetic map of the region is essential for localising the
disorders more precisely and for planning strategies to clone the
genes. The first aim of this thesis, therefore, was to clarify the
order of probes assigned to proximal Xq and make a physical map of the
probes linked to XLA and XSCID. Fourteen DNA markers detecting
polymorphisms were studied in four families selected because of
recombinations on Xq and in a male with an Xq deletion. The
investigation of both recombinant chromosomes and the X chromosome
deletion provided information about the order of probes on proximal
Xq. Studies of somatic cell hybrids have clarified the order of these
probes further. Combining all available information the order of the
probes is (pTAK8 - M27J3) - cpX203 - p8 - cpX289 - pSPT/PGK - pX65H7 -
pDP34 - 19.2 - (pXG12 - p212) - S21. The localisation of cpX203
proximal to p8 has not yet been confirmed by other studies. The probes
G3-1 and pA13.Rl have been shown, in this study, to detect the same
polymorphism but their position in the map is uncertain. The order of
pXG12 and p212 and the order of pTAK8 and M270 is not known.
Pulsed field gel electrophoresis was used to generate a physical
map around the probes pXG12, p212 and S21. The most likely distance
between pXG12 and S21 from genetic linkage data is 2cM, which is
equivalent to two megabases. The total length of the genome detected
in this study without linking these three probes was two megabases.
Further experiments are required to make a physical map linking these
probes and clarify whether there is a low recombination rate in this
region of the X chromosome.
X-LinkedAgammaglobulinemia
XLA has been mapped to Xq21.3-q22 and the probes pXG12 and S21 have
been used for predictive testing. Recombinations have been observed
between the disease locus and 19.2 but no close distal flanking marker
has been identified. From previously published data the XLA locus is
distal to 19.2 but could be proximal to pXG12, between pXG12 and S21
or up to lOcM distal to S21. S21 was the most distal of the fourteen
DNA markers ordered in the first part of the study and, therefore, in
this group of probes there were no probes that could be tested to find
distal flanking markers. In the mapping section of this thesis p212
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was shown to be between 19.2 and S21. Linkage analysis between p212
and XLA gave a two point lod score of 3.74 at 8 = 0 and p212 is,
therefore, an additional linked probe that can be used for predictive
testing in this disorder.
Recombinations were observed between the disease locus and pXG12
and S21 in one family, pedigree JAM. Analysis of the data with the
LINKMAP section of LINKAGE 4.7 excludes linkage of the disease between
19.2 and S21 in this family, but does not exclude linkage 3.3cM distal
to S21. If the disease locus in this family is the same as in the
other families studied then the XLA locus is distal to S21. An
alternative explanation of the results in this family, however, is
non-allelic heterogeneity. This would be resolved by finding XLA
families where the disease locus segregates with pXG12 but not S21,
indicating that the disease locus is proximal to S21 and thus
supporting non-allelic heterogeneity, or finding more distal markers
and testing whether they segregate with the disease in this family.
X-Linked Severe Combined Immunodeficiency
XSCID has been mapped to Xqll-ql3 in a collaborative study between
groups in London, Paris and Strasbourg. Recombinations were observed
between the disease locus and p8 proximally and pDP34 distally. In the
additional families investigated in this study recombinations were
observed between the disease and cpX203 and the disease and pDP34.
These recombinations did not provide closer flanking markers. However,
the XSCID locus must be proximal to pX65H7 as males with deletions
extending from the XY homologous region and including pX65H7 have been
described in two families. The affected males in these families had
choroideremia and mental retardation, but did not have XSCID.
In the probe ordering section of this study pSPT/PGK was shown to
be between cpX289 and pX65H7. Linkage analysis between pSPT/PGK and
XSCID gave a two point lod score of 3.01 at 8 = 0 when including
females whose carrier status was determined by X Inactivation patterns
in the analysis. This probe can be used as an additional linked marker
for XSCID, making predictive testing possible in more families.
There are X-linked and autosomal recessive forms of severe
combined immunodeficiency. This caused difficulties in counselling
couples who had one affected son and where there was no previous
family history of the disorder. It has been shown in this thesis that
female carriers of XSCID have a non-random X inactivation pattern in
E positive cells. This has also been demonstrated by Conley using
somatic cell hybrids. We have used methylation analysis of X
inactivation patterns for carrier detection in women in X-linked
pedigrees not informative for the linked probes and in families where
the inheritance pattern was not clear. Forty percent of women at high
risk of being carriers of XSCID were heterozygous for the polymorphism
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detected by PGK or the polymorphism detected by HPRT and could be
offered the test.
In addition as the probe pSPT/PGK, which was used for analysis of
X inactivation patterns, was linked to the disease locus carrier
detection and assignment of phase could be carried out in one
procedure. This allowed assignment of phase in women with no living
male offspring and who could be carrying a new mutation.
It has been thought that XSCID results from a defect in a T
lymphocyte specific gene because the phenotype is predominantly a lack
of T lymphocytes and because host B lymphocytes produce functional
antibody following transplantation and engraftment of T lymphocytes.
Finding a non-random pattern of X chromosome usage in a mature cell
population implies that the defective gene is expressed in that cell
type and this technique was used to investigate gene expression. Non-
random X chromosome usage was found in T lymphocytes, B lymphocytes,
monocytes and granulocytes. These findings do not support the
hypothesis that XSCID results from a defect in a T lymphocyte specific
gene or a gene specific to lymphocyte development. The pattern of
expression suggests that the underlying defect in XSCID is in a
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lOmM Tris-HCl (pH 8.0)
1 mM EDTA (pH 8.0)
SSC (20X)
3M sodium chloride
0.3M tri sodium citrate
pH adjusted to 7.0 using HCl
Denhardt's solution (100X)





































1 litre double distilled water
Solution C:
NaHC03 22.5g
1 litre double distilled water
All three solutions are stored in 20ml aliquots at 4°C. Gey's solution
is freshly prepared by mixing 7mls of sterile water with 2mls of
solution A (warmed at 37°C prior to use to melt the gelatine) 0.5 mis
of solution B and 0.5mls of solution C.
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RPMT 1640 supplemented with 25rrM hepes (Gibco)













































Fig 7—Pedigree family 6.
In pedigree 4 the proband who had had two affected sons
had a non-random pattern ofX inactivation in her T cells.
Methylation analysis showed that her sister, II4, is
heterozygous and after the addition of Hpall the 105 kb
band was lost (fig 7, lanes 3a and 3b). The disease in this
family must therefore be X-linked and both these sisters
carriers. The third sister, II6, is also heterozygous but both
bands remained after the addition of Hpall and she is
therefore not a carrier (fig 7, lanes 4a and 4b).
The subject in pedigree 5 has had two affected sons and
one normal son; there is no previous family history and the
disease could therefore be eitherX-linked or autosomal. She
is heterozygous, and after the addition ofHpall both bands
remain (fig 7, lanes 5a and 5b), which suggests that she is a
carrier ofone of the autosomal recessive forms of SCID and
therefore her sister and niece will not be at risk of having
affected offspring.
Sporadic Cases
For II2, in pedigree 6, only the 1-05 kb band remained
after the addition ofHpall. She therefore has a non-random
population of T lymphocytes and is likely to be a carrier of
the X-linked form of SCID.
The results ofall theX-inactivation studies on known and
possible carriers of X-linked SCID are summarised in the
table.
Discussion
We have established that DNA methylation analysis can
be used for carrier detection of the X-linked form of SCID.
The basis of the method is that when a gene is required for
cell survival, the normal gene will always be found on the
active X chromosome and the defective gene on the inactive
X chromosome in the mature cell population, even though
initial X inactivation is random. In X-linked SCID the
mature T lymphocytes therefore show a non-random X
inactivation pattern. This finding is of clinical importance
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because carriers of SCID do not have any known
biochemical or immunological abnormalities except for
carriers of adenosine deaminase deficiency, in which case
measurement of the enzyme may be useful.
The non-random pattern of X inactivation has been
demonstrated in T lymphocytes in X-linked SCID
previously by the use of somatic cell hybrids,7 but this
method would clearly not be practical as a routine clinical
test. Similarly, a protein polymorphism of glucose-6-
phosphate dehydrogenase has been used to investigate
X-inactivation patterns in X-linked disorders,8 but few
Caucasian females are informative for this polymorphism.
Over 50% of Caucasian females are informative for the
HPRT and PGK polymorphisms3 and this method will
therefore be clinically useful.
In families with clear X-linked pedigrees the use of linked
probes is considerably easier. However, in a number of
families this approach is not possible because there are no
surviving males to give linkage phase or because key females
are not heterozygous for the probe. In these situations
methylation analysis will be of great value.
In addition, in families in which a couple have had several
affected males, methylation analysis distinguishes the X-
linked form of SCID from recessive varieties. The method
can also be used in families referred for investigation after a
diagnosis of SCID has been made in a single male infant.
Where there is no prior family history it may be possible to
show that the mother is a new mutation by demonstrating
that it is the paternal X that is inactive in all of her T
lymphocytes.
All of this information is valuable in giving accurate
genetic counselling to an extended family. The options
available to those at risk who ask for prenatal diagnosis
include first trimester chorion villus sampling for fetal
sexing, prediction in males using the linked probes in some
families, or fetal blood sampling at 18 weeks' gestation for
absolute diagnosis.9 Apart from the immediate clinical
application of the test, the finding ofmore X-linked families
will be useful in refining the linkage data in this disorder.
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Fig 6—Analysis of X chromosome inactivation patterns.
T lymphocyte DNA has been digested with PstljBstXl in track a and
digested with Pstl BstXl I[pall in track b of each sample. Sample 1 is from
an obligate carrier, pedigree 1, and sample 2 is from her daughter. Sample 3 is
from subject II4, pedigree 4, and sample 3 her sister, subject II6. Sample 5 is
from subject II2, pedigree 5. Sample 6 is from subject II2, pedigree 6.
been investigated. In pedigree 5 (fig 5) a boy diagnosed as having
SCID died; the second pregnancy was terminated because fetal
blood sampling revealed an affected male fetus; and prenatal
diagnosis in the third pregnancy revealed a normal male. In
pedigree 6 (fig 6) there was an affected boy with no previous family
history.
Cell Separation
Mononuclear cells were isolated from 50ml ofheparinised blood
on a Ficoll-Hypaque density gradient. The mononuclear cells were
then separated into T-enriched and T-depleted fractions by
rosetting with aminoethylisothiouroniumbromide-hydrobromide
(AET)-treated sheep red cells (E). The purity of the E-positive
fraction of cells was assessed with the monoclonal antibodies
UCHT1(CD3), HNK1, UCHM1(CD14), and B1(CD20).
75-85% of the E-positive cells stained with UCHT1 and 7-23%
stained with HNK1. B1 and UCHM1 were less than 1 % with the
exception ofone cell separation (pedigree 5, subject 11, where 4% of
the AET-positive fraction were stained by Bl).
DNA Analysis
DNA was extracted from the E-positive fractions by standard
methods. 15 pg of DNA was digested with Pstl (Northumbria
Biologicals Ltd) in 50 mmol/1 "tris"-HCl pH8, 10 mmol/1 MgCl2,
50mmol/1NaCl at 37°C for 3 h in a reaction volume of 80 pi, BstXI
(Northumbria Biologicals Ltd) was added, and then the sample was
incubated at 56°C for 3 h. The nucleic acids were then precipitated
by adding 40 pi 7-5 mmol/1 ammonium acetate and 240 pi ethanol
with 20 pg glycogen (Boehringer) as a carrier. After 1 h at - 20°C
the sample was centrifuged in a microfuge for 30 min. The DNA
pellet was dried in vacuo and then resuspended in 60 pi of 10mmol/1
"tris"-HCl pH8,l mmol/1 edetic acid, pH8. This was divided into
two equal portions. One portion was digested with Hpall (New
England Biolabs Inc) for 3 h at 37°C in 6 mmol/1 KC1, 10 mmol/1
"tris"7-4,10 mmol/1MgCl2, and 10mmol/1mercaptoethanol. The
samples were run on 0-8% agarose gels and transferred onto nylon
membranes ('Hybond N', Amersham). The probe used was an 800




pattern in for X-linked
Subject investigated T cells SCID Comment
X-linked
Pedigree 1
Obligate carrier Non-random Carrier
Daughter at low risk with
linked probe Random Non-carrier
Pedigree 2
Obligate carrier Non-random Carrier
Daughter at risk,
uninformative with








affected sons Non-random Carrier X-linked
Sister Non-random Carrier inheritance
Sister Random Non-carrier
Pedigree 5
Female with two Autosomal
affected sons Random Non-carrier recessive
inheritance
Pedigree 6
Female with sporadic X-linked
affected male Non-random Carrier inheritance
by Fearon and Vogelstein. Before hybridisation the probe was
preannealed to sonicated salmon sperm DNA (concentration 1
mg/ml) by boiling for 5 min in 3 mol/1 NaCl, 0-4 mol/1 sodium
citrate, and then incubating at 65°C for 30 min. Filters were washed
at a final concentration of 15 mmol/1 NaCl, 1-5 mmol/1 sodium
citrate, 01 % sodium dodecyl sulphate at 65°C, and then exposed to
XAR-5 film at - 70°C for 10 days.
In addition all the family members in the X-linked pedigrees
were investigated with the Pstl polymorphism of the probe
DXS159 as previously described.
Results (Table)
Carrier Detection in X-linked Pedigrees
The linked probe DXS 159 was helpful only in the first of
the three X-linked pedigrees. In pedigree 1, subject II4 is at
low risk ofbeing a carrier because she had inherited the same
allele as her normal brother and the opposite allele from her
carrier sister. The second family was not informative with
the probe, and key members of the third family had died, so
linked probes were not helpful.
Methylation analysis of the T-cell DNA from the obligate
carrier, I2, in pedigree 1 showed the PGK polymorphism
(fig 1, lane la) and loss of the 0-9 kb band after the addition of
Hpall (lane lb). When DNA from her daughter, predicted
with the linked probe to be at low risk, was analysed both
bands were still present after the addition of Hpall (fig 7
lanes 2a and 2b), hence there is a random active X
population in her T cells, which is in accordance with the
linked-probe data and which confirms that she is not a
carrier.
The obligate carrier from pedigree 2 had a non-random
pattern. The two daughters of obligate carriers in pedigrees
2 and 3 had random X populations in their T lymphocytes
and are therefore not carriers.
Testingfor X-linkage
In families 4 and 5 it is not clear from the pedigree
whether the inheritance is autosomal or X-linked.
730 THE LANCET, APRIL 2, 1988
EcoRI
0 DS™ Bgll
BstXI Pvu" BarnHI Pstl : Bglll BstXI
1 1 1 1 I I I I
tintftfI
1 2 3C 5 67 8 9




Fig 1—Restriction map of the 5' region of the PGK gene.
The ZtaXI and Bgll I sites are polymorphic. DNA digested with BstXI and
Pstl in a heterozygote gives bands of 105 kb and 0-9 kb. f indicates Hpall
site.
60% ofall casesmust be X-linked.1 Since the obligate carrier
females in X-linked pedigrees have no immunological
abnormalities, it has often not been possible to differentiate
between X-linked and autosomal inheritance.
The X-linked form has been mapped recently to Xql 1-
ql 3 and carrier detectionmay be possible by use ofthe probe
DXS159 (C, = 5-27 at 8 = 000) (heterozygosity = 0-37).2 This
is useful, but only in families with a clearly X-linked
pedigree and either affected or unaffected males to give
linkage phase.
Another approach to carrier detection for X-linked
disease is the investigation of X inactivation in the cell
population affected by the primary defect. By exploiting the
differences in DNA methylation patterns betwen the active
and inactive X chromosome,3 Vogelstein et al demonstrated
that obligate carriers ofX-linked hypogammaglobulinaemia
have non-random X inactivation in their B cells.4 In the
same way obligate carriers of Wiskott-Aldrich syndrome
have been found to have non-randomX-inactivation in their
T-cells.5We have applied the same technique to SCID and
have used it to differentiate between autosomal recessive and
X-linked inheritance of the disease and to investigate
mothers of sporadic male cases.
Subjects and Methods
Principle of the Method
The Lyon hypothesis states that permanent inactivation ofone of
the two X chromosomes occurs at random in every somatic cell in
the female early in embyrogenesis.6 The pattern ofX chromosome
inactivation is transmitted in stable fashion to all progeny cells. If
one considers a zygote in which one of the X chromosomes carries a
mutant gene, initially the normal X will be active in approximately
halfof the cells and the mutant X active in half of the cells in all the
cell populations in the embryo. However, in cells requiring the
mutant gene for development, cells with the normal X active will
have a selective advantage, so although the initial inactivation was
random, themature cell population will show a non-random pattern
of X inactivation.
Themethod developed by Vogelstein3 takes advantage of the fact
that some genes on the X chromosome have different methylation
patterns on the active and inactive X, and that this methylation
Fig 2—Analysis ofX chromosome inactivation in a normal control.
The fragments indicated by the -» are the 1 05/0 9 kb polymorphism of
PGK. In the first track the DNA has been digested with Pstl and BsiXl but
no Hpall. In the second track the DNA has been digested with Pstl, BstXI
and 11pall.
DXS159 has a PsrI polymorphism with alleles 7-3 kb and 2-3 kb. The
polymorphic bands are marked on the pedigree.
pattern is transmitted in a stable form. Probes from the 5' end of
the hypoxanthine phosphoribosyltransferase (HPRT) and
phosphoglycerate kinase (PGK) genes which will detect both a
polymorphism and also a difference in methylation between the
active and inactive X chromosome are used. One endonuclease is
used to demonstrate the polymorphism and amethylation-sensitive
endonuclease to demonstrate the methylation pattern. The probes
used are not themselves linked to the disease but are used simply to
demonstrate the X-inactivation pattern in the cell population of
interest. The recognition site of Hpall is CCGG but Hpall only
digests when the 5'CG3' dinucleotide is unmethylated. The first
eight Hpall sites shown in figure 1 aremethylated on the inactive X
chromosome and unmethylated on the active X chromosome; the
ninth Hpall site is unmethylated on the active X but is also
unmethylated on 20-40% of inactive X chromosomes. The first
eight Hpall sites and the polymorphic BsrXI site can be
conveniently bracketted by digesting with Pstl and BstXI. This
excludes the ninth Hpall site and so avoids difficulties in
interpreting results which it could cause. Hpall therefore cuts
BstXI/Bstl-digested DNA from this region of active X
chromosomes into small fragments. Hpall does not cut any of the
sites on this region of the inactive X chromosome and so the
polymorphic fragment sizes are unchanged at 1 05 or 0-9 kb. Figure
2 shows T lymphocyte DNA from a heterozygous normal control.
There are two bands present before and after the addition ofHpall
demonstrating a random active X population in these cells.
Subjects
17 females from 6 families were tested for methylation-sensitive
restriction fragment length polymorphisms (RFLPs) for the HPRT
and PGK probes. 10 females from 6 separate families were found to
be heterozygous for the PGK polymorphism and were investigated
further. None of the women were heterozygous for the HPRT
polymorphism. X-inactivation in the T lymphocytes of the 10
females heterozygous for PGK was investigated.
In pedigree 1 (fig 3) an obligate carrier, I2, and her at-risk
daughter, II4, were investigated. An obligate carrier and her
daughter were investigated from pedigree 2. From pedigree 3
another daughter of an obligate carrier was investigated.
In pedigree 4 (fig 4) proband II2 had had two sons who had died
from SCID and two brothers who had died in infancy, but
unfortunately there was no clinical information about them and it
was therefore not clear whether this was the X-linked form of the
disease. In this pedigree the proband and her sisters II4 and II6have
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while in hospital, and only 3-4% of such patients suffered a
morbid cardiovascular event. Thus decisions about
transfusion may need to take into account both the
preoperative haemoglobin level and the expected amount of
blood loss during surgery—the latter depending on the
surgical procedure, the surgeon, and the technique used.
The increase in mortality we found when haemoglobin
levels fell below 8 g/dl corresponds to what is known about
physiological responses to both anaemia and surgery.1
Anaemia reduces the oxygen-carrying capacity of the blood,
and the cardiac output usually rises when haemoglobin
drops acutely to less than 8 g/dl.1 Thus the cardiac reserve
needed to compensate for new increases in oxygen demand
or hypoxaemia is diminished. Surgery and anaesthesia can
cause hypoxia by several mechanisms. Therefore the risk of
tissue hypoxia is enhanced in the anaemic patient
undergoing surgery.
These considerations suggest that thresholds for
transfusion may need to be modified for patients with
underlying disease and those who are subject to additional
physiological stresses unrelated to the surgical procedure,
such as hypoxaemia or serious infection. Patients in whom
the response of cardiac output to stress is already impaired
and those in whom cardiac output has already risen in
response to a stress occurring before surgery may be more
susceptible to the adverse effects ofanaemia during surgery.
There is evidence that patients with acute blood loss may
tolerate surgery less well than those with chronic
compensated anaemia, such as that due to chronic renal
failure.12 Thresholds for transfusion may also need to be
modified for patients with other specific types of anaemia.
Anaemiamay also be amarker formore severe underlying
illness, which may, in turn, increase the surgical risk.13 In
our study, however, the relation between preoperative
haemoglobin and operative blood loss, on the one hand, and
postoperative mortality, on the other, were independent of
all confounding variables measured.
Our data on potential confounding variables, obtained
retrospectively, might not truly reflect the patient's clinical
status. However, there is no reason to think that this method
of data collection caused any systematic bias. Our patients
differed from others only in their refusal to accept blood
transfusion. Intraoperative and postoperative management
was otherwise identical to that provided for other surgical
patients, and blood volume was maintained with standard
methods. If only the least ill patients with preoperative
haemoglobin levels between 8 and 10 g/dl had been accepted
for surgery, the effect of anaemia on mortality would have
been underestimated. However, we found no evidence of
such selection.
Our study corroborates the widely held belief that the
haemoglobin level is an important independent predictor of
postoperative death but calls into question the accepted
transfusion threshold of 10 g dl. Our results also suggest that
the amount of blood loss expected is an important
consideration in deciding whether to transfuse a patient
before operation.
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Strom, Dr Randall Cebul, and Dr Sankey Williams for their helpful
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USE OF X CHROMOSOME INACTIVATION
ANALYSIS TO ESTABLISH CARRIER STATUS
FOR X-LINKED SEVERE COMBINED
IMMUNODEFICIENCY
J. Goodship S. Malcolm
Y. L. Lau M. E. Pembrey
R. J. Levinsky
Departments of Immunology and Paediatric Genetics, Institute of
Child Health, London
Summary Analysis of X chromosome inactivation in
T-lvmphocyte DNA from two obligate
carriers of X-linked severe combined immunodeficiency
showed a non-random pattern. This method was then used
to establish carrier status in at-risk females in X-linked
pedigrees. It was further used to differentiate between
X-linked and autosomal recessive inheritance of the disease
when the mode of inheritance was not clear from the
pedigree. In addition, a mother of a boy affected by the
sporadic form of the disease was found to have non-random
X inactivation in her T lymphocytes and she is therefore a
carrier of the X-linked disease.
Introduction
Severe combined immunodeficiency (SCID) is a
heterogeneous group of disorders that can be inherited in
X-linked or autosomal recessive forms. The children are
born without any cell-mediated or humoral immunity and
invariably die of infection within the first 2 years of life
unless treated by bone-marrow transplantation. The clinical
features do not allow distinction between the different
modes of inheritance and, although all children have absent
T-cell function, there is considerable variation in numbers of
T and B cells. Approximately 25% of cases of the autosomal
recessive form are due to deficiency of the purine-
degradation enzyme, adenosine deaminase, and this form
can be readily identified. For all types of SCID combined,
the ratio ofmales to females affected is approximately 4:1, so
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Linkage of PGK1 to X-linked severe combined immunodeficiency (IMD4)
allows predictive testing in families with no surviving male
Judith Goodship1*, Roland Levinsky2, and Sue Malcolm1
department of Paediatric Genetics and department of Immunology, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
Summary. We present a linkage map of DNA probes around
the X-linked severe combined immunodeficiency (IMD4)
locus at Xqll-13. DXS159 and PGK1 show no cross-overs
with the disease locus (Lod 3.01 at 0 = 0.00). The order of loci
is DXS1-DXS106-(DXS159-PGK1-IMD4)-DXS72-DXYS1.
Members of families whose carrier status has been established
by X-inactivation patterns were included in the analysis. As
the probe (pSPT/PGK), which is used for investigation of X-
inactivation patterns, has been shown to be linked to the dis¬
ease itself, it is possible to assign phase in mothers of sporadic
cases who have been shown to be carriers, even when they
have no surviving male offspring.
Introduction
Severe combined immunodeficiency (SCID) is a syndrome in
which affected infants lack both cellular and humoral immun¬
ity; they die in infancy from overwhelming infection if bone
marrow transplantation is not successful. There is an X-linked
recessive form and several autosomal forms of SCID, which
cannot be distinguished on clinical or immunological grounds,
although the autosomal form caused by adenosine deaminase
deficiency can be diagnosed by enzyme assay. Female carriers
of the X-linked form are immunologically normal but have a
non-random pattern of X-inactivation in their T cells (Puck et
al. 1987; Goodship et al. 1988). The X-inactivation pattern
can be investigated in women who are heterozygous for re¬
striction fragment length polymorphisms detected by probes
from the 5' end of the phosphoglycerate kinase and hypo-
xanthine-guanine-phosphoribosyl transferase genes (Vogel-
stein et al. 1987). There are differences in the methylation pat¬
tern on the active and inactive X chromosome at the 5' end of
these genes, differences that are transmitted from cell to cell
in a stable fashion and that can be demonstrated using the
methylation-sensitive endonuclease Hpall.
IMD4 has been mapped to Xqll-ql3 (de Saint Basile et
al. 1987). A maximum Lod score of 5.27 at 0 = 0 has been re¬
ported for DXS159 and recombinants have been observed be¬
tween IMD4 and DXS1, and between IMD4 and DXYS1 (de
Saint Basile et al. 1987). Three additional probes in the re¬
gion, pSPT/PGK, cpX203 and pX65H7, detecting the loci
PGK1, DXS106 and DXS72, respectively, have been included




Five families were investigated (Fig. 1). Families KHA, TEB
and BER were included in our previous report (de Saint
Basile et al. 1987). At least one male in each family had been
investigated and fulfilled the diagnostic criteria set out by the
WHO Committee on immunodeficiency (WHO Report 1986).
In four families, there was unequivocal X-linked transmission
on pedigree grounds and, in the fifth family, there was a non-
random pattern of X-inactivation in the mother of two affect¬
ed males. The carrier status of females who had not had af¬
fected offspring and who were heterozygous for the pSPT/
PGK polymorphism was determined by methylation analysis
(Goodship et al. 1988). Eleven females were obligate carriers
on pedigree, and the carrier status of an additional seven
women was determined by methylation analysis.
DNA analysis
The probes p8 (DXS1), cpX289' (DXS159), pSPT/PGK
(PGK1), cpX203 (DXS106), pX65H7 (DXS72) and pDP34
(DXYS1) were used to detect restriction fragment length
polymorphisms (Davies et al. 1987). DNA extraction, restric¬
tion endonuclease digestion, electrophoresis, blotting and
hybridisation were carried out using standard procedures (Old
1986). Fibroblasts from two affected males who had had bone
marrow transplants were cultured for DNA extraction.
Data analysis
Data were prepared for analysis using LINKSYS (Attwood
and Bryant 1988). Two point linkage analysis was carried out
using LIPED. The data were also analysed using the LINKMAP
section of LINKAGE version 4.7.
The loci used in the LINKMAP analysis were DXS106,
DXS159, PGK1 and DXYS1, detected by the probes cpX203,
cpX289, pSPT/PGK and pDP34, respectively. No figure is
available for the distance between DXS106 and DXS159, and
an arbitrary figure of 2cM was used for the analysis. The dis-
* Present address: Department ofChild Health, Newcastle-upon-Tyne
NE2 4HH, UK
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'The probe used to detect this polymorphism was originally described
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Fig.l. The families used in the linkage study.
© Obligate carrier female; ® female with a non-
random pattern of X-inactivation; © female with a
random pattern of X-inactivation; O female of un¬
known carrier status, homozygous for the BslXl poly¬
morphism detected by pSPT/PGK. + Indicates pres¬
ence of a polymorphic site; — indicates absence of a
polymorphic site; ■ result not obtained. The order of
loci on all the pedigrees is DXS1, DXS106, DXS159,
PGK1, DXS72 and DXYS1. The two recombinations
are marked <—
BER TEB
pg^ir i ^ I in 0
tance estimated between the probes DXS159 and DXYS1 is 8
cM (Arveiler et al. 1987). A recent report gave a DXS159-
PGK1 distance of 10 cM with confidence limits ranging from 4
to 19 (Mahtani and Willard 1988). We have not observed any
recombinations between DXS159 and PGK1. There is no pub¬
lished estimate of the distance between the probes PGK1 and
DXYS1. In view of this discrepancy, three analyses were car¬
ried out first using recombination fractions 0.02 0.01 0.07,
then 0.02 0.04 0.04 and then using 0.02 0.07 0.01, so moving
PGK1 from DXS159 to DXYS1.
Results
The haplotypes are shown on the pedigrees in Fig.l. The
order of loci on which the haplotypes are based is DXS1-
DXS106-DXS159-PGK1-DXS72-DXYS1. The haplotype
for I2 of pedigree HAL is ambiguous but there are no cross¬
overs between the five informative probes in any of the possi¬
ble haplotypes.
There were no recombinations between IMD4 and DXS159,
PGK1 or DXS72. The maximum Lod score by two point anal¬
ysis for IMD4-PGK1, including females whose carrier state
was determined by methylation analysis, was 3.01 at 0 = 0.
Adding the new information from these pedigrees for DXS159-
Table 1. Lod scores for X linked immunodeficiency between DXS106
and DXYS1 generated by LINKMAP. In analysis 1 the distances be¬
tween the four loci were 0.02:0.01:0.07, in analysis 2 the distances
were 0.02:0.04:0.04 and in analysis 3 the distances were 0.02:0.07:
0.01
DXS106 DXS159 PGK1 DXYS1
1 — 00 5.11 5.03 — 00
2 — 00 5.11 4.70 — 00
3 — 00 5.11 4.00 — 00
IMD4 linkage to our previously published data (de Saint
Basile et al. 1987) increases the two point Lod score to a max
of 7.08 at 0 = 0.
Only two crossovers were observed within any of the hap¬
lotypes. These were between DXS159 and DXS106 in II3 of
pedigree TEB and between PGK1 and DXYS1 in IV! of pedi¬
gree KHA (Fig. 1).
LINKMAP analysis of IMD4 against the data from these
five pedigrees for the set of markers that flank the gene, i.e.
cpX203, cpX289, pSPT/PGK, and pDP34, is presented in
Table 1. The maximum Lod scores using LINKMAP become
5.11 at the cpX289 locus and 5.03 at the pSPT/PGK locus in
the first analysis (Fig. 2), falling to 4.7 at the pSPT/PGK locus
in the second analysis, and 4 at the pSPT/PGK locus in the
third analysis with pSPT/PGK placed 7cM from cpX289 and
only lcM from pDP34.
PGK1 linkage and X-inactivation analysis for family LAW
is presented in Fig. 3a. There was a single affected boy in the
family but no material for DNA analysis was available; it was
therefore impossible to test which pSPT/PGK or cpX289 al¬
lele he had inherited. X-inactivation studies (Fig. 3b) show
that his mother has a non-random pattern of active X chromo¬
somes in her T cells and that the active, i.e. normal, X chro¬
mosome carries the lower 0.9 kb allele; this is the X chromo¬
some inherited from her father. We are therefore able to pre¬
dict that the defective gene is carried on the chromosome with
the upper 1.05 kb band; in view of the close linkage of IMD4
and PGK1, prenatal diagnosis could be offered in a future
pregnancy.
Discussion
IMD4 has been previously mapped to Xqll-13 by its close
linkage to DXS159 (de Saint Basile et al. 1987). The order of
other probes in the region has been established by a number
of studies using somatic cell hybrids, X chromosome deletions
13
pDP34
Fig. 2. Lod scores calculated by LINKMAP for varying locations for
IMD4 on proximal Xq
a b
Fig. 3. a Southern blot analysis of family LAW showing the alleles de¬
tected by pSPT/PGK after DNA digestion with Bgll. This poly¬
morphism is in linkage disequilibrium with the BstXI polymorphism.
The allele sizes are marked in kb. b X-inactivation analysis of proband
in family LAW. The DNA in the first track has been digested with
Pstl and BstXl, and shows the polymorphism. The DNA in the sec¬
ond track has been digested with Pstl, BstXl and Hpall. The allele
sizes are marked in kb
and duplications, and is known to be centromere-p8-cpX203-
cpX289-pSPT/PGK-pX65H7-pDP34 (Cremers et al. 1987;
Arveiler et al. 1987; Mahtani and Willard 1988; Cremers et al.
1988). Recombinations have previously been reported be¬
tween IMD4 and DXS1, and IMD4 and DXYS1 (de Saint
Basile et al. 1987). From the recombination observed in fam¬
ily TEB, IMD4 is distal to DXS106. In addition, two families
have been reported in which there were deletions on the X
chromosome in males with choroideremia; these deletions ex¬
tended from the XY homologous region and included the
probe pX65H7 (Schwartz et al. 1988; Nussbaum et al. 1987).
As the males with these deletions did not have SCID, the dis¬
ease locus must lie proximal to DXS72. Thus, DXS106 and
DXS72 are closer flanking markers for the disease locus, and
the order is cen-DXSl-DXS106-(DXS159-PGKl-IMD4)-
DXS72-DXYS1.
Despite two extensive linkage studies (Arveiler et al. 1987;
Mahtani and Willard 1988), the distances between the probes
remains uncertain. This has caused difficulties in using LINK-
MAP. However, the maximum location score found at pSPT/
PGK varies comparatively little within the range of possible
distances.
The linkage data for PGK1 and IMD4 and the physical
mapping information placing PGK1 between DXS159 and
DXS72 provides an additional polymorphic marker that can
be used for predictive testing. Using the probes cpX289 and
pSPT/PGK, 65% of females should now be heterozygous for
closely linked probes.
Furthermore, pSPT/PGK is one of the probes that can be
used for investigation of X-inactivation patterns in carrier test¬
ing. As we have shown that PGK1 is linked to IMD4, we can
assign phase in a female without following the tracking proce¬
dure normally used. It is now possible to assign phase in fam¬
ilies that do not have an adequate family structure for tracking
the linked probe through the family. In addition, it is possible
to assign phase in mothers of sporadic males, mothers who are
shown by inactivation studies to be carriers even if their affect¬
ed child has died before tissue could be stored for DNA ex¬
traction and although they may themselves carry a new muta¬
tion. This ability to assign phase in a woman without looking
at the mutation directly or tracking haplotypes is a novel situa¬
tion.
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Close linkage of random DNA fragments from Xq 21.3-22
to X-Iinked agammaglobulinaemia (XLA)
S.Malcolm1, G.de Saint Basile", B.Arveiler, Y.L.Lau1, P.Szabo4, A.Fischer, C.Griscelli:, M.Debre2, J.L.Mandel3,
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Summary. Linkage analysis of 15 families affected by X-linked
agammaglobulinaemia (XLA) showed close linkage with
three probes located towards the centre of the long arm of the
X chromosome. No cross-overs were found using pXG12
(DXS94) lod 6.6 or S21 (DXS17) lod 4.4. One cross-over was
found with 19.2 (DXS3). This confirms and extends a previous
linkage study (Kwan et al. 1986) which demonstrated linkage
with S21 and 19.2. Of the families 14 were informative for
either pXG12 or S21 and these probes should thus be of great
diagnostic value. No evidence of heterogeneity was found in
the XLA families but several cross-overs within this region
were detected in a family with the X-linked hypcr-lgM syn¬
drome confirming this disease as a separate clinical entity.
Introduction
X-linked agammaglobulinaemia (XLA) is a severe humoral
immunodeficiency in which affected males lack all immuno¬
globulin isotypes. Prior to treatment with antibiotics and regu¬
lar immunoglobulin therapy, the children died of infections in
early childhood (Rosen et al. 1984). Since the majority of af¬
fected children have pre-B cells in their bone marrow (Bur¬
rows et al. 1979) but lack circulating mature B cells, the mu¬
tated gene responsible for the disease is presumably involved
in B cell differentiation. After the age of 6-9 months, once
maternal acquiredljrG has diminished, affected males present
clinically with repeated bacterial infections. The diagnosis is
readily made by the hypo- or agammaglobulinaemia involving
all isotypes, the lack of circulating B cells and consequent lack
of plasma cells. Obligate carrier females are not detectable by
any immunological criteria. Although B cells can be detected
prior to 20 weeks gestation in foetal blood (Linch et al. 1982)
this may not be sufficiently reliable to offer accurate prenatal
diagnosis especially as some heterogeneity with respect to the
presence or absence of B cells in XLA patients has been de¬
scribed (Leickley and Buckley 1986). With the advent of
DNA probes that loosely mapped the XLA locus (Kwan et al.
1986; Mensink et al. 1986) carrier detection and prenatal diag¬
nosis by analysis of chorionic villus biopsy material became
Offprint requests to: R.J.Levinsky
feasible. We now report that a further probe pXG12 together
with probe S21 closely maps the XLA locus to the Xq 21.3-22
region of the X chromosome.
Materials and methods
Sample collection
Samples were collected from members of 15 families in each
of which an affected boy with X-linked agammaglobulinaemia
had been a patient at either the Hospital for Sick Children,
London, East Birmingham Hospital, Northwick Park Hospi¬
tal, London or Hopital d'Enfants Maladcs, Paris. Fifteen
index patients were diagnosed as having XLA with character¬
istic immune profiles. The index patient in a 16th family was
diagnosed as having the hypcr-lgM syndrome; he had abnor¬
mally high scrum IgM levels, no serum IgG or IgA and his B
cells present in normal numbers had only IgM and IgD on the
cell surface. Women were only considered to be carriers if
they had at least two affected sons or an affected son plus an
affected maternal uncle or cousin.
Blood samples were collected in ethylenediaminetetraace-
tate (EDTA). One patient (MB) suffered from choroiderae-
mia and mild mental retardation and was shown by cytogenet¬
ics and DNA analysis to have an Xq deletion (Robertson et al.
1986). ' '
X-chromosome probes
Probes PXG12 (DXS94). S21 (DXS17) and 19.2 (DXS3) were
used to detect restriction fragment length polymorphisms.
PXG12 detects a Pst 1 polymorphism with alleles 7.2 kb and
6.5 kb; S21 a Taq 1 polymorphism with alleles 2.2 kb and 2.0
kb; 19.2 a Taq 1 polymorphism with alleles of 5.0kb or a
doublet of 2.9 and 2.2 kb.
Detection ofpolymorphisms
DNA extraction, restriction enzyme digestion, electrophore¬
sis, blotting and hybridisation were carried out by standard
procedures (Old 1986). Lod scores were calculated using the




pXG12 had previously been mapped to the proximal region of
the long arm of the X chromosome (Goodfellow et al. 1985).
Two lines of evidence show that it lies between 19.2 and S21.
pNA was extracted from a man. MB, suffering from choroid-
eraemia and mild mental retardation but in whom there was
no impairment of either cellular or humoral immune function.
[Tiah resolution chromosome studies showed that band Xq21
was about half its normal size, probably due to a deletion of
sub-band Xq21.1 (Hodgson et al. 1987). DNA studies showed
that both the X locus of DXYS1 (pDP34) and DXS3 (19.2)
were deleted. However, a clear 6.5 kb allele of PXG12 was
observed, showing that PXG12 lies outside the DXYS1-DXS3
segment. Evidence that it falls below 19.2 rather than above
pDP34 comes from multi-point analyses in families. In one
family with individuals heterozygous for all four probes the
pattern of inheritance could most simply be explained (i.e.
only assuming single cross-overs) if the order is pDP34, 19.2,
PXG12, S21 (Arveiler and Saint Basile, in preparation).
Table 1. Summary of lod scores between XLA and DXS17 and
DXS94, both of which map to Xq21.3 to Xq22
Locus DXS17 DXS94 DXS3
Probe S21 pXG12 19.2




0.00 4.44 6.65 -
0.01 4.43 6.64 2.40
0.05 3.97 5.97 3.63
0.10 3.48 5.27 3.41
0.15 2.98 4.56 3.07
0.20 2.45 .3.82 2.65
0.25 1.93 3.07 2.19
0.30 1.42 2.33 1.71
0.35 0.93 1.61 1.24
0.40 0.51 1.06 0.78
0.45 0.18 0.39 0.32
0.45 0.00 0.00 0.00
Combined data this study and Kw an et al. (1986)
0.00 6.61
•
0.05 :t - 7.2S
Linkage of S21, pXG12 and 19.2 in families with XLA
Members of 15 XLA families were analysed for restriction
fragment length polymorphism (RFLPs) using the probes
pXG12. S21 and 19.2. No cross-overs were found using cither
S21 or pXG12 and lod scores of 4.44 and 6.65 respectively
were calculated (see Table 1). Combining this data for S21
with that published by Kwan et al. (1986), a lod score of 6.61
at 0 = 0 is found. One cross-over was found with the probe
19.2 but this was in the only family uninformative for both
pXG12 and S21. Therefore using the two probes S21 and
pXG12 it is possible to improve considerably carrier detection
for female relatives at risk.
Linkage studies in a family
with X-linked hyper-lgM syndrome
Analysis for RFLPs was carried out in a family with X-linked
hyper-lgM syndrome (Fig.l). One cross-over with known
phase was observed with probes 19.2 and pXG12 as pedigree
individual IIL carries the same haplotype as his affected
brother: S21 was uninformative in this case. A further cross¬
over with S21 was observed in a different part of the pedigree.
The normal brother (IL) has inherited the same haplotype as
his two carrier sisters. As L is also informative for S21 the
cross-over in this case does not lie between pXG12 and S21.
The results from this family indicate that X-linked hyper-lgM
syndrome and XLA are not allelic.
Discussion
There are several X-linked immunodeficiency syndromes that
can result in hypo- or agammaglobulinacmia. These are XLA,
X-linked hyper-lgM syndrome, Wiskott-Aldrich syndrome,
X-linked lymphoprolifcrative syndrome where a minority of
cases present hypogammaglobulinacmia, and X-linked severe
combined immunodeficiency where both cellular and humoral
immunity are lacking. The genetic defects in these syndromes
although resulting to some extent in hypogammaglobulinae-
mia probably comprise distinct gene mutations. Evidence in
favour of this comes from the work of Conley et al. (1986)
who showed that the mutation in XLA was specific to B cells
whereas that in X-linked severe combined immunodeficiency
affected both T and B cells (Puck ct al. 1986).
Although it is usually possible to differentiate between all
these syndromes on the basis of immunity function testing,'
some heterogeneity has been described in families with XLA
with respect to the presence or absence of B cells (Leickley
and Buckley 1986). Because of this, it is important to have as







Fig.l. Pedigree with RFLP data of family with
X-linked hyper-lgM syndrome. Results are given
for 19.2 (top) pXG12 (centre) S21 (bottom);
(+) indicates presence of restriction site;
(—) indicates absence of restriction site. Recombi¬
nations have occurred between the disease locus
and all the probes represented in the haplotype in
the meioses leading to IL and IIL
1,74 -
firm genetic linkage. The diagnostic criteria for XLA were the
lack of immunoglobulins of all isotypes and < 1% circulating
B cells in the peripheral blood. All of the families studied had
clear-cut X-linked pedigrees.
Initial indication of the chromosomal localisation of XLA
came from Kwan et al. (1986) who found linkage with 19.2
0 = 0.04 with a lod score of 3.65 and with S21 at 0 = 0 with a
lod score of 2.17. Mensink et al. (1986) confirmed linkage
with 19.2 by examining a single large family which gave a lod
score of 3.30 at a recombination fraction of 0.06. However,
examination of a further family suggested to them that there
may be genetic heterogeneity with clinically and immunologi¬
cally indistinguishable forms of the disease mapping to differ¬
ent loci. We have confirmed and extended linkage data with
1.9.2 and S21 and also found another probe pXG12 which is
very closely linked (0 = 0, lod score 6.66). As 14 out of 15 of
our families were informative for either S21 or pXG12 and as
we-have observed no-cross-overs with either probe we have
found no evidence for any genetic heterogeneity. The 15th
family unfortunately was not informative for either S21 or
pXG12. In this pedigree one cross-over with unknown phase
was observed with probes 19.2 and pDP34.
Nonetheless it is difficult to reconcile the lack of genetic
heterogeneity found by our study and that of Kwan et al.
(1986), with the clear-cut XLA family described by Mensink
et al. (1986) in whom no linkage with the Xq21-22 region was
found. The authors claim that the affected males were indis¬
tinguishable from others with XLA by immunological criteria.
As they found negative lod scores with the markers they ex¬
amined along all of the X chromosomes, they suggest autoso¬
mal dominant and male limited inheritance (Ott et al. 1986).
Since the presumed genetic defect in XLA involves the dif¬
ferentiation step from pre-B cell to B cell there should be non-
random inactivation of the X chromosome in surviving B cells
of carrier females (Conlcy et al. 1986). If the disease is autoso¬
mal such X-inactivation would be random and this could be
tested by methylation patterns (Vogelstein et al. 1985). Alter¬
natively Mensink et al. (1987) propose that the heterogeneity
found in their family could be due to mosaicism in the mater¬
nal grandfather (half chromatid mutation).
In contrast to the XLA families, at least two cross-overs
were observed in the X-linked hvper-IgM pedigree. This
clearly indicates a distinct localisation for the genetic defect in
this disease.
Previous mapping data has placed S21 and 19.2 within
bands Xq21.3-22 (Goodfellow et al. 1985). Extensive probe-
to-probe linkage data are not available and the best estimate
of the distance between 19.2 and S21 is 0 = 0.06, based on one
cross-over in 17 meioses (Dravna and White 1985). The same
study suggested on linkage grounds that 19.2 maps above S21
on Xq. Our overall figures in the XLA families of 0 = 0.05 for
19.2 and 0 = 0 for S21 agrees well with this map distance.
The combination of deletion data and probe-to-probe data
indicates that the gene order is centromere-pDP34—19.2—
pXG12-S21. Due to the lack of recombination events in the
families we have studied we are unable to place XLA exactly
within this cluster although the two cross-overs observed with
19.2 (0 = 0.05) and the fact that 19.2 is deleted in the patient
with choroideraemia but normal immunity suggests that the
XLA locus must lie very close to S21 and pXG12. Since both
probes are highly polymorphic and closely linked to XLA and
to each other (B. Arveiler and G.de Sainte Basile; in prepara¬
tion), they can be used in genetic counselling to greatly im¬
prove genetic prediction. Some female relatives can be show
to have a high risk of being a carrier, and coupled with pe(j;
grce information others can be given a reassuringly low risk
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Genetic Prediction in X-Linked
Agammaglobulinaemia
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Hospital, Harrow, Middlesex, United Kingdom
S21 (DXS17) and pXG12 (DXS94), two probes linked to the locus of X-linked
agammaglobulinaemia (XLA), were used for genetic prediction in 13 such families. A
method of allowing for nonallelic genetic heterogeneity was demonstrated in the
calculation of the genetic risks, specifying a certain proportion of unlinked families. We
further estimated the impact due to the uncertainty of the proportion of unlinked
families on the final genetic risks in each family and this can be taken into account
during genetic counselling.
Key words: XLA, nonallelic genetic heterogeneity, genetic linkage, gene tracking
INTRODUCTION
X-linked agammaglobulinaemia (XLA), first described by Bruton [1952], is
characterised by panhypogammaglobulinaemia, virtual absence of B lymphocytes in
blood, and normal number of pre-B cells in bone marrow [Pearl et al., 1978; Rosen et al.,
1983; Conley, 1985]. It was always fatal until the use of antibiotics and immunoglobulin
replacement. Even with treatment, long-term survivors may suffer chronic lung disease
and are susceptible to severe disseminated viral infections [Lederman and Winkelstein,
1985]. The female carriers of this X-linked recessive disease are healthy and cannot be
identified immunologically. However, carrier status can be ascertained by analysing
X-chromosome inactivation in the B-cell lineage [Fearon et al., 1987], but this is not easy
in practice. Since the XLA gene locus has recently been mapped to Xq21.3-22 using
linkage to restriction fragment length polymorphism (RFLP) [Kwan et al., 1986; Mensink
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et al., 1986; Malcolm et al., 1987], it is now possible to offer carrier detection and prenatal
diagnosis using gene tracking. However, the question of nonallelic genetic heterogeneity
[Mensink et al., 1986; Mensink et al., 1987a; Ott et al., 1986] has complicated this
approach in genetic counselling.
Here we demonstrate that the closely linked probes pXG12 and S21 are clinically
useful in most families and demonstrate a method of allowing for nonallelic genetic
heterogeneity in the risk calculation.
MATERIALS AND METHODS
Families
All index patients satisfied the diagnostic criteria of the WHO scientific group on
immunodeficiency [Rosen et al., 1983]. Out of 13 XLA families, 11 were studied
previously and demonstrated linkage between the XLA locus and probes pXG12
(DXS94), S21 (DXS17), and 19-2 (DXS3) [Malcolm et al., 1987], One of the other 2
families has only one affected male living, with an affected brother who died. One family
contains a single affected male with the mother wanting prenatal exclusion. Seventeen
obligate carriers and 34 females at risk of being carriers were studied.
We also include one additional family previously reported in 1962 [Jamieson and
Kerr, 1962] as XLA, which has been studied since the original linkage analysis [Malcolm
et al., 1987]. The only living affected male was investigated by Dr. Roifman in Toronto
recently and was found to have no peripheral B cells and panhypogammaglobulinaemia.
DNA Analysis
DNA extraction from blood and chorionic villi, restriction enzyme digestion,
electrophoresis, Southern blotting, and hybridisation were performed by standard methods
[Old, 1986]. X-chromosome specific probes pXG12 (DXS94), S21 (DXS17), and 19-2
(DXS3) [Drayna et al., 1984; Aldridge et al., 1984; Goodfellow et al., 1985] were used in
the initial linkage analysis [Malcolm et al., 1987], but only pXG12 and S21 were used in
the genetic counselling of potential carriers and prenatal prediction.
Risk Calculations
Proportion of families unlinked to S21/pXG12. There are now 27 XLA families
published [Kwan et al., 1986; Malcolm et al., 1987; Ott et al., 1986] which are informative
for linkage analysis with S21 and/or pXG12. Two families have significantly negative lod
scores in relation to the S21 locus using multipoint linkage analysis and thus appear not to
be linked to the S21 locus [Ott et al., 1986], but there are no other crossovers with S21 or
pXG12 in the remaining 25 families. One family (pedigree Z) definitely demonstrates
nonallelic genetic heterogeneity [Mensink et al., 1986; Ott et al., 1986], but the other
(pedigree EsB) depends on the assumption that one boy (III-1) who died in childhood
before 1950 was affected with XLA. Another such family is the additional family
previously reported by Jamieson and Kerr [1962] as XLA and in whom the only surviving
affected male was found to have no peripheral B cells and panhypogammaglobulinaemia,
which are the immunological features of XLA. Our recent linkage analysis shows 2
crossovers between S21 and the disease locus out of 3 informative meioses. On the present
evidence the proportion ofXLA families unlinked to the region of Xq21.3-22 is likely to be
about 10% and unlikely to exceed 30%.
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Method of allowing for nonallelic genetic heterogeneity. The published families with
S21 linkage data [Kwan et ah, 1986; Mensink et al., 1987a; Malcolm et ah, 1987],
excluding the 3 unlinked families, give a maximum lod score of 10.5 at a recombination
fraction (0) of 0 with 90% confidence intervals 0 to 0.04 as defined by taking the range of 6
at one less than the maximum lod score [Conneally et ah, 1985], This represents 40
informative meioses observed in 15 families with no recombination between the disease
locus and S21. Twenty-two informative meioses were observed with no recombination with
pXG12 in 11 families in our original study [Malcolm et ah, 1987]. Therefore, we decided
to use S21 and pXG12 in genetic counselling of XLA families, quoting a recombination
fraction of 0.04.
As most pedigrees are small, significant lod scores are unlikely to be observed within
any one family. However, the larger the family and the greater the number of informative
meoises, the greater is the certainly that the disease locus in that family is linked to
S21/pXG12. We have developed a method of calculation that allows for nonallelic genetic
heterogeneity which incorporates a specified proportion of unlinked families as well as the
probability of linkage within that particular family to the DNA markers used for genetic
prediction. The correct figure for the proportion of unlinked families is uncertain but we
show what effect using figures between 10% and 30% have on the final prediction in any
particular family. This can be taken into account when counselling the family.
The formal calculations are as follows. For any individual the probability of a
specific XLA genotype, given the pedigree and marker (RFLP) data, can be expressed
as
t . Pr(genotype,pedigree)Pr (genotype!pedigree)
Pr(pedieree) <D
If there is genetic heterogeneity, the numerator and denominator in this expression
will be made up of 2 parts, depending on whether the pedigree is linked or unlinked, for
example the numerator will be
Pr (linked) • Pr (genotype, pedigree | linked)
(2)
+ Pr (unlinked) • Pr (genotype, pedigree | unlinked)
In the first part of the above expression (Eq. 1), the prior probability that the disease
segregating in that pedigree is in fact linked with the marker locus is multiplied by the
probability of the specific genotype in the individual in question and the pedigree data
given that the disease is linked to the marker (9 = 0.04). In the second part of the
expression (Eq. 2), it is assumed that the disease is not linked to the marker (i.e., d = 0.5).
Probability (Eq. 1) can therefore be expressed as
Pr (linked) • Pr (genotype, pedigree| linked)
+ Pr (unlinked) • Pr (genotype, pedigree | unlinked) ^
Pr (linked) • Pr (pedigree | linked)
+ Pr (unlinked) • Pr (pedigree | unlinked)
Pr(pedigree | linked) is the probability of the pedigree's assuming the XLA genotype
of the individual at risk is unknown and given that the disease is linked to the marker.
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Fig. 1. Pedigrees of the 13 families with S21 (DXS17) Taq 1 polymorphism (SI - 2.2 kb; S2 = 2.0 kb) and
pXG12 (DXS94) Pst 1 polymorphism (XI - 7.2 kb; X2 = 6.5 kb).
These probabilities, together with their equivalents where the disease is unlinked to the
marker, can be obtained from the computer programme Liped [Ott, 1974], in which
recent versions give specific instructions for risk calculation.
RESULTS
Carrier Detection
The pedigrees and the segregation of the S21 and/or pXG12 alleles are shown in
Figure 1. Table I lists all obligate and potential female carriers from the 13 families, giving
risk estimates and the possibility of prenatal diagnosis. The final risks combining pedigree
and DNA data are calculated assuming the proportion of unlinked families to be 0%, 10%
and 30%. Of the 17 obligate carriers, 7 are under the age of 45 yr and can all be offered
prenatal diagnosis, using S21 in 2, pXG12 in 4, and either probe in one. Of the 34 females
at risk of being carriers, 17 have their risks increased, 15 decreased and 2 unchanged by
the RFLP results. Eleven of the 17 women whose risks were increased are under 45 yr and
7 of them can be offered prenatal prediction.
The Impact of Varying the Proportion of Unlinked Families in Predicting
Low Risks
Of the 15 women whose carrier risks were decreased, 3 were already below 5% and 7
were reduced to under 5% if the proportion of unlinked families is assumed to be 10%. Of
these seven, 6 would still have a risk below 5% if a figure of 30% unlinked families were
used; the other would have a risk of 5.14% (Table I).
Prediction in Males
In family 3, II-1 was shown to be at high risk of being a carrier with both S21 and
pXG12. She is heterozygous for S21 and hence prenatal diagnosis is possible. However,
she was well into the last trimester of her second pregnancy before the linkage study of
XLA was completed. Pregnancy proceeded to term and a male infant (III-2) was born.
RFLP analysis of cord blood indicated that he runs a low risk of being affected with XLA.
With the family having three meioses supporting linkage with S21, the risk to her son is
4.25-5.62% (assuming 10% or 30% unlinked families, respectively). He was shown to have
normal numbers of circulating B lymphocytes and normal immunoglobulin level and is
clinically normal at age one yr.
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A woman (family 13) with only one son affected with XLA but no family history
presented for prenatal exclusion at 9 wk of pregnancy. She was shown to be heterozygous
for S21 and the affected son inherited the 2.2-kilobase (kb) allele. Chorionic villus
sampling was performed and the fetus was shown to have a 46, XY chromosome
constitution and inherited the opposite 2.0-kb allele to the affected boy. A residual risk of
10% of the fetus being affected with XLA was quoted to the parents. This figure takes into
account the possibility that the affected boy is a new mutation and that the mother is
linkage phase unknown if she were a carrier. The calculated risk was 7.97%, 10.79%, and
13.6% according to whether 10%, 20%, or 30% of families are unlinked. They accepted the
risk and a male infant was born at term. Analysis of both cord blood at birth and
peripheral blood at age 2 wk showed a normal number of B lymphocytes. As he is still
under age 6 months, serum immunoglobulins are mainly of maternal origin.
DISCUSSION
Of the 8 described X-linked immunodeficiency syndromes [Rosen et al., 1983;
Densen et al., 1987], 6 have been mapped by RFLP linkage to different loci on the
X-chromosome in the last 18 months [Kwan et al., 1986; Baehner et al., 1986; Mensink et
al., 1987b; Skare et al., 1987; de Sainta Basile et al., 1987; Peacocke and Siminovitch,
1987]. For XLA, the presumed defect is a block in the differentiation from pre-B cells to B
cells [Pearl et al., 1978] and has been shown to be intrinsic to the B-cell lineage [Fearon et
al., 1987], Until recently female carriers could not be detected, but once linkage to RFLPs
was demonstrated it became possible to use gene tracking in genetic prediction [Kwan et
al., 1986]. In our study of 34 potential carriers, gene tracking with S21 and pXG12 gave
information that could be used in genetic counselling in 32. Of a total of 19 obligate or
potential carriers under the age of 45, prenatal prediction using these probes is possible in
15. However, the present sample is biased towards optinum family structure since most
were selected for the original linkage study [Malcolm et al., 1987]. The combination of
S21 (heterozygosity frequency 0.45) and pXG12 (heterozygosity frequency 0.48) can be
expected to render about 70% of females in other families amenable to gene tracking.
There is no evidence of linkage disequilibrium between S21 and pXG 12. As expected with
an X-linked lethal disease, we detected no linkage disequilibrium with XLA and either
probe.
There are several potential unrelated sources of error in using linked probes. The
problems of recombination, nonpaternity, and new mutation have been discussed previ¬
ously [Winter et al., 1985; Pembrey, 1986]. Here we have particularly addressed the
problem of nonallelic genetic heterogeneity. Until tests independent of linkage analysis can
distinguish which gene locus is involved in any particular XLA family, nonallelic genetic
heterogeneity must be incorporated into any genetic prediction.
We demonstrated here how one can allow for the problem of nonallelic genetic
heterogeneity in risk calculation. However, there is still a degree of uncertainty in risk
prediction due to the fact that one cannot be sure about the proportion of unlinked families,
whether it is 10%, or perhaps 30%; though it is likely to be about 10% on present evidence.
This degree of uncertainty (depending on whether unlinked families are 10% or 30%) is
less in a large family (family 1) with linkage data from many members than a smaller
family (family 9) with little or no linkage data with the marker.
This difference in the degree of uncertainty can be illustrated by comparing 11-12 in
family 1 with 1-2 in family 9 where the RFLP results favour a new mutation during
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TABLE I. Genetic-risks of Female Carriers Using Pedigree Information Alone or With RFLP Results*
Pedigree + DNA risk
(%) when proportion of
Pedigree risk unlinked families is Prenatal prediction with
Subjects (%) 0 0.1 0.3 S = S21,X = XG12
Family 1
1-1 100 (O.C.) >45 years
1-12 100 (O.C.) >45 years
1-14 100 (O.C.) >45 years
1-6 27.27 24.17 24.23 24.38 >45 years
1-10 50 50 50 50 >45 years
II-l 50 95.98 95.08 92.71 N.I.
11-2 50 95.98 95.08 92.71 N.I.
11-5 9.09 1.48 1.62 2.01
11-7 25 48.13 47.69 46.53 S + X
11-8 25 48.13 47.69 46.53 S + X
11-12 33.33 2.05 2.64 4.22
11-13 50 95.99 95.12 92.8 X
11-14 20 1.04 1.34 2.16
III-l 25 48 47.57 46.4 N.I.
111-2 25 48 47.57 46.4 X
1II-5 16.67 1.03 1.32 2.11
Family 2
I-l 100 (O.C.) >45 years
1-2 100 (O.C.) >45 years
1-4 33.35 58.15 57.7 56.49 >45 years
11-5 16.68 55.82 55.11 53.21 N.I.
Family 3
1-2 100 (O.C.) >45 years
11-1 20 92 89.29 82.55 S
111-2" 16.67 3.69 4.25 5.62
Family 4
1-2 27.28 10.32 11.5 14.1 >45 years
11-1 100 (O.C.) S + X
11-4 9.1 3.46 3.85 4.71
111-4 4.57 1.75 1.94 2.38
Family 5
1-2 33.34 0.02 1.52 5.14 >45 years
11-1 100 (O.C.) X
Family 6
1-2 20 63.86 62.7 59.69 >45 years
II-l 100 (O.C.) X
11-3 10 61.3 59.94 56.43 X
Family 7
II-l 100 (O.C.) >45 years
II-2 100 (O.C.) >45 years
11-3 50 96 94.94 92.16 >45 years
II-4 33.33 92.31 90.95 87.39 >45 years
Family 8
1-2 50 66.63 65.98 64.4 >45 years
II-l 100 (O.C.) S
11-2 25 5.15 5.92 7.82
Family 9
1-2 42.86 4.16 10.24 20.35 >45 years
11-2 100 (O.C.) S
II-3 14.3 3.56 5.25 8.05
111-3 50 88.65 82.58 72.49 S
(icontinued)
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TABLE I. Genetic-risks of Female Carriers Using Pedigree Information Alone or With RFLP Results*
{continued)
Pedigree + DNA risk




Subjects (%) 0 0.1 0.3 S - S21, X - XG12
Family 10
1-2 8.57 0.00 0.29 1.01
II-2 100 (O.C.) X
11-6 2.87 0.01 0.11 0.34
II-7 4.31 0.02 0.17 0.53
Family 11
1-2 100 (O.C.) >45 years
II-1 100 (O.C.) X
Family 12
1-2 11.11 36.52 36.23 35.42 >45 years
11-2 100 (O.C.) >45 years
Family 13
1-2 66.67 66.67 66.67 66.67 S
II-2b 33.33 5.15 7.97 13.61
♦O.C., obligate carrier; N.I., not informative.
"Newborn male at risk.
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Fig. 2. Change of carrier risks with the proportion of unlinked families rising from 0% to 100%.
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spermatogenesis in 1-1. Both are potential carriers with pedigree risks between 33% and
43% which are reduced to under 5% with the RFLP results if all XLA mutations were
linked to S21 /pXG12. However, if one assumes 30% of families are unlinked, the risk of
1-2 in family 9 will be 20.35% while that of 11-12 in family 1 is still 4.22%. The change of
these 2 women's carrier risk with the proportion of unlinked families is shown in Fig¬
ure 2.
Defining a subgroup of families unlinked to Xq21.3-22 by RFLP analysis will refine
our classification of X-linked agammaglobulinaemia and facilitate the discovery of
immunological differences between the subgroups.
Another possible explanation for pedigree Z as reported by Mensink et al. [ 1987a] in
which recombinations between disease and S21 occurred can be germline mosaicism. This
phenomenon has been convincingly demonstrated in Duchenne muscular dystrophy
[Darras and Francke, 1987], but it is difficult to validate this possibility in pedigree Z.
Regarding the family which was first reported by Jamieson and Kerr, [1962], germline
mosaicism cannot explain the recombinations observed between disease and S21.
It is also feasible, with the linkage data, to indicate where the mutation first started
in a family, e.g., in families 5 and 10, the mutation most likely arose during spermatogene¬
sis in the grandfathers. There are both practical and biological interests in determining
whether the mutation rate in males and females is equal with respect to any X-linked
disease [Winter, 1980]. However, the immediate practical benefit in pinpointing the
mutation in a family is to exclude risks in all relatives except descendants of the carrier of
the new mutation.
It is our experience when using these linked probes in counselling XLA families that
most of the women welcome clarification of their carrier risks despite the limitations and
inherent errors of the test. We also mention the availability of prenatal prediction if it is
appropriate and possible. The attitudes of potential carriers towards prenatal diagnosis are
mixed depending on personal experience of the disease within a family and individual
belief. Obviously, the uncertain prognosis of the disease with better treatment is another
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Summary. We describe a family in which an X-chromosome
deletion is segregating with choroideremia, an X-linked reces¬
sive condition. The DNA sequences DXYS1 and DXS3, de¬
fined by the probes pDP34 and 19.2 respectively, are absent in
the affected male (who is also mentally retarded), and hemi-
zygous in his mother and in his carrier sister, who presented
early in pregnancy. Analysis of chorionic villus DNA formed
the basis of prenatal exclusion of choroideremia in her male
fetus. In three female relatives, studied with late-labelling
techniques, the deleted X was preferentially inactivated in 86-
100% of cells studied. This family confirms the localisation of
the choroideremia locus to within Xql3^>21, and places the
loci for anhidrotic ectodermal dysplasia and the X-linked
immunodeficiencies outside this region.
Introduction
Choroideremia is a bilateral progressive degeneration of the
choroid and retina, inherited as an X-linked recessive trait
(McCulloch and McCulloch 1948; Sorsby et al. 1952; McKu-
sick 1983). Onset of symptoms in affected males is usually in
the second or third decade, with initial night blindness.
Peripheral visual field defects develop, but central vision is
lost late. The fundal abnormality begins with pigmentary
changes, followed by atrophic changes, allowing the white
sclera to show through in patches. Retinal vessels are normal.
Mental retardation is not a feature of the condition. Female
carriers, although normally asymptomatic, show a character¬
istic combination of pigmentation and depigmentation, most
marked at the mid-periphery of the fundus.
No linkage has been found between the Xg blood group
and choroideremia (Other 1968; Bell and McCulloch 1971).
Recently Nussbaum et al. (1985) have found linkage between
choroideremia and the polymorphic site DXYS1, defined by
the random sequence probe pDP34. This has been localised to
within Xql3—>21 by in situ hybridisation (Page et al. 1984).
The published linkage data show no recombination between
DXYS1 and choroideremia at a LOD of 5.78. Since that pub¬
lication, more family studies have confirmed this linkage
(0 = 0.02 at LOD 10.25; R.L. Nussbaum, personal communi-
Offprint requests to: M.Bobrow
cation), thus making the use of DXYS1 for prenatal diagnosis
of choroideremia a realistic proposition. Positive LODs have
also been found between choroideremia and DXS3, localised
to Xq21.3 (0 = 0.04 at LOD 12.32 [R. L. Nussbaum, personal
communication]) and DXS11, localised to Xq24—>26 (0 = 0 at
LOD 1.54) (Nussbaum et al. 1985; Gal et al. 1986).
We describe a kindred in which a man with classical
choroideremia also suffered from mental retardation. A sis¬
ter, who showed the fundoscopic changes of the carrier state
for choroideremia presented 9 weeks into her first pregnancy,
requesting prenatal diagnosis. For this reason, the family un¬
derwent urgent DNA analysis. The affected male was found
to be deleted for the DXYS1 sequence, whilst analysis of the
chorionic villus DNA from the fetus revealed a male without
the deletion (Robertson et al. 1986). Family studies revealed
that the choroideremia was segregating with an X chromo¬
some rearrangement. Cytogenetic studies of the chorion sam¬
ple showed that the fetus did not carry the abnormal X chro¬
mosome.
Materials and methods
The family members investigated are indicated in Fig. 1.
DNA analysis
The DNA was extracted from 10-20 ml of venous blood (with
EDTA anticoagulant), and detection of restriction fragment
length polymorphisms was by standard methods (Old 1986).
Cytogenetics
Chromosome preparations were obtained from peripheral
blood lymphocytes by standard methods (Hungerford 1965;
Moorhead et al. 1960). Late-labelling of the X chromosome
was demonstrated by addition of bromodeoxyuridine (BrdU)
to the cultures at a concentration of 1mg/ml for the final 6 or
7h of culture time. The slides were subsequently stained with
Hoechst 33258 and Giemsa (Latt 1973). Late prometaphase
chromosomes for high resolution banding studies were ob¬
tained by a modification of the method of Yunis (1981).
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Fig. 3. Gross choroidal sclerosis with pigmentary changes, diagnostic
of choroideremia, in affected individual III. 1
this was done at 11 weeks of pregnancy. Once it had been
demonstrated that the deletion present in the affected indi¬
vidual (III. 1) was not present in the fetus (see below), the con-
sultand elected to continue the pregnancy.
The affected individual (III.l) was born by normal delivery
at full term, and his neonatal progress was normal. His motor
developmental milestones were as follows: he sat at 5 months,
crawled at 8 months, and walked at 14 months. Hair and eye
color was dark, and he had no skin abnormalities. At 4 years
of age, he developed a convergent squint, and was noted to be
clumsy. On examination at 8 years old, he had a convergent
strabismus and a high-arched palate with maxillary prognath¬
ism, and he dribbled constantly. He was clumsy and had diffi¬
culty with fine finger movements. His visual acuity was im¬
paired, but could be corrected to 6/9 (right eye) and 6/18 (left
eye). Fundoscopy showed gross choroidal sclerosis with pig¬
mentary changes, while the discs and vessels were normal
(Fig. 3), and a diagnosis of choroideremia was made. His IQ
was assessed as 67 on a full-scale Wechsler test. He attended
an ESN (educationally subnormal) school. He was not prone
to recurrent illness or skin infections. No formal hearing as¬
sessment was performed, but he had no apparent hearing im¬
pairment.
On re-examination at 13 years of age, his eyesight had de¬
teriorated to 6/60 in both eyes, and he had marked night blind¬
ness. He attended a sheltered workshop from his ESN school.
He had never had an epileptic fit. EEG examination at this
time showed a moderate diffuse abnormality of an unusual
kind, with rhythmic components. His IQ was reassessed at 61
on the WISC scale, with a verbal IQ of 80, and a performance
IQ of 47. At the age of 30 years he was registered blind, al¬
though he could still find his way about in daylight without as¬
sistance.
His mother, II.2, was of limited intelligence. She showed
the characteristic fundoscopic changes of a choroideremia car¬
rier, with depigmented patches in the periphery of the retina,
and although her electro-oculogram was normal, the static vi-
Fig.2. Typical fundoscopic changes of carrier state, showing charac¬
teristic "salt and pepper" pigmentary changes at periphery of retina
Results
Clinical history and examination
The consultand (III.4) was referred for genetic counselling at
9 weeks gestation in her first pregnancy, knowing that she was
a carrier of X-linked choroideremia. She had developed epi¬
lepsy following measles encephalitis at the age of 18 months,
for which she was receiving medication, and at the age of 15
years her verbal IQ was assessed as 82. At 17 years old, her
visual acuity was 6/9 (right eye), and 6/12 (left eye). Fundos¬
copy revealed "salt and pepper" pigmentary changes at the
periphery of the retina, as typically found in choroideremia
carriers (Fig. 2).
After discussion, it was decided that a chorion biopsy
would be performed for fetal sexing and DNA studies, and
Fig.4. A Taql DNA digest from the consultand (III.4), her parents X
(II.1 and II.2), her affected brother (III. 1), and her fetus (IV.4), hy- >"*■ '
bridised with the DXYS1 (pDP34) probe. As discussed in the text, the | ' '
affected brother shows only the Y-specific band, the X-specific se- ' H
quence being deleted. The fetus (IV.4) shows both a Y-specific and an
X-specific band
sual screener showed minor defects in her central field of vi¬
sion. She had several epileptic fits as a child, but not after the
age of 7 years, and was not on anti-epileptic medication in
adult life.
Her eldest daughter, III.2, was of normal intelligence. She
was also shown to have the changes found in carriers of
choroideremia on fundoscopy. She had epileptic seizures as a
child, and had a few grand mal fits at 21 years of age, but since
that time had no further attacks, and did not require medica¬
tion. Her twin daughters (IV. 1 and IV.2) have both had epi¬
leptic fits since they were 1 year of age. Twin IV. 1 has severe
epilepsy; twin IV.2 is more mildly affected. They were devel-
opmentally normal at 4V2 years old, and both were on anti¬
convulsant maintenance treatment.
Individual III.3 had normal fundi, and was not thought to
be a carrier of choroideremia. She was of normal intelligence,
and had never had an epileptic fit.
DNA studies
DXYS1 (pDP34). This probe hybridizes to a Y-specific se¬
quence present in a 15 kb fragment of a Taq 1 digest, as well as
an X-specific sequence which may show a Taql restriction
fragment length polymorphism with 12 and llkb bands. Fig¬
ure 4 shows an autoradiograph of the DNA from the consul¬
tand (III.4), her parents (II.1 and II.2), her affected brother
(III. 1), and her fetus (IV.4). The fetus is male, with a Y-spe-
cific band like those found in individuals II. 1 and III. 1. The af¬
fected brother has no X-specific band, indicating that there is
a deletion of this sequence from his X chromosome. The fetus
has an X-specific band, and therefore has not inherited the de¬
letion. The consultand and her mother have a single X-specific
band compatible with their carrying the deleted X. It was on
the strength of this analysis that the consultand was reassured
that the fetus had a low risk of having choroideremia (5% was
quoted, given the observed linkage, and the belief that one
should err on the cautious side until more data are available).
DXS3 (19.2). This probe reveals a Taql restriction fragment
length polymorphism, the alleles being represented by an
upper 5.1 kb band, or a lower doublet of 2.95 and 2.15 kb. The
same filter as in Fig. 4 was re-hybridized to the 19.2 probe
Fig. 5. The same Taql DNA digest filter as in Fig.4, rehybridised to
the DXS3 (19.2) probe. The Taql RFLP gives one allele represented
by the upper (5.1 kb) band, and another by the lower doublet of 2.95
and 2.15 kb. The affected brother (III. 1) shows no bands. His father
(II. 1) has the lower doublet, and his mother (II.2) just the upper
5.1 kb band. The consultand (III.4) appears only to have inherited the
lower doublet from her father, and therefore a deleted X chromo¬
some from her mother. The fetus (IV.4) (O) has the lower doublet
(the upper band of which is faint but clearly visible on the original)
Fig.6a, b. The X chromosome pairs from individuals IV. 1 (a) and
IV.2 (b). The abnormal X is on the left
(Fig. 5), and reveals that the affected brother (III. 1) is deleted
for this sequence also. His father (II.1) has the lower doublet,
and his mother (II.2) only an upper 5.1 kb band. If the mother
had been homozygous for the 5.1 kb band, then the consul¬
tand (III.4) should have had both the doublet and a 5.1 kb
band. In the event, the consultand has only the doublet inher¬
ited from her father, and therefore both she and her mother
carry the deletion. The fetus (IV.4) has the doublet (upper
component faint), which is on the normal X chromosome orig¬
inally derived from II. 1.
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Fig. 7a, b. X chromosome pairs from two cells of the minority popula¬
tion, showing late replication of the normal X chromosome. The ab¬
normal X is on the left of each pair
Cytogenetic studies
High resolution chromosome studies of the affected male
showed him to have an abnormal X chromosome. The consul-
tand (III.4) and the sister (III.2) were found to be heterozyg¬
ous carriers of the same structurally abnormal X chromosome.
In addition, 2/50 cells from III.2 had the karyotype 45,X, with
loss of the abnormal X. The twin daughters of III.2 (IV. 1 and
IV.2) were both heterozygous for the abnormal chromosome
(Fig. 6). III.3 had a normal female chromosome complement.
The band Xq21 is about half its normal size, due to dele¬
tion of sub-band Xq21.1. The distance from the centromere to
band Xq21.3 often appears greater in the deleted chromo¬
some than in its normal homologue. This is probably due to
variation in the pericentric heterochromatic band Xqll.l, but
the possibility of a more complex rearrangement in proximal
Xq cannot be ruled out. Late labelling studies with BrdU
showed the abnormal X to be late replicating in all 39 informa¬
tive cells from III.2. In IV.1, however, 5 out of 50 cells
showed the normal X to be late replicating, and the same pat¬
tern was seen in 7 out of 50 cells scored from her sister IV.2
(Fig. 7). The cytogenetic studies from the chorion villus sam¬
ple (IV.4) from direct and cultured preparations showed a
normal X chromosome.
Discussion
This report describes a family in which a cytogenetically ab¬
normal X chromosome, including a deletion of the DNA se¬
quences DXYS1 and DXS3, is segregating with choroid-
eremia. The affected male, who demonstrates the typical
ophthalmological features of choroideremia, also has moder¬
ate mental retardation, and an abnormal EEG. Four of his re¬
lations who carry the deleted X show fundal changes typical of
heterozygotes for choroideremia, have all had epileptic fits,
and two show mild intellectual impairment.
Given the close linkage of the choroideremia locus to
DXYS1 (Nussbaum et al. 1985), it is reasonable to conclude
that this locus, or the sequences concerned with its transcrip¬
tion, are removed or disrupted by the Xq21.1 deletion. Men¬
tal retardation is not a feature of regular X-linked choroid¬
eremia, so the intellectual impairment and EEG abnormali¬
ties in this affected male can be attributed to the loss of other
X-linked gene(s) within the deletion.
It is striking that our patient has so few abnormalities, de¬
spite having such a large deletion of his X chromosome. He
apparently only expresses a single X-linked disorder in addi¬
tion to mild mental retardation. In particular, he shows no
manifestations of anhidrotic ectodermal dysplasia, which was
recently assigned to Xql2 (MacDermot et al. 1986), or of X-
linked agammaglobulinaemia, mapped to Xq21.3-22 (Kwan
et al. 1986). This enables us to exclude the gene loci for these
two conditions from the region of the X chromosome deleted
in our patient. It is of interest that a previously described fam¬
ily (van den Bosch 1959) showed an association of choroid¬
eremia, mental deficiency, anhidrosis, and other features. It is
tempting to speculate that this may have resulted from a dele¬
tion including the loci for choroideremia and anhidrotic ecto¬
dermal dysplasia, but unfortunately no cytogenetic studies
were performed on this family. In this respect, it may be rele¬
vant that one of the deleted sequences, DXYS1, falls within a
large region of the X chromosome showing homology with the
Y chromosome, which may contain rather few active genes.
In the carrier women in this family, in whom X-inactiva-
tion studies were performed in lymphocytes, the abnormal X
was inactivated in 86-100% of cells scored. In almost all re¬
ported cases of deletions of the X chromosome, the structur¬
ally abnormal X chromosome was late-replicating in lympho¬
cytes and fibroblasts (Francke 1984). Exceptions to this ob¬
served pattern are reports of two patients with Turner syn¬
drome who had terminal deletions of Xp (Petrinelli et al.
1978; Kaosaar and Mikkelsaar 1980), where in a small propor¬
tion of lymphocytes the deleted X chromosome replicated
early; the mildly retarded woman with an Xp deletion de¬
scribed by Francke (1984); and the mother of the boy de¬
scribed by Ferguson-Smith et al. (1982), in both of whom late-
replication of the X was random. Similarly, although late-
labelling of the normal X in female carriers of balanced X/
autosome translocations is the general rule, late replication of
the translocated X chromosome in a proportion of cells has
been described (Mattei et al. 1982). This bias in inactivation
has often been ascribed to cell selection in favor of the most
balanced karyotype. However, it is difficult to argue that null-
isomy for this X deletion in cells in which the normal X is inac¬
tivated would be cell-lethal and lead to selection in favor of
cells in which the normal X is active, because the deletion has
not been lethal to the affected male.
Individual III.4 had fundoscopic changes of the carrier
status for choroideremia, despite the fact that in all her scored
lymphocytes the deleted X chromosome was late-labelled.
However, because the relationship between late-labelling and
X inactivation is unclear, and differential inactivation in dif¬
ferent tissues has been described (Hellkuhl et al. 1982), we
cannot make assumptions about which X chromosome was ac¬
tive in her retinal tissues. The deletion could, alternatively, af¬
fect development in the early stage of embryonic life at which
both X chromosomes are active, causing abnormalities of the
fundus which become apparent in adult life.
The chromosome abnormality and DNA deletion we de¬
scribe are segregating with choroideremia in this family. In
view of the linkage previously demonstrated between choroid¬
eremia and DXYS1, we propose that the deletion was causally
related to the disorder, and that the gene locus for choroid¬
eremia lies within the region defined by the deletion in this
family. The gene locus for X-linked ectodermal dysplasia, by
the same argument, must lie outside the region of the dele¬
tion.
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